',6&/2685(
5('$&7('35272&2/$0(1'0(17
&&'/&
3+$6(5$1'20,=(''28%/(%/,1'3/$&(%2&21752//('
08/7,&(17(5678'<72&203$5(7+(()),&$&<$1'6$)(7<2)
/(1$/,'20,'(&&3/865&+23&+(027+(5$3<5&+239(568 6
3/$&(%23/865&+23&+(027+(5$3<,168%-(&76:,7+35(9,286/<
8175($7('$&7,9$7('%&(//7<3(',))86(/$5*(%&(///<03+20$
7KH¬≥52%867¬¥6WXG\ 
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 
&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQH¬∂VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW
,QIRUPDWLRQDERXW&HOJHQH¬∂VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1(35235,(7$5<,1)250$7,215686866
286/<86/<
03+20$03+20$
VKRXOGQRWKRXOG
WRUHVHDUFKHUHVHDUFK
ZVDQGUHJXZVDQGUH
KDYHOHJDORKDYHOHJDOR
RUUHODWHGWRUHODWHG
EXWFHEXWFHUWDLQDLQ
WRSURWHFW&RSURWHFW&
OORZLQJSULQOORZLQJSULQ
HGE\JUH\VHGE\JUH\
WKHLGHQWLILFHLGHQWLIL
DWFRQWDLQFDWFRQWDLQF
WKDWFRQWDLQWKDWFRQWD
7KH\DOVR7KH\D
K\SRWKHVLVK\SRWKHVLV
WRWKHVHDWWDWKHVHDWWD
WKHERG\RIWKHERG\R
WLRQDOLRQDO
WLRQDERXW&LRQDERXW&
RVXUHRIWKDWUHRIWKD
RUPDWLRQDERUPDWLRQDE
QIRUPDWLRQQIRUPDWLRQ
EHIRXQGHIRXQG
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 1 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019TITLE PAGE
PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO 
CONTROLLED, MULTICENTER STUDY TO COMPARE 
THE EFFICACY AND SAFETY OF LENALIDOMIDE 
(CC-5013) PLUS R-CHOP CHEMOTHERAPY (R2-CHOP)
VERSUS PLACEBO PLUS R-CHOP CHEMOTHERAPY
IN SUBJECTS WITH PREVIOUSLY UNTREATED
ACTIVATED B-CELL TYPE DIFFUSE LARGE B-CELL 
LYMPHOMA
The ‚ÄúROBUST‚Äù Study
INVESTIGATIONAL PRODUCT (IP): Lenalidomide (CC-5013)
PROTOCOL NUMBER: CC-5013-DLC-002
ORIGINAL DATE: 16 May 2014
AMENDMENT No. 1 DATE: 25 Aug 2015
AMENDMENT No. 2 DATE: 24 Jan 2017
AMENDMENT No. 3 DATE: 04 Feb 2019
AMENDMENT No. 4 DATE: 12 Jun 2019
EudraCT NUMBER: 2013-004054-21
IND NUMBER: 60,100
SPONSOR NAME / ADDRESS: Celgene Corporation
86 Morris AvenueSummit, NJ 07901
USA
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or 
consultant for review by you, your staff, and ethics committee/institutional 
review board.  The information contained in this document is regarded as 
confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by 
law or regulations.  Persons to whom the information is disclosed must be 
informed that the information is confidential and may not be further 
disclosed by them.YY
D
CELL CELL
de (CCe (CC -501-501
-DLCDL -002-002
May 2014May 2014
55AugAug 2012
242Jan Ja
044
SS:SS:
This protocohis protoco
consultaonsult
revierevi
concon1((1
(/&(
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 2 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Name:
Title:
Address: Celgene Corporation, 86 Morris Ave, Summit, NJ 07901
Phone:
E-mail:
Note: The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls
Back-up 24 Hour Global Emergency Contact Call Center: 
&(/*(1(35235,(7$5<5<< ,1)250$7,21$$$0$0$0$500$
d only be ud only be u
Monitor oMonitor
<, 15<,
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 3 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
(See Appended Electronic Signature Page)
Signature of Celgene Therapeutic Area Head dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I ha ve reviewed this protocol and find its content to be 
acceptable.  
&(/*(1(35235,(7$5<,1)250$7,21$$0$0$50
its contentts conten
<,<,
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 4 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaratio n of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
&(/*(1(35235,(7$5$5$5<,1)250$7,210$0$5000
s studys study  at m atyy
, informed nformed
ocedures, inedures, i
GoGood Clinod C
ct of clinicaof clinic
$5
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 5 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator dd mmm yyyy
Printed Name of Coordinating Principal Investigator
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as needed.
&(/*(1(35235,(7$5<,1)250$7,210$0$50000
wiwiththiiICH GICH h
ghout the stout the st
5<5<
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 6 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019PROTOCOL SUMMARY
Study Title
Phase 3 Randomized, D ouble-Blind, Placebo Controlled, Multicenter Study to Compare the 
Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP)
Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated 
B-cell Type Diffuse Large B-cell Lymphoma
Indication 
Previously untreated, activated B-cell (ABC) type diffuse large B-cell lymphoma (DLBCL).
Objectives
To evaluate the efficacy and safety of lena lidomide, rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy 
in subjects who have previously untreated ABC type DLBCL.
Study Design
This randomized, pl acebo controlled study is designed to evaluate the efficacy and safety of R2-
CHOP chemotherapy versus placebo-R-CHOP chemotherapy in previously untreated ABC type 
DLBCL.  The study is divided into the Screening Period, Treatment Period, and Follow-up Period.  A pproximately 560 subjects will be randomized over approximately a 34-month accrual 
period.
The Screening Period for eligibility determination may begin after the subject signs the informed 
consent form.  During the Screening Period s ubjects will undergo safety and other assessments, 
including central pathology confirmation of DLBCL diagnosis and determination of ABC type.  
Following confirmation of eligibility, subjects will undergo rando mization to either the 
experimental or control arm in a 1:1 ratio.  
The Treatment Period begins with Cycle 1 Day 1 dosing.  Subjects will receive protocol-
specified treatments for 6 cycles.  Treatment will continue to completion; or until the outcome of 
the computed tomography (CT) scan at Midcycle (between Weeks 9 ‚Äì 12 which is after Cycle 3 
but before Cycle 4) indicates a treatment change based on response assessment; disease 
progression; unacceptable toxicity; death; or withdrawal of consent, whichever occurs first. End of Treatment is defined as the later date of either End of Lenalidomide/Placebo or End of R-
CHOP.
The Follow-up Period for each subject begins immediately after their End of Treatment date.  
Subjects will be followed for first and second progressions, subsequent antilymphoma therapy, 
development of any second primary malignancies (SPMs), and overall survival (OS) according 
to the schedule described in Table 5 . After the 12 Apr 2019 primary analysis, subjects will only 
be followed for SPM and OS data collection.
The pharmacokinetic (PK) substudy is designed to evaluate the PK of lenalidomide when co-
administered with and without R-CHOP.  It will be conducted at selected sites and will be optional for subjects at those sites.  Approx imately 20 subjects will be included in the PK 
substudy.&(/hh(/*(1(35235,(7$5<,1)250$7,21).)
, doxorubidoxorub
ab, b, 
OPOP))chemochem
e the efficathe effica
in previousin previo
reateatmementnt P P
over approover app
nmay beginmay beg
bjectbject sswill will 
DLBCLDLBCL dd
bjectbject sswill will 
atiatio.  o.  
h Cycle 1 Dh Cycle 1 
es.  s.  TreatmTreatm
CTCT))scan scan a
ateatsa treata tre
able toxicitable toxi
ined as thed as the
-up -up PeriPeriodod
will be foll be fo lll
opment of aopment of a
e schedule schedul
be e fofollolowedwed
he phhe ph
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 7 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Study Population
Subjects must have a diagnosis of ABC type DLBCL, be previously untreated, have at least one 
measurable lesion by CT scan, and have ade quate liver, renal, cardiac, and bone marrow 
function. 
Length of Study
The primary analysis will occur when the re quired 192 progression free survival (PFS) events 
(progressions/deaths) in the intent-to-treat (I TT) population ha ve occurred, which is 
approximately 42 months from the start of enrollment.  After the primary analysis, those subjects 
who are alive will st ill be followe d exclusively for sec ond primary malignancies and overall 
survival for up to 5 years from the date th e last subject is randomized. The total study duration is 
approximately 8 years (34 months accrual period + 5 years SPM follow-up).  
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
study, or the date of receipt of the last data point from the last subject that is required for primary, secondary  analysis, as pre-specified in the protocol and/or the 
Statistical Analysis Plan, whichever is the l ater date.
Study Treatments
Study treatments in a 21-day cycle are: lena lidomide / placebo Days 1 ‚Äì 14; rituximab, 
cyclophosphamide, doxorubicin, and vincristine Day 1; prednisone Days 1 ‚Äì 5. Refer to Table 7
for complete details.
Overview of Efficacy Assessments
The International Working Group (IWG) Response Criteria for non-Hodgkin‚Äôs lymphoma 
(NHL) ( Cheson, 2014) , and the Deauville Criteria for scan interpretation ( Itti, 2013; Meignan,
2013) , will be used for eff icacy assessments.  The local investigator will perform real time 
efficacy review to guide subject management, with the exception of the assessment performed 3 
‚Äì 4 weeks after Cycle 6 which will be reviewed in real time by the Independent Response Adjudication Committee (IRAC).  The IRAC will also perform a subsequent batched review of 
all assessments. Add itional efficacy evaluation includes a CT scan to support disease restaging
at Midcycle (once between Weeks 9 ‚Äì 12 which is after Cycle 3 but before Cycle 4).  
Overview of Safety Assessments
Safety will be monitored throughout the study.  Safety evaluations will include adverse event 
(AE), SPM, and concomitant medication assessment, physical examinations, vital sign measurements, and clinical laboratory safety tests.  
Second primary malignancies will be monitored as events of interest and should be included as 
part of the assessment of AEs throughout the course of the study. Investigators are to report any SPMs as serious adverse events (SAEs), regardless of causal relationship to investigational 
product (IP) (lenalidomide, placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, or 
prednisone), occurring at any time for the durati on of the study, from the time of signing the 
Informed Consent Document (ICD) for up to 5 years from the date the last subject is 
randomized.
&(/*(1(35235,(7$5<,1)250$7,21jects ject
all all
duratidurati on is on is
to completeo compl
required forequired 
otocol and/otocol and/
DDays 1 ays 1 ‚Äì1
dnisone Dnisone D
nse Cnse C ririterierii
iteria for sciteria for sc
ts.  The locThe loc
ementment , witwih
e reviewede review
 The IRACThe IRA
ficacy evalucacy eval
Weeks 9 Weeks 9 ‚Äì
sessmentssessment
tored throutored throu
concomitaconcomita
s,and and cliniclini
rimary malmary mal
f the assessmf the assessm
MsMsas seriouas serio
product (roduct ( IPIP
prednisoprednis
form
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 8 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019TABLE OF CONTENTS
TITLE PAGE ..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1. INTRODUC TION ..................................................................................................15
1.1. Diffuse Large B- cell Lym phoma ............................................................................15
1.2. Biological and Clinical Signi ficance of DLBCL  Typi ng.........................................15
1.2.1. GCB versus ABC Gene Expression Profiling Assay Used in This Protocol .............16
1.3. Biomarkers in DLBCL............................................................................................16
1.3.1. Biomarkers in DL BCL Pathoge nesis ...................................................................... 16
1.3.3. Mechanistic Biomarkers .........................................................................................17
1.4. Preclinical Data on Len alidomide in DLBCL..........................................................17
1.5. Clinical Efficacy Data on Lenalidomide in  DLBCL................................................18
1.5.1. Relapsed / Refr actory DL BCL ................................................................................18
1.5.2. Front Line DLBCL .................................................................................................20
1.5.2.1. Mayo Clinic R2-CHOP D ata..................................................................................20
1.5.2.2. FIL R2-C HOP Data ................................................................................................23
1.5.3. Clinical Efficacy Data Conclusion ..........................................................................26
1.6. Clinical Safety Events of Interest for Len alidomid e ................................................26
1.6.1. Deep Vein Thrombosis ...........................................................................................26
1.6.1.1. Deep Vein Thrombosis in Multiple Myelom a .........................................................26
1.6.1.2. Deep Vein Thrombosis in Non-Hodgkin‚Äôs Lymphoma ...........................................27
1.6.2. Tumor Flare Reactio n .............................................................................................28
1.6.3. Tumor Lysi s Syndrom e ..........................................................................................29
2. STUDY OBJE CTIVES ...........................................................................................31
2.1. Primary Objective ...................................................................................................31
2.2. Secondary Objectiv e...............................................................................................31
3. STUDY ENDPOI NTS............................................................................................32
3.1. Primary Endpoint ....................................................................................................32
3.2. Secondary Endpoints ..............................................................................................32&(/*(1(35235,(7$5<,1)250$7,2155
.......1616
..................... 161
.........................
.........................
..........................
...........................
......................
.................
........................
..........................
..........................
est for Lenest for Len
......................
is in Mults in Mult ip
mbosis in Nmbosis in N
ReactiReacti ono
ysis Syndroysis Synd
DY OBJECDY OBJEC
Primary ObjPrimary Ob
SeconSecon da
..
.1..1.25
/*
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 9 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20194. OVERALL STUDY DESIGN ................................................................................33
4.1. Study De sign..........................................................................................................33
4.1.2. Screening Period ..................................................................................................... 33
4.1.3. Treatment Pe riod....................................................................................................34
4.1.4. Treatment Decisions Based on Midcycle CT Scan ..................................................34
4.1.5. Treatment Decisions Based on End of Treatment CT and PET Scans ......................34
4.1.6. End of Treatmen t Date ............................................................................................35
4.1.7. Follow-up Period ....................................................................................................35
4.1.9. Independent and Central Assessment Committees ...................................................36
4.2. Study Design Rationale ..........................................................................................36
4.3. Study D uration .......................................................................................................39
5. TABLE OF EVENTS.............................................................................................40
6. PROCEDURES......................................................................................................44
7. STUDY POPULATION .........................................................................................54
7.1. Number of Sub jects and Sites .................................................................................54
7.2. Inclusion Criteri a ....................................................................................................54
7.3. Exclusion Criteri a...................................................................................................56
8. DESCRIPTION OF ST UDY TREATM ENTS........................................................59
8.1. Description of Investigational Products ...................................................................59
8.2. Treatment Schedule and Administratio n .................................................................59
8.2.1. Optional Prepha se Treatment..................................................................................59
8.2.2. Optional Consolidation Treatment (Pre-Specified) ..................................................60
8.2.3. Mandatory Primary Neutropenia Prophylaxis .........................................................60
8.2.4. Lenalidomide/Placebo-R-CHOP Regimen ..............................................................60
8.2.5. Lenalidomide / Placebo ..........................................................................................61
8.2.6. Ritux imab ...............................................................................................................6 1
8.2.7. Cyclophosph amide .................................................................................................62
8.2.8. Dox orubicin ............................................................................................................ 62
8.2.9. Vincri stine.............................................................................................................. 62
8.2.10. Predni sone.............................................................................................................. 62
8.2.11. Lenalidomide/Placebo-R-CHOP Regimen Modifications ........................................63&(/*(1(35235,(7$5<,1)25..........................
..........................
..........................
..................
.........................
..........................
.........................
........................
.......................
DYYTREATTREAT
gatgioional Pr Pr
le and Admle and Ad
hase Treatmhase Treat
Consolidatonsolid
datorydatory  PrimPrimyy
enalidonalido midmid
LenalidoLenalido
RiRi250$7,2144
.......343
..............353
.........................
tutii
.2.7..2.7.
8.2.8..2.8.25
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 10 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20198.2.12. Requalification Criteria For Subsequent Treatment Cycles .....................................63
8.2.13. Overdose ................................................................................................................68
8.2.14. Disconti nuation ...................................................................................................... 68
8.5. Method of Treatment Assignment ...........................................................................71
8.6. Packaging and Labeling ..........................................................................................71
8.7. Investigational Product Accountability and Disposal ..............................................72
8.8. Investigational Product Compliance ........................................................................72
9. CONCOMITANT MEDICATI ONS AND PROC EDURES ....................................73
9.1. Prohibited Concomitant Medications ......................................................................73
9.2. Permitted Conco mitant Med ications .......................................................................73
9.2.1. Hematopoietic G rowth Factors and Transfusions ....................................................73
9.2.2. Pneumocystis Pneumonia Prophylaxis ....................................................................73
9.3. Recomme nded Concomitant Medications ...............................................................73
9.3.1. CNS Lymphoma Prophylaxis .................................................................................73
9.3.2. Nausea Prophylaxis ................................................................................................73
9.3.3. Rituximab Infusion Reaction Prophylaxis ...............................................................73
9.3.4. HBV Reactivation Prophylaxis ...............................................................................74
9.3.5. TLS Prophylaxis .....................................................................................................74
9.3.6. Venous Thromboembolism Prophylaxis .................................................................74
9.4. Mandatory Concomitant Medi cation.......................................................................74
9.4.1. Primary Neutropenia Prophylaxis ...........................................................................74
10. STATISTICAL ANALYSES ..................................................................................75
10.1. Overvi ew................................................................................................................75
10.2. Study Population Definitions ..................................................................................75
10.3. Sample Size and Po wer Consider ations ...................................................................76
10.4. Background and Demographic Characteristics ........................................................77
10.5. Subject Dispos ition.................................................................................................77
10.6. Efficacy Analysis ....................................................................................................77
10.6.1. Primary Efficacy Endpoi nt Defini tion..................................................................... 77
10.6.2. Secondary Efficacy E ndpoint Defini tions ...............................................................78&(/*(1(35235,(7$5<,1)250$7,2111
.......717
..............727
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
.........................
hylaxishylaxis ......
s......................
.................
olism Proplism Prop
mitmitant Meant Me
ropenia Proropenia Pro
ICAL ANACAL A
viewiew..............
tudytudy PopulPopu
SamSample ple m
BacBa
0.5.0.5.
10.6.0.6.
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 11 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201910.6.4. Analysis Method ..................................................................................................... 80
10.7. Safety An alysis.......................................................................................................81
10.8. Interim An alysis .....................................................................................................82
11. ADVERSE EV ENTS ..............................................................................................83
11.1. Monitoring, Recording, and Re porting of Advers e Even ts ......................................83
11.2. Evaluation of A dverse Events.................................................................................83
11.2.1. Se riousness............................................................................................................. 83
11.2.2. Severity / Intensi ty..................................................................................................85
11.2.3. Caus ality ................................................................................................................86
11.2.4. Dur ation ................................................................................................................ .86
11.2.5. Action Taken .......................................................................................................... 86
11.2.6. Outco me................................................................................................................. 86
11.3. Abnormal Labor atory V alues ..................................................................................86
11.4. Pregna ncy...............................................................................................................87
11.4.1. Females of Childbear ing Poten tial:......................................................................... 87
11.4.2. Male Subjects .........................................................................................................87
11.5. Reporting of Serious Adverse Events......................................................................88
11.5.1. Safety  Querie s ........................................................................................................ 88
11.6. Expedited  Reporting of Adverse Events ..................................................................88
12. DISCONTINUATIONS .........................................................................................90
12.1. Discontinuation of Investigational Product ..............................................................90
12.2. Discontinuation f rom the Study ..............................................................................90
13. EMERGENCY PROCEDURES .............................................................................91
13.1. Emergency Contact .................................................................................................91
13.2. Emergency Identification of Investigational Products .............................................91
14. REGULATORY CONSIDERATIONS ...................................................................92
14.1. Good Clinical Practice ............................................................................................92
14.2. Inve stigator Responsibilities ...................................................................................92
14.3. Subject Information and Informed Consent .............................................................92
14.4. Confidentiality ........................................................................................................93
14.5. Protocol A mendments.............................................................................................93
14.6. Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................ 93&(/*(1(35235,(7$5<,1)250$7,2133
.......838
..............858
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
.........................
........................
se Eventsse Events
.................
esttigatigioona
omom the Stu the Stmm
Y PROCEDPROCE
cycyContactContayy
gencygency  IdenIdenyy
EGULATOGULAT
Good ClGood C
Invenv
4.3.4.3.
14.4.4.4.
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 12 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201914.7. Ongoing Information for Institutional Review Board / Ethics Committee ................94
14.8. Closure of the St udy...............................................................................................94
15. DATA HANDLING AND RECORDKEEPING .....................................................95
15.1. Data/Docu ments .....................................................................................................95
15.2. Data Management ...................................................................................................95
15.3. Record Retention ....................................................................................................95
16. QUALITY CONTROL AND QUALITY ASSURANCE ........................................97
16.1. Study Monitoring and S ource Data Veri ficatio n......................................................97
16.2. Audits and Inspections............................................................................................97
17. PUBLICATIONS ...................................................................................................98
18. REFERENCES.......................................................................................................99
19. APPENDICES ......................................................................................................108
19.1. Ann Arbor Stag ing Sys tem...................................................................................108
19.2. Modified Cumulative Illness Rating Scale (Salvi, 2008a) ......................................109
19.3. Deauville Criteria for PET Scan  Interpretation (M eignan, 2009) ........................... 119
19.4. IWG Response Criteria for NHL (Cheson, 2014) ..................................................120
19.5. Cairo-Bishop Definitions of Tumor Lysis Syndrome ............................................122
19.6. EQ-5 D..................................................................................................................123
19.7. FACT-LY M .........................................................................................................126
19.8. Pregnancy Prevention Risk Manag ement P lan...................................................... 129
&(/*(1(35235,(7yy7$5<,1)250$7,2155
.......979
..............979
.........................
..........................
..........................
..........................
..........................
2008a)008a) .....
(Meignan, Meignan
2014)2014) ........
sis Syndrosis Syndro
........................
.......................
k Managemk Managem
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 13 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019LIST OF TABLES
Table 1: Mayo Clinic Study M C078E Baseline Cha racteris tics.............................................21
Table 2: Mayo Clinic Study MC078E Efficacy  Resu lts........................................................22
Table 3: FIL Study REAL07 Ba seline Character istics ..........................................................24
Table 4: FIL Study REAL07 Efficacy Re sults ......................................................................25
Table 5: Table of Events.......................................................................................................40
Table 6: Performance Status by Eastern Coope rative Oncology Group Scal e........................49
Table 7: Lenalidomide/Placebo-R-CHOP Regimen ..............................................................61
Table 8: Dose Modification Rules ‚Äì Lenalidomide / Placebo ................................................64
Table 9: Dose Reduction Levels ‚Äì Lenalidomide ..................................................................66
Table 10: Recommended Dose Modificatio n Rules ‚Äì Cyclophosphamide and/or 
Doxorubicin ............................................................................................................66
Table 11: Recommended Dose Modification Rules ‚Äì Vincristine ...........................................67
Table 12: Recommended Dose Modification Rules ‚Äì Lenalidomide/Placebo R-CHOP 
Regimen .................................................................................................................67
Table 16: IWG Response Criteria for NHL (Cheson, 2014) ..................................................120
Table 17: Cairo-Bishop Definition of Laboratory Tumor Lysis Syndrome (LTLS) ...............122
Table 18: Cairo-Bishop Definition of Clinical TLS ..............................................................122
Table 19: Cairo-Bishop Gradi ng System f or TLS .................................................................122
&(/*(1(35235,(L (Cheson,L (Cheson,
LaboratoryLaborato
n ofof ClinicClinicf
ing Syng Sy stemstem(7$5<,1)250$7,214040
......4949
....................... 616
...........................
.........................
 and/or and/or 
....................
.....................
omide/Placmide
.....................
7$5(7$5,(7
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 14 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019LIST OF FIGURES
Figure 1: Mayo Clinic Study MC078E PFS by Subtype .........................................................23
Figure 2: FIL Study REAL07 PFS and OS by Subtype ..........................................................25
Figure 3: Overall Study Design ..............................................................................................38
&(/*(1(35235,(7$5<,1)250$7,21
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 15 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20191. INTRODUCTION 
Please refer to the Investigator‚Äôs Brochure for detailed information concerning the available 
pharmacology, toxicolo gy, drug metabolis m, clinical studies, and AE profile of lenalidomide.
1.1. Diffuse Large B-cell Lymphoma
Diffuse large B- cell Lymphoma is a distinct histological type within mature B-cell NHL that is 
characterized by large tumor cells and aggressive clinical behavior.  This type accounts for approximately 31% of all newly diagnosed malignant lymphomas ( Armitage, 1998 ).
CHOP chemotherapy in combination with the anti-CD20 m onoclonal antibody rituximab on a 
21-day schedule is a standard of care in newly di agnosed cases in most countries worldwide 
(Feugier, 2005; Ketterer, 2013 ). In the GELA study of R-CHOP versus CHOP front line therapy 
in elderly subjects, following R-CHOP treatment  the 5-year event-free survival (EFS) was 47%, 
the 5-year progression free survival (PFS) was 54%, and the 5-year overall survival (OS) was 58% ( Feugier, 2005 ).  While approximately 50% to 60% of patients are cured ( Feugier, 2005 ; 
Micallef, 2011 ), for those patients who are refractory or who progress following R-CHOP, 
treatment options are limited and outlook is poor; most  die within the next two years.  Since 
roughly 40% to 50% of patients are not cured on initial therapy, evaluating other front line 
treatment options is warranted.  Other attempts  to improve cure rate, including R-ACVBD, 
CHOEP, dose dense regimens (R-CHOP14), and high dose regimens (DA-EPOCH), have not 
replaced R-CHOP21 as a standard of care ( Ketterer, 2013 ; Micallef, 2011 ; Recher, 2011 ).  
1.2. Biological and Clinical Significance of DLBCL Typing
As initially described by Staudt and colleagues, DLBCL is composed primarily of two 
biologically distinct pathophysiologic entities ( Alizadeh, 2000 ).  The authors classified DLBCL 
by gene expression profiling (GEP) into th e germinal center  B-cell (GCB) and the activated B-
cell (ABC) types, derived from different cells of ori gin.  Subsequently, an additional type was 
noted by GEP called type III, ( Rosenwald, 2002 ), which has since been renamed as unclassifiable 
type. Although GEP is now capable of discerning all three types, GCB, ABC, and unclassifiable; 
immunohistochemistry (IHC) is capable of discerning only two, GCB and non-GCB.  The less precise IHC method groups ABC and unclassifiable together as the non-GCB type.  The 
Lymphoma/Leukemia Molecular Profiling Project reported approximately 60% GCB and 40% 
non-GCB (including ABC and unclassifiable) in 240 newly diagnosed DLBCL subject biopsy samples examined by GEP ( Fu, 2008 ; Lossos, 2004 ; Rosenwald, 2002) .  
The different DLBCL types have been reported to have different clinical outcomes with CHOP 
(Rosenwald, 2002 ) and R-CHOP ( Fu, 2008 ) therapy, supporting the concept that these are 
distinct clinical and molecular subtypes.  In the first line setting the 5-year OS rates for the GCB, 
unclassifiable, and ABC types were 60%, 39%, and 35%, respectively, with CHOP treatment 
(Rosenwald, 2002 ).  With R-CHOP, the 3-year EFS for GCB and non-GCB subtypes was 67% 
and 52% respectively, and the 3-year OS was 85% and 69%, respectively ( Fu, 2008 ). With R-
CHOP and predominantly higher risk patients (IPI 0/1 = 21%, IPI 2/3 = 63%, and IPI 4/5 = 15%) 
the median PFS for the ABC type was 1.5 years ( Lenz, 2008 ).  In the relapsed setting, the 
prognosis appears to be approximately the sa me for both the GCB and non-GCB subtypes&(/*(1(35235,(7$5<,1)250$7,21mab ab on a on a 
worlorldwide dwide
front line tfront lin
val (val (EFSEFS))w
ll survival ll survival 
eecurecured(d(FeF
essfofollollowinwin
n the next the next 
y, y, evalevaluatinualll
cure rate, iure rate,
ose regimeose regim
20132013 ; MicaMica
ficance ofcance o
gues, ues, DLBCDLB
ttititiesies((AlizA
ntnto the o the germg
fferent cellsfferent cells
RoRosenwald,senwald,
capable of capable 
HC))is capais c
roupsoups ABCC
mia Moa Mo leculecu
ding ABC ading ABC a
mined by ned by GEG
rent DLBCnt DLBC
nwald, 2002wald, 2002
nct clinicanct clinica
nclassifiabnclassifiab
(RosenwRosenw
d5 2d5 2
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 16 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019(Costa, 2008; Wilson, 2008 ), which may possibly reflect the selection of GCB subjects with 
poorer prognosis not cured initially by R-CHOP.
1.2.1. GCB versus ABC Gene Expression Profiling Assay Used in This Protocol
The cell of origin (COO) as characterized by GEP a nd performed on fresh tissue biopsy samples 
is considered a gold standard.  However defining COO is not currently the routine diagnostic 
work-up in clinical practice.  Moreover, it is  not a practical method for subject selection in 
clinical trials due to the fresh biopsy sample requirement as well as the substantial time and technological expertise required to perform the assay.
This protocol will use a validated GEP based assay performed on  
 with formalin-fixed paraffin-embe dded (FFPE ) biopsy material to identify 
eligible subjects with the required ABC type. The  was validated 
against the original COO model defined by Lenz ( Lenz, 2008 ) using an independent cohort of 68 
FFPE biopsies.  In the validation cohort the assay was accurate, as only one case with definitive COO was incorrectly assigned by  and robust, with >95% concordance of COO 
assignment between two i ndependent laboratories ( Scott, 2014 ). Although the assay is 
technically verified, it has not received marketing approval by a health aut hority beyond being 
Conformit√© Europ√©enne (CE) marked in the European Union (EU).  The assay is being 
developed as a companion diagnostic to len alidomide in conjunction with the assay 
manufacturer, .  Analytical assay validation is not a part of this CC-5013-DLC-002 protocol.
1.3. Biomarkers in DLBCL
1.3.1. Biomarkers in DLBCL Pathogenesis
In recent years a number of chromosomal rearra ngements, acquired mutations, or aberrant 
expression of genes coding for proteins as well as for micro ribonucleic acid (miRNA) have been 
identified in DLBCL.  Many are associated with  a particular DLBCL subtype or yield prognostic 
information.  For example, BCL2 is a commonly a ffected gene in the GCB subtype, and EZH2 is 
also mutated in the GCB subtype ( Morin, 2010 ; Schuetz, 2012 ).  Activation of NF- Œ∫B and 
mutation of MYD88 are more co mmon in the ABC type ( Compagno, 2009 ;Ngo, 2011 ).  Co-
expression of MYC/BCL2 is associated with a very aggressive clinical course in both subtypes, 
although it has been reported to be more common in the ABC type (Green, 2012 ; Hu, 2013 ; 
Johnson, 2012 ).  Additionally, mutations in MYC, CDKN2A, SOCS1, MYD88, CARD11, 
TP53, and other genes have demonstrated prognostic information in patients with DLBCL 
receiving front line treatment ( Gisselbrecht, 2012 ; Horn, 2013 ;Jardin, 2008 ;Schif, 2013 ).  
Single nucleotide polymorphisms (SNPs) are also reported to be associated with prognosis(Ding, 2013; Li, 2013) .
 
 
 
 
 &(/*(1(35235,(7$5<,1)250$7,21entntify ify 
validated validated 
ndent cohorndent coh
case wiase w thhidh
ncordance ocordance o
ough the assugh the a
althhl authoriauthorihh
U).  The ass  The as
unctunctioion win wthi
validatialidati on on
enesisnesis
ll rearrange rearranll
ns as well ans as well a
sociated wociated w
2 is a comm2 is a com
ype (ype ( MorinMori
more commre co
L2L2is associs asso
reported toeported t
AdditAddit ioionallnal
errgenes hagenes h
ont lineont line tretre
ucleotide peotide p
, 2013, 2013 ;LiLi000$
&((&&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 17 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019 
 
 
 
 
 
 
1.3.3. Mechanistic Biomarkers
Recent research on the mechanism of action of lenalidomide, pomalidomide, and thalidomide 
suggest that in tumor cells and T cells, cereblon, a component of E3 ubiquitin ligase complexes, is a target for binding by these compounds. These studies showed that the loss of cereblon or a 
binding partner, such as DDB1, decreases or eliminates the antitumor and immunomodulatory 
activity of lenalidomid e and pomalidomide ( Ito, 2010; Zhu, 2011; Lopez-Girona, 2012) .  A 
number of recent studies have reported correlation between pre-treatment levels of cereblon 
measured by GEP or by IHC methods to clinical outcomes in subjects treated with regimens 
containing lenalidomide, pomalidomide or thalidomide. Very recently multiple groups have described Aiolos ( IKZF3 ) and Ikaros ( IKZF1 ) as two direct substrates of the CRL4 CRBN E3 
ligase complex. These proteins act as transcriptional repressors in T-cells and are also drivers of 
proliferation in multiple myeloma (MM) cells ( Lu, 2013; Gandhi, 2013; Kr√∂nke, 2013) .
 
 
 
 
 
 
1.4. Preclinical Data on Lenalidomide in DLBCL
There is biological plausibility and als o preclinical data that provide strong support for why 
lenalidomide should be expected to significantly enhance the efficacy of the current standard of 
care R-CHOP in the treatment of the ABC type of DLBCL.   
In DLBCL cell line models, lenalidomide preferenti ally suppresses the proliferation of ABC
cells in vitro and delays tumor growth in a human tumor xenograft model, with minimal effect 
on GCB cells. This tumoricidal effect was associated with down-regulation of interferon regulatory factor 4 (IRF4, also known as MUM1), a hallmark of ABC cells ( Zhang, 2013 ).  IRF4 &(/*(1PrecliniPreclini
iis bis biologicogic
alidolidomide mide 
care Rare R -CHCH
 DLBDLB35235,(7$5<,1)250$7,21ddththalidoalid m
n n ligase coligase c
loss of cerloss of ce
nd immunnd immu
Lopezpez-GiGroni
reatmatent lnt le
subjects tresubjects 
erry y recentrecent ly
ect substract substr
repressorsrepresso
, 2013; Gan 2013; Gan$7$
5,(735,(35235523352(31(31((1
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 18 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019inhibition by lenalidomide induced down-regulation of B-cell receptor (BCR)-dependent NF- Œ∫B, 
and this effect was reported to require co -expression of cereblon, a molecular target of 
lenalidomide ( Zhang, 2013 ).  It has also been reported that NF- Œ∫B mediates resistance to 
chemotherapy and that decreased NF- Œ∫B expression may restore sensitivity to chemotherapy 
agents ( Bottero, 2001 ; Luo, 2005 ).  Independently, Yang also reported on the activity of 
lenalidomide in ABC type DLBCL cell lines ( Yang, 2012 ).  Lenalidomide k illed ABC cells by 
augmenting autocrine interferon beta (IFN-√ü) production, which was dependent on oncogenic MYD88 mutations in these lymphomas.  In a cereblon-dependent fashion, lenalidomide down-
regulated IRF4 and SPIB transcription factors which repress IFN-√ü production. 
In addition to the direct antitumor effects on the ABC tumor cells, lenalidomide exerts potent 
immunomodulatory activity.  Preclinical studies have shown an enhancement of antibody 
dependent cell mediated cytotoxicity ( Wu, 2008 ) and antitumor effects in vivo ( Hernandez-
Ilizaliturri, 2005; Zhang, 2009 ) when lenalidomide was combined with rituximab.  In a murine 
NHL model, lenalidomide induced significant increase in the recruitment of NK cells to tumor 
sites, resulting in enhanced antitumor activity of rituximab ( Reddy, 2007 ). When combined with
rituximab, lenalidomide improved survival in a mouse NHL model and the antitumor activity was shown to be NK cell-mediated ( Hernandez-Ilizaliturri, 2005 ).
Preclinical studies suggest that lenalido mide may promote restoration of antitumor 
immunological effects in patients with certain  hematological malignancies .  Impaired T-cell 
immunological synapse formation has been repor ted in chronic lymphocytic leukemia (CLL), 
follicular lymphoma (FL) and DLBCL patients and is thought to be a mechanism of cancer 
immune evasion ( Ramsay, 2008 ; Ramsay, 2009 ). Lenalidomide treatment of the T-cells and the 
tumor cells collected from these patients repair ed the immune synapse defects by enhancement 
of the F-actin synapse. In vitro studies have shown that lenalidomide induced actin cytoskeleton 
reorganization and polarizat ion of NHL cells as early as 30 minutes, a process termed ‚Äúcapping,‚Äù 
which is considered an important subcellular component of the immune synapse formation 
(Gaidarova, 2009 ).  Additionally it has been shown that the combined use of lenalidomide and 
rituximab enhances NK cell-mediated immune synapse formation and the resultant cytotoxicity, versus using each agent alone.  Lenalidomide induces CD20-localization within the ‚Äúcap,‚Äù and 
the addition of rituximab can enhance immune synapse formation ( Gaidarova, 2009 ).  The 
capping of CD20 is accompanied by redistribution of other proteins that become part of the immune synapse complex.  Therefore, the capping process induced by lenalidomide appears 
integral to immune synapse formation and may coordinately enhance the clustering of both the 
CD20 antigen and the attached ritux imab, potentially further enhanci ng its activity, which would 
support the clinical combination of these agents.
1.5. Clinical Efficacy Data on Lenalidomide in DLBCL
1.5.1. Relapsed / Refractory DLBCL
Single agent lenalidomide activity in relapsed or refractory DLBCL subjects has been noted in 
two Celgene-sponsored single arm clinical trials in aggressive NHL: study CC-5013-NHL-002 
(Wiernik, 2008 ) and study CC-5013-NHL-003 ( Witzig, 2011 ).  Data from both studies were 
combined for a revised analysis of 134 DLBCL subjects as study design was nearly ident ical and 
subject baseline characteristics were similar.  Results showed an overall response rate (ORR) of &(/*(1(35235,(7$5<,1)250$7,21otent ent
odydy
nandeznandez --
b.  In a murb.  In a mu
NK cells toNK cells to
When coWhen co
the antie anti tumtii
ation onof ananf
malignancimalignan
ronic lymphnic lymp
ought to ought to bb
nalidonalid midmie
the immunthe immu
own that lewn that l
s as early as as early a
ular compoular compo
been shoween show
ted immuned immun
LenalidoLenalido mimi
enhance imenhance im
mpanied by ranied by 
ex.  Therefex.  There
ynapse formynapse fo
d the attachd the attach
nical conical co mbim
ClinicaClinica
1.1. ReRe
SiSingle agengle age
wwo Ceo Ce
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 19 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201926.1% (35/134), a median PFS of 2.7 months, and a median response duration of 6.0 months 
(Czuczman, 2010 ).  In these clinical trials, COO typing was not conducted.  
Hernandez-Ilizalit urri et al re ported in a retrospective analysis of 40 relapsed/refractory 
aggressive NHL subjects (34 DLBCL, 6 composite/transformed DLBCL) treated with single agent lenalidomide at Roswell Park Cancer Institu te, Mayo Clinic, University of Bologna, and 
Hackensack University that there was a prefere ntial clinical activity of lenalidomide in patients 
with the non-GCB subtype DLBCL ( Hernandez-Ilizaliturri, 2011 ).  The tumor response rate was 
52.9% (5 CR, 4 PR) in the non-GCB subtype (n=17) compared to 8.7% (1 CR, 1 PR) in the GCB 
subtype (n=23).  Median PFS for lenalidomide wa s 6.2 months for the non-GCB and 1.7 months 
for the GCB subtype (p=0.004).  There were no differences in age, disease stage at time of treatment, international prognostic index (IPI) scores, or number of prior therapies between the 
GCB and non-GCB groups.
These observations led to the CC-5013-DLC-001 Ph ase 2/3 randomized clinical trial of single 
agent lenalidomide versus investigator‚Äôs choice in  subjects with relapsed/refractory DLBCL in 
GCB and non-GCB subtypes.  In this trial, subjects with relapsed DLBCL underwent GCB 
versus non-GCB typing during the screening phase, and the typing information was used to assign subjects to two different cohorts defined by the subtype.  The subjects were then 
randomized to receive lenalidomide or single agent of investigator choice.  This study is still 
ongoing.    
At the time of planned final analysis (N=102 mITT; 54 non-GCB, 48 GCB), the CC-5013-DLC-
001 study showed a statist ically signif icant improvement of median PFS for lenalidomide versus 
investigator‚Äôs choice treatment in the non-GCB subtype as assessed by the IRAC (control 7.1 weeks versus lenalidomide 15.2 weeks; p = 0.021, HR [95% CI] = 0.50 [0.27, 0.92]).  There was 
a favorable trend in ORR as assessed by IRAC (control 11.5% versus lenalidomide 28.6%, 
p=0.179) and dORR (control 3.8% versus lenalidomide 21.4%, p = 0.102).  There was also a favorable trend in median OS in the non-GCB subtype (control 20.4 weeks versus lenalidomide 
32.3 weeks; p = 0.253, HR [95% CI] = 0.70 [0.38, 1.30]).  Of note, 16/26 (61.5%) of non-GCB 
subjects in the control arm crossed over to lenalidomide upon radiological evidence of disease progression on the comparator treatment ( Czuczman, 2014 ).  
The CC-5013-DLC-001 study also included explorat ory objectives related to gene expression 
profiling. If medically feasible, subjects were required to provide a fresh frozen lymph node or tumor biopsy at study enrollment; biopsies for 65 subjects were provided.  Samples were then 
typed as ABC, GCB, or unclassifiable using Affymetrix U133 Plus 2.0 GeneChip microarrays.  
At the time of planned final analysis (N= 65 mITT, 27 ABC type, 8 unclassifiable type, 30 GCBtype) the study showed a favorable trend in median PFS for lenalidomide versus investigator‚Äôs
choice treatment in the ABC type as assessed by IRAC (control 6.3 weeks versus lenalidomide 
82.0 weeks; p = 0.105, HR [95% CI] = 0.44 [0.15 ‚Äì 1.23]).  There was also a favorable trend in median OS in the ABC type (control 18.6 weeks versus lenalidomide 108.4 weeks; p = 0.144, 
HR [95% CI] = 0.47 [0.17, 1.33]).
Taken together, these data of lenalidomide single agent in subjects with relapsed DLBCL suggest 
that lenalidomide has preferential activity in non-GCB and ABC types of DLBCL.  Further 
evidence supporting this preferential activity in the non-GCB subtype is observed in preclinical 
models (Section 1.4).
&(/*(1(35235,(7$5<,1)250$7,21CB CB 
nths nths
f f 
ween the ween the 
al trial of sil trial of 
fractoryfractory DLDy
L underwenunder
ormatormat ioion wn w
e subjeubjectsct
or choice.  or choice. 
on-on-GCB, 4GCB, 4
ent ofent of medmedii
type as assype as as
1, HR [95%1, HR [95%
C (control 1C (control 
lenalidomidnalidomi
n-GCB subt-GCB su
= 0.70 [0.3= 0.70 [
d over to led over to 
treatmreatm entent((
udydy also inc also inyy
easibleeasible ,s u b,s u
yenroenroy llllmenm
CB, or B, or uncluncl
planned finplanned f
dydyshowedshowedyy
atment in tment in t
weeks; p = 0weeks; p = 0
dian OS in ian OS in 
HR [95% CHR [95% C
Taken taken 
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 20 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20191.5.2. Front Line DLBCL
The chemo-immunotherapeutic regimen of R-CHOP is a standard of care worldwide for the 
treatment of patients with newly diagnosed DLBCL.  Two academic clinical research groups 
have developed the combination regimen of lenalidomide + rituximab + CHOP (R2-CHOP) in patients with newly diagnosed DLBCL: the Mayo Clinic Cancer Center in the US and the Italian 
cooperative group, Fondazione Italiana Linfomi (FIL).  
1.5.2.1. Mayo Clinic R2-CHOP Data
Protocol MC078E is an investigator initiate d Phase 1/2 study of R2-CHOP in subjects with 
newly diagnosed, previously untreated DLBCL and follicular grade IIIA/B B- cell lymphoma, 
sponsored by the Mayo Clinic. 
The objective of the Phase 1 cohort of this study was to establish the maximum tolerated dose 
(MTD) of lenalidomide that could be combined with R-CHOP.  A total of 24 subjects with newly diagnosed, untreated CD20-positive DLBCL or follicular grade III NHL were enrolled.
Twenty of these 24 subjects had DLBCL.  Subjects received oral lenalidomide on Days 1-10 
with standard dose R-CHOP every 21 days. Th e lenalidomide dose levels tested were 15, 20,
and 25 mg. The median age was 65 (35-82) year s and 54% were over 60 years. Three subjects
received 15 mg, 3 received 20 mg, and 18 received 25 mg of lenalidomide. No dose- limiting 
toxicity was f ound, and 25 mg on Days 1-10 was the r ecommended dose for th e Phase 2 portion 
of this study. The incidence of Grade 4 neutropenia and thrombocytopenia was 67% and 21%, 
respectively. Febrile neutropenia was rare (4%) and there were no deaths due to toxicity. The 
ORR was 100% with a CR rate of 77%. It was concluded that lenalidomide at the dose of 25 mg/day administered on Days 1 to 10 of 21-day cycle can be safely combined with R-CHOP in 
the initial chemotherapy of aggressive B-cell lymphoma ( Nowakowski, 2011 ). 
Based on these phase 1 results, the phase 2 cohort of the study was conducted to assess the 
efficacy of this combination.  Response was evaluated using positron emission tomography or 
computed tomography (PET/CT) by standard criteria ( Cheson, 2007 ). The study is still ongoing; 
data from this study were presented at ASH 2012 and at the International Conference on Malignant Lymphoma (ICML) 2013 ( Nowakowski, 2012, Nowakowski 2013 ).  Sixty-seven
subjects were accrued to the Phase 2 cohort with median follow up of 2.1 years; 55 (88%) 
subjects had previously untreated DLBCL.  All subjects received R-CHOP21 for 6 cycles plus lenalidomide 25 mg (R2-CHOP) on Days 1 ‚Äì 1 0 of each cycle.  Although not prospectively 
planned, subjects were retrospectively subtyped by IHC using the Hans algorithm ( Hans, 2004 ).  
Furthermore, 87 consecutive subjects with DLBCL and similar clinical characteristics participating in the Mayo Clinic Lymphoma Database and treated with standard R-CHOP alone 
served as a contemporaneously matched control. Table 1 below describes the baseline 
characteristics of the 55 DLBCL subjects treated with R2-CHOP in the Mayo Clinic phase 2 trial 
and the 87 subjects treated with R-CHOP as m atched control.  Subjects treated with R2-CHOP
had fewer subjects with low IPI score and were also older as compared to the R-CHOP cohort.
&(/*(1(35235,(7$5<,1)250$7,21homa, ma,
olerated doerated do
subjectsubjects witw
NHL NHL were ewere e
omide on Dmide 
vels tevels te stedsted
over 60 yeaver 60 ye
nalidomidenalidomide
mended dosmended do
hrombocyhrombocy tty
ere were noere were n
luded that uded tha
cyclycle can e c bb
ymphoympho ma ma 
2 cohort of 2 cohort of
e was evaluwas eval
y standard cstandard
ed at ASH ed at ASH
))2013 (2013 ( NoN
e PPhase 2 chase 2 
untreated Duntreated
R22--CHOPCHO )
were retrospwere retrosp
7 consecutiv7 consecuti
in the Mayin the May
a contemcontem popom
eristeriiccs of so f
the 87 the 87 subjsubj
ad ad fewer fewer sus
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 21 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 1: Mayo Clinic Study MC078E Baseline Characteristics
CharacteristicR2-CHOP
(N=55)R-CHOP
(N=87) P value
Age
Median (range) 68 years (22-87) 61 years (41-86) 0.0077
Sex
Male 38 (69.1%) 50 (57.5%) 0.1647
ECOG PS
012324 (43.6%)
25 (45.5%)
6 (10.9%)
032 (36.8%)
41 (47.1%)11 (12.6%)
  3 (3.4%)0.6093
Stage (Ann Arbor)
II
III
IV 8 (14.5%)
16 (29.1%)
31 (56.4%)20 (23.0%)
14 (16.1%)
53 (60.9%)0.3213
IPI
LowLow-intermediateHigh-intermediateHigh   3 (5.5%)
22 (40.0%)22 (40.0%)
8 (14.5%)18 (20.7%)
16 (18.4%)38 (43.7%)15 (17.2%)0.0096
DLBCL Subtype (Hans)
GCB
Non-GCB34 (62%)
21 (38%)59 (68%)
28 (32%)n/a
DLBCL = diffuse large B-cell lymphoma; ECOG PS = Eastern Cooperative Oncology Group Performance Status; 
GCB = germinal center B-cell; IPI = international prognostic index ( Nowakowski, 2013). 
Safety data of the R2-CHOP regimen showed the most common Grade 3 and 4 toxicities with
R2-CHOP were neutropenia (12% Grade 3, 74% Grade 4), thrombocytopenia (30% Grade 3, 16% Grade 4), anemia (20% Grade 3, 0% Grade 4), febrile neutropenia (12% Grade 3, 0% Grade 
4), pneumonia (2% Grade 3, 0% Grade 4), sepsis (0% Grade 3, 2% Grade 4), venous thrombosis 
(0% Grade 3, 2% Grade 4), fatigue (2% Grade 3, 0% Grade 4) and dehydration (2% Grade 3, 0% Grade 4). Overall, R2-CHOP is considered well tolerated (Nowakowski, 2013 ).
Efficacy data from 51 evaluable subjects treated with R2-CHOP showed CR 73%, PR 27%,
ORR 100% ( Table 2 ), and 3-year PFS 65% overall.  The ORR, CR, and PFS compare favorably 
with the matched control cohort Figure 1.&(/*(1(35235,(7$5<,1)250$7,217$760930930$$
1)
23.0%)23.0%
14 (16.1%)4 (16.1%)
53 (60.9%53 (601111
%)%)
0.0.0%)%)
(14(14.5.5%)%7$(7
34 3423
(3(3(3(3cell lymphomell lymphom
B-cell; IPI =cell; IPI =
f the R2he R2 --CHCH
were neutrwere neutr
rade 4), aneade 4), ane
neumneum onia (onia 
0% Grade 30% Grade 3
GGrade 4). rade 4).
fica
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 22 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Although not prospectively planned, subjects were retrospectively subtyped as GCB or non-GCB 
by IHC using the Hans algorithm ( Hans, 2004 ).Table 2 summarizes the phase  2 eff icacy data 
for the overall population and also by GCB vs. non-GCB subtype reported thus far 
(Nowakowski, 2012, Nowakowski 2013 ).  In non-GCB subjects, the ORR and CR were better in 
subjects treated with R2-CHOP when compared with the subjects treated with R-CHOP (ORR 
100% vs 69%; CR 80% vs 50%).  This level of difference was not observed in the GCB subtype.
An updated manuscript was recently published ( Nowakowski, 2015 ).
Table 2: Mayo Clinic Study MC078E Efficacy Results
R2CHOP1
N=55R-CHOP ‚Äúcontrol‚Äù2
N=87
ORR 51/51 (100%) 68/83 (82%)
CR 37/51 (73%) 56/83 (67%)3
PR 14/51 (27%) 12/83 (14%)
GCB
N=31Non-GCB
N=20GCB
N=57Non-GCB
N=26
ORR 31 (100%) 20 (100%) 50 (88%) 18  (69%)
CR 23 (74%) 16 (80%) 43 (75%) 13 (50%)
PR 8 (26%) 4 (20%) 7 (12%) 5 (19%)
NR/PD 0 (0%) 0 (0%) 7 (12%) 8 (31%)
CR = complete response; GCB = germinal center B-cell; NR = no response; ORR = objective response rate; PD = 
progressive disease; PR = partial response ( Nowakowski, 2013 ). 
1Assessment by Cheson 2007 criteria; 4 sub jects were not ev aluable because of refusal (n=3) or death before 
evaluation (n=1)
2Assessment by Cheson 1999 criteria; 4 sub jects unev aluable for response assessment
3Including CR=54, complete response unconfirmed (CRu)=2
&(/*(1(35235,(7$5<,1)250$7,21$7$7$7
%)%)5
3 (67%)(67%3)2
12/83 (142/83 (1)
GCBGCB
N=57N=57<,
50 50($
((((7,(0%)0%)5,,,,
0 0(0%)(0%)2352minal center Bminal center B
sponsesponse ((NowNow
riteria; 4 teria; 4 subjsub
999999criteria; criter
mplete responlete respon
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 23 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Figure 1: Mayo Clinic Study MC078E PFS by Subtype 
GC = germinal center; GCB = germinal center B-cell; ( Nowakowski, 2013 ). 
1.5.2.2. FIL R2-CHOP Data
The Italian cooperative group FIL conducted a pros pectively designed multicenter phase 1/2 
study to evaluate the toxicity and efficacy of lenalidomide plus R-CHOP21 in untreated elderly 
DLBCL subjects, the REAL07 trial. 
The objective of the Phase 1 cohort of the REAL07 trial was to determine the maximum 
tolerated dose of this combination.  Four lenalidomide doses (5, 10, 15, and 20 mg/day on Days 
1-14) using the continual reassessment method were planned in combination with each course of 
R-CHOP for a total of 6 courses. Seven subject cohorts (n=3 each) were treated (total n=21) at 10, 20, 15, 15, 15, 10, and 10 mg of lenalidomide. Dose- limiting tox icities occurred in seven 
subjects during the first three treatment courses. The third dose-level of lenalidomide (15 
mg/day) was selected as the maximum tolerated dose, with an estimated dose- limiting toxicity
probability of 0.345 (95% credibility interval 0.164-0.553). Grade 3-4 h ematologic adverse 
events were: neutropenia in 28% of the courses, thrombocyt openia in 9%, and anemia in 3%. 
Non-hematologic toxicities were moderate: grade 4 increase of creatinine phosphokinase (n=1), grade 3 cardiac (n=2), grade 3 neurologic (n=3), and grade 3 gastrointestinal (n=1). In this phase 
1 study, 90% of subjects achieved an overall res ponse with 81% achieving complete remission.  
It was concluded that this combination is tole rable in elderly DLBCL subjects, and lenalidomide 
given at 15 mg on Days 1-14 of each cycle in combination with standard R-CHOP21 was the 
recommended dosing schedule for Phase 2 study ( Chiappella, 2013a ).  Nine subjects were 
treated at this dosing schedule in the Phase 1 cohort.
Phase 2 of the REAL07 trial was a study to investigate the efficacy of R2-CHOP in CD20+ 
elderly DLBCL or FL grade IIIB subjects.  Key inclusion criteria included age 60-80, Ann Arbor 
stage II-IV, and IPI > 2.  The primary endpoints were ORR and CR rate after 6 courses of R2-
CHOP by using Cheson, 2007 criteria and included PET negativity as a requirement for CR.  The 
secondary endpoints were 2-year OS, 2-year  PFS, and relationship between response and 
ively desigively desi
omide plus mide plu
AL07 triAL07 tri alalll
enalidomidenalidomid
method wermethod w
ven ven subjectsubj
of lenalidoof lenalid
eatment coeatment co
maximum maximu
%credibilitedib
nia inia in 28% %
xiicicititiiiesesww
(n=2),n=2), gradgrad
offsubsubjectsjectbb
cluded thatuded that
t 15 mg on 15 mg on
mmended dmmended 
eated ated at thiat thi
PPhase 2 hase 2
derll0$7,21

Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 24 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019histopathological features.  Subjects were treated with lenalidomide given at 15 mg on Days 1-14 
of each cycle in combination with standard R-CHOP21 for 6 cycles.  Subjects were 
retrospectively subtyped by IHC using the Hans algorithm ( Hans, 2004 ), although this analysis 
was not prospectively planned.  
Forty subjects were enrolled.  The phase 2 cohort data analyses included these 40 subjects plus 9 
subjects from the phase 1 cohort treated at the recommended phase 2 dose/schedule (total N=49).
Table 3 describes the subject baseline characteristics.
Table 3: FIL Study REAL07 Baseline Characteristics
R2-CHOP, N = 49 
Median age (range) 69 (61-79) Bone marrow 17 (35%)
Male 29 (59%) B symptoms 21 (43%)
Stage III/IV 8/35 (16/71%) LDH > normal 22 (45%)
PS >1 31 (63%) IPI IH/H risk 29 (59%)
DLBCL/FLgIIIb 45/3 (92/8%) Œ≤2m > normal 34 (69%)
PS = performance status, DLBCL = diffuse large B-cell lymphoma, FL = follicular lymphoma, LDH = 
lactase dehydrogenase, IPI = international prognostic index, IH = intermediate / high risk, H = high risk, Œ≤2m = beta 2 microglobulin ( Chiappella, 2013b). 
The most significant common hematological toxiciti es recorded in 277 cycles of treatment were 
neutropenia (9% grade 3, 22% grade 4), leukocytopenia (15% grade 3, 13% grade 4), febrile 
neutropenia (3% grade 3, 1%, grade 4), thrombocytopenia (5% grade 3, 7% grade 4), and anemia 
(4% grade 3, < 0.5% grade 4) ( Chiappella, 2013b ).
Table 4 summarizes the response data reported thus far from the REAL07 trial, for the 40 
subjects enrolled in the phase 2 cohort plus 9 subjects from the phase 1 cohort treated at the 
recommended phase 2 dose/schedule (total N=49). The overall results for all 49 subjects showed a CR rate of 86%, ORR 92%, 2-year PFS 73%, and 2-year OS 92%.  
Among these 49 subjects, GCB vs. non-GCB typing assignment was achieved in 34 subjects (17 
subjects with GCB, and 17 subjects with non-GCB) by Hans criteria ( Table 4 ). The CR rate in 
subjects with non-GCB subtype appears to be better than the in G CB subtype s ubjects (88% vs 
76%).  In addition, as was observed in the Mayo Clinic study, among the subjects treated with 
R2-CHOP regimen, the PFS and OS curves of the subjects with the non-GCB subtype appear to be about the same as or better than the GCB subtype subjects, suggesting that adding 
lenalidomide to standard therapy improved treatment outcome in non-GCB subjects who have a 
poor prognosis and typically have a worse outcome to treatment ( Figure 2 ).
An updated manuscript was recently published ( Vitolo, 2014 ).&(/*(1(35235,(7$5<,1)250$7,210 %)%)50505021 (43%)21 (43%)25
22 (4522 (4)2,,,,1<, ormrmal al 5<<<
$5<
yymphoma, mphoma, yyy FF
ndex, IH = inndex, IH =
oxicitixiciti es es rere
ukocykocy topentopenyyy
thrombocythromboc
pellpella, 2013ba, 20
data reportdata repo
2 cohort plu2 cohort p
/schedule (schedule
92%, 292%, 2 --yeay
jectsects, GCB, GCB
B, and 17B, and 17
onon-GCB suGCB 
dditdditioion, as wn, as 
OP regimen,egimen
out the samut the sam
alidolidomide mide 
poor prognpoor progn
n updn upd
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 25 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 4: FIL Study REAL07 Efficacy Results
Total
N=49GCB
N=17Non-GCB
N=17
ORR 45/49 (92%) 15/17 (88%) 15/17 (88%)
CR 42/49 (86%) 13/17 (76%) 15/17 (88%)
PR 3/49 (6%) 2/17 (12%) 0/17
NR 3/49 (6%) 2/17 (12%)1/17 (6%)
NA (death) 1/49 (2%) 0/17 1/17 (6%)
PFS73%1
(95% CI: 57-84)71%2
(95% CI: 43-87)81%2
(95% CI: 53-94)
OS92%1
(95% CI: 79-97)88%2
(95% CI: 59-97)94%2
(95% CI: 65-99)
ORR = overall response rate, CR = complete response, PR = partial response, NR = no response, NA = not 
applicable, PFS = progression free survival, OS = overall survival ( Chiappella, 2013b ). 
1At 2-years
2At 18 months
Figure 2: FIL Study REAL07 PFS and OS by Subtype
A. PFS
&(/*(1(35235,(7$5<,1)250$7,212
5-99)99)22
1)2
= no responno respon
a, 2013b2013b )). . 
SubtypeSubtype

Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 26 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019B. OS
GC = germinal center ( Chiappella, 2013b ). 
1.5.3. Clinical Efficacy Data Conclusion
In summary, the R2-CHOP efficacy data from th e Mayo Clinic MC078E study and the FIL 
REAL07 study compare favorably to historical R-CHOP21 data with a better CR rate at the end 
of induction therapy and better PFS.  Furthermore, promising efficacy results were also 
demonstrated in the non-GCB subtype, which generally has a poorer outcome when treated with R-CHOP alone.  Clinically meaningful improvements as demonstrated by higher CR rate (80% 
in Mayo study, 88% in FIL study, vs 50% in the R-CHOP historical control) and longer PFS 
(18-month PFS of 80% in Mayo study, 81% in FIL study vs 30% in 87 subjects from Mayo Clinic Lymphoma Database who were treated with R-CHOP as matched control) in non-GCB 
DLBCL subjects are considered significant in this  difficult to treat sub-population.  The addition 
of lenalidomide could ameliorate the poor prognosis effect of the ABC phenotype and improve treatment outcome in this subgroup of subjects. 
From a safety perspective, this combinatio n is tolerable, without unexpected toxicities. The 
Grade 3 and 4 toxicities ar e primarily hematological in nature, and manageable with s upportive 
care.    
1.6. Clinical Safety Events of Interest for Lenalidomide
1.6.1. Deep Vein Thrombosis
1.6.1.1. Deep Vein Thrombosis in Multiple Myeloma
Venous thromboembolic events (VTE), such as deep venous thrombosis (DVT) and pulmonary 
embolism (PE), have occurred in  subjects with multiple myeloma treated with lenalidomide 
combination therapy, and in subjects with MDS or lymphoma treated with lenalidomide 
&(/*(1(35235,(7$5<,ayayo Clinic o Clin
CHOP21 dCHOP21
ore, promisre, promi
ch generallych generally
mprovemenmprovemen
0% in % in the
udydy, 81% in, 81% i
were were treattrea
ed significed signific
liorate the orate the
his subgroupis subgrou
pectective, thisive, this
xixicicititiiiies arees ar
ClinicClinic
6.1.1. DD
1.6.1.1..6.1.1)250$7,21

Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 27 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019monotherapy. A significantly increased risk of DVT and PE has been observed in subjects with 
multiple myeloma who were treated with lenalidomide and dexamethasone therapy (see 
Revlimid prescribing information).  Clinical data in multiple myeloma subjects treated with 
lenalidomide suggests that concomitant administration of gluco-corticosteroids or erythropoietin can increase the thrombotic risk. Male gender a nd smoking history have also been reported to 
increase the risk of VTE in myeloma subjects treated with lenalidomide ( Leleu, 2011 ).
In two randomized studies (MM-009 and MM-010) a significantly increased risk of DVT and PE 
was seen in subjects with multiple myeloma who were treated with REVLIMID¬Æ (lenalidomide) 
in combination with dexamethasone (see Revlimid Prescribing Information). In these pivotal 
trials for lenalidomide in subjects with mu ltiple myeloma receiving lenalidomide plus 
dexamethasone, DVT and PE were reported as SAEs in 7.4% and 3.7% of subjects, respectively,
compared to 3.1% and 0.9% of subjects receivi ng placebo and dexamethasone.  The protocols
did not require systematic DVT prophylaxis. An analysis of pooled data from the MM-009 and 
MM-010 studies demonstrated that thromboembolic ev ents were significantly higher in subjects 
treated with lenalidomide/dexamethasone in the absence of prophylactic use of an anticoagulant 
(p < 0.001) ( Dimopoulos, 2009 ). The effect of adding erythropoietin to lenalidomide/
dexamethasone demonstrated a higher, but not statistically significant rate of thrombosis in the 
erythropoietin gr oup 18% versus 10% for the lenalidomide/dexamethasone group without the 
addition of erythropoietin (p =0.14) ( Weber, 2007 ). 
The Eastern Cooperative Oncology Group (ECOG) trial E4A03 evaluated lenalidomide 25 mg 
on Days 1-21 plus high-dose dexamethasone 40 mg on Days 1-4, 9-12 and 17-20 of a 28-day 
cycle (RD) versus lenalidomide plus low-dose dexamethasone 40 mg on Days 1, 8, 15, and 22 
(Rd) in subjects with newly-diagnosed multiple myeloma. Overall, VTEs including DVT and 
PE occurred in 26% of 223 subjects in the RD arm and in 12% of 220 subjects in the Rd arm 
(Rajkumar, 2010 ). DVT prophylaxis was to be used in both arms.
1.6.1.2. Deep Vein Thrombosis in Non-Hodgkin‚Äôs Lymphoma
Factors known to increase thrombotic risk in cancer patients in general, not necessarily those 
receiving lenalidomide, include the underlying disease, family history, immobilization, hormonal therapy, central venous catheter p lacement, recent DVT , doxorubicin and other factors ( Zhou, 
2010; Park, 2012; Lyman, 2013 ).
Venous thrombotic events, including DVT and PE, have been reported in patients during 
treatment for NHL, generally occurring at incidences from ~7% up to 20% ( Komrokji, 2006 ; 
Mohren, 2005 ; Ottinger, 1995 ; Zhou, 2010 ).  The risk is significantly higher for females, patients 
with renal dysfunction or high hemoglobin levels, and patients receiving doxorubicin- or methotrexate-based regimens ( Zhou, 2010 ). Ottinger et al analyzed incidence, risk factors, 
causes and prognostic significance of VTE in high-grade NHL in a prospective clinical trial of 
593 subjects.  They reported a 6.6% incidence of VTE, with 77% of all cases occurring before or within the first 3 months of chemotherapy. Vessel compression by high-grade NHL was 
identified as the leading cause of VTE ( Ottinger, 1995 ).
In lymphoma lenalidomide clinical trials, DVT and PE were reported in 7 (2.6%) and 6 (2.2%) 
of 266 subjects with relapsed or refractory aggressive NHL receiving lenalidomide in clinical 
studies NHL-002 and NHL-003 ( Wiernik, 2008 ; Witzig, 2011 ). In clinical study NHL-001, 
DVT and PE were reported in 0 (0%) and 1 (2.3%) of 43 subjects with indolent relapsed or &(/*(1(35235,(7$5<,1)250$7,21de) e) 
al 
spectivelypectively
e e protocolsprotocols
he MM-he MM- 009009
y higher in y higher in 
e of an ante of an ant
lenalidomnalido
nt rate of thrate of th
methasone gethasone g
4A03 A03 evalueval
Days 1ays 1 --4, 94,
mmethasone 4ethason
myeloma. yeloma. O
arm and rm and in in
o be used in be used in
NonNon--HodgHod
otic risk in otic risk in 
the undethe unde rlrl
terterplacemplacem
, 2013, 2013 ).).
ventsents,,incluinc
,,generallygenerally
OttiOttnger, 1nger, 1i
ysfunctysfunct ioion on o
atee-based rbased r
and prognoand progno
subjects.  Tsubjects.  T
wiwithin the fithin the fii
identdeifiedified
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 28 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019refractory NHL ( Witzig, 2009 ). Antithrombotic prophylaxis was not suggested in NHL-001 or 
NHL-002 but was required for subjects considered to be at high risk of developing DVT in 
NHL-003. In the recent CALGB 50401 Phase 2 study evaluating lenalidomide plus rituximab 
versus lenalidomide single-agent therapy in relapsed FL subjects (N=89), thrombosis was reported in 2 (4%) of 44 subjects in the lenalidomide plus rituximab arm versus 7 (16%) of 45 
subjects in the lenalidomide arm ( Leonard, 2012 ). In a study evaluating lenalidomide plus 
rituximab in relapsed / refractory mantle cell lymphoma (MCL) subjects (n=44), 3thromboembolic events were reported (2 [5%] Grade 3; 1 [5%] Grade 4) after 379 cycles of 
lenalidomide plus rituximab ( Wang, 2012 ).
In two front line DLBCL clinical trials evaluating lenalidomide plus R-CHOP, VTE rates were 
reported.  In REAL07 (n=49), which required LM WH heparin as VTE prophylaxis, the Grade 3 
VTE rate was 2% and the grade 4 rate was 0% ( Chiappella, 2012 ).  In a Mayo Clinic study 
(n=47) which required 325 mg aspirin daily as VTE prophylaxis, the grade 3 VTE rate was 0% and the grade 4 rate was 2% ( Nowakowski, 2015 ).
It cannot be excluded that the risk of VTE is incr eased in the subjects participating in this study 
treated with R-CHOP and lenalidomide. For recommendations on VTE prophylaxis in the present study see Section 9.3.6 .
1.6.2. Tumor Flare Reaction
Tumor flare reaction (TFR) is defined in the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) Versi on 3 as a constellation of signs and symptoms 
of tumor pain, inflammation of visible tum or, hypercalcemia, diffuse bone pain, and other 
electrolyte disturbances in direct relation to initiation of therapy ( Cancer Therapy Evaluation 
Program, 2003 ). 
TFR is an adverse effect of lenalidomide prev iously reported in subjects with CLL ( Chanan-
Khan, 2008a ).  In clinical studies of lenalidomide in subjects with NHL, TFR has also been 
reported, but at a lower rate than in CLL patients ( Corazzelli, 2010 ; Eve, 2010 ; Witzig, 2011 ). 
The clinical manifestations of TFR seen in subjects treated with lenalidomide are similar for 
CLL and lymphoma subjects, and typically occur in  the first cycle.  Symp toms include a sudden 
increase in the size and tenderness of the disease bearing sites, including the lymph nodes, spleen 
and/or the liver, often accompanied by pain and sometimes accompanied by low-grade fever and 
non-pruriti c diffuse rash ( Chanan-Khan, 2008a ; Witzig, 2009 ). The increase in 
lymphadenopathy may be localized or generalized.  In lymphoma patients, TFR is not usually 
accompanied by lymphocytosis.  The onset of TFR has been as early as within a few hours after 
the first dose, but in the vast majority of cases is within the first 2-3 weeks of the first cycle
(Witzig, 2009 ).  Tumor flare reaction can recur to a le sser extent if the dose is increased ( Witzig, 
2009 ). Based on experience in Celgene-sponsored clinical studies, TFR subsides over time and 
usually resolves in 1-2 weeks with or without intervention ( Witzig, 2009 ).
TFR data on single-agent lenalidomide in over 400 subjects with relapsed or refractory 
aggressive or indolent NHL who received lenali domide in four Celgene sponsored Phase 2 
clinical studies (NHL-001, NHL-002, NHL-003, and MCL-001) are now available.  These werePhase 2 multicenter, single-arm, open-label studi es that evaluated lenalidomide 25 mg/day for 21 
days of a 28-day cycle. In NHL-001 there were 43 previously treated subjects with indolent 
NHL ( Witzig, 2009 ), in NHL-002 49 subjects with relapsed/refractory aggressive NHL &(/*(1(35235,(7$5<,1)250$7,21were were 
e G Grade 3 rade 3 
ic studyic study
TE rate wasTE rate was
ticipating iicipati
TE prophylaE prophyl
cer Instcer Inst itituu
as a constels a constel
calcalcemia, dcemia,
tion of therion of the
previouslypreviously
nalidoalido mide mide
CLL patCLL pat ieien
R R seen in seen in 
and tyand ty picalpicayyy
dernessernes ofoftf
cocompaniedpani
ash (ash ( ChanaChan
mmayay b bye le lococ
y lymphocyy lymphocy
, but in the, but in the
200909).  .  TumTum
Based on Based on 
ally resoally reso lvelve
TFRTFR datadata
aggressggress
i
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 29 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019(Wiernik, 2008 ), in NHL-003 217 subjects with relapsed/refractory aggressive NHL ( Witzig, 
2011 ), and in MCL-001 134 subjects with MCL ( Goy, 2012 ).  Tumor flare reaction occurred in 4 
subjects (Grade 1 [n = 1] and Grade 2 [n = 3]) in the NHL-001 study ; none in the NHL-002 
study; 7 of 217 subjects in the NHL-003 study (Grade 1 [n = 2], Grade 2 [n = 2] and Grade 3 [n = 3]); and 13 of 134 subjects in the MCL-001 study (Grade 1 [n = 7], and Grade 2 [n = 6]).  The
data from these protocols suggested that subjects experienced TFR during the first 1 to 2 weeks 
of Cycle 1 and that the TFR may be treated symptomatically with non-steroidal anti-
inflammatory drugs (NSAIDs).  
In a single-center, open-label Phase 2 investigator initiated study, Ahmadi et al evaluated the use 
of lenalidomide, dexamethasone and rituximab (cohort 1) versus lenalidomide plus rituximab (cohort 2) in subjects with relapsed or refractory  indolent B-cell or MCL re sistant to rituximab 
(Ahmadi, 2011 ).  Tumor flare was reported in 12 (5 in cohort 1 and 7 in cohort 2) of the 45 
subjects (MCL and FL).
It is important to note that the increased lymphadenopathy seen in TFR may mimic progressive 
disease (PD).  Therefore, careful monitoring and evaluation to differentiate TFR from PD is 
necessary for addressing treatment of individual s ubjects including making decisions whether to 
discontinue treatment ( Chanan-Khan, 2008b ). There are currently no laboratory or radiological 
tests that distinguish TFR from PD. The distinction may be made on clinical grounds, 
incorporating observations such as timing of the event relative to the start of lenalidomide, associated physical findings, laboratory findings, a nd pace of disease before and after institution 
of lenalidomide treatment. Also, in the case of TFR, inflammation and edema may be reduced or 
disappear after short-term tr eatment with NSAI Ds and/or corticosteroids.
1.6.3. Tumor Lysis Syndrome
Tumor lysis syndrome (TLS) is a well-known constellation of metabolic abnormalities resulting 
from spontaneous or treatment-related tumor necrosis or fulminant apoptosis. The metabo lic 
abnormalities include: hyperkalemia, hyperuricemia and hyperphosphatemia with secondary 
hypocalcaemia with risk of renal failure. TLS has been reported in subjects receiving rituximab 
plus lenalidomide, and rituximab plus chemotherapy.
The presence of known risk factors such as bulky disease, pre-existing (moderate) renal 
insufficiency, high ALC and high uric acid levels (> 8 mg/ dL) prior to therapy are known to 
increase the likelihood of TLS.  Early  identification of subjects at risk, initiation of prophylactic 
measures, as well as the careful monitoring for early signs of laboratory TLS, and prompt 
initiation of supportive care are critical to prevent potentially life-threatening metabo lic 
derangements ( Cairo, 2010 ).  
The experience with tumor lysis syndrome in Celgene-sponsored studies of single-agent
lenalidomide in NHL is summarized below.  Four Phase 2 multicenter, single-arm, open-label 
studies evaluated lenalidomide 25 mg/day for 21 days of a 28-day cycle: NHL-001 in 43 previously treated subjects with indolent non-Hodgkin lymphoma ( Witzig, 2009 ), NHL-002 in 
49 subjects with relapsed/refractory aggressive NHL ( Wiernik, 2008 ), NHL-003 in 217 subjects 
with relapsed/refractory aggressive NHL ( Witzig, 2011 ), and MCL-001 in 134 subjects with 
relapsed/refractory MCL ( Goy, 2012 ).  All four protocols suggested that subjects receive TLS 
prophylaxis (allopurinol or equivalent) and be well hydrated during the first 7 days of &(/*(1(35235,(7$5<,1)250$7,21e use use
mab mab
tuximab uximab 
of the 45 f the 45 
mimic mimi propr
te TFR froe TFR
aking decisiking decis
no laboratono labora
de on clinicde on clinic
e to the stare to the st
of disease f disease
lammatlammat ioionn
d/or corticd/or cor
wn constellwn conste
mmor necroor nec
hyperuricehyperu
ailure. TLSailure. TLS
ab plb plus chemus chemll
k factors sufactors s
and high uand high
d of TLS.  d of TLS
as the carefas the caref
portive carportive car
ts (ts (CaiCairo, 2ro, 2iii
erience withnce wi
dodomide in Nmide in 
diies evaluaes evalua
previouslypreviously
49 subje9 subj
h
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 30 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019lenalidomide administration in the first cycle or as clinically indicated. Grade 1 TLS occurred in 
1 of the 433 (< 0.3%) subjects receiving lenalidomide. 
In an investigator initiated study, a single-cen ter, open-label Phase 2 study, Dutia et al ( Dutia, 
2010 ) evaluated the use of lenalidomide and rituximab in subjects with relapsed or refractory 
indolent B-cell NHL.  Two of the first 4 subjects treated using the lenalidomide dose of 25 mg 
developed TLS.  Thus, the lenalidomide dose wa s reduced to 20 mg and allopurinol prophylaxis 
was used in all subsequent subjects with no further TLS events recorded.  
For recommendations on TLS prophylaxis in the present study see Section 9.3.5 .
&(/*(1(35235,(7$5<,1)250$7,21
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 31 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20192. STUDY OBJECTIVES
2.1. Primary Objective
The primary objective of the study is to compare the efficacy of R2-CHOP versus placebo-R-
CHOP.
2.2. Secondary Objective
The secondary objective of this study is to comp are the safety of R2-CHOP versus placebo-R-
CHOP.  
 
&(/*(1(35235,(7$5<,1)250$7,21-
250)251)21),1)
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 32 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20193. STUDY ENDPOINTS
3.1. Primary Endpoint
!Progression-free Survival (PFS)
3.2. Secondary Endpoints
Key secondary endpoint
!Event-free Survival (EFS)
Other secondary endpoints
!Overall Survival (OS)
!Complete Response (CR) rate 
!Duration of CR
!Time to next lymphoma therapy (TTNLT)
!Objective response rate (ORR)
!Health-related quality of life (HRQoL) as measured by the E uroQol 5 D imension 
Scale (EQ-5D) and the Functional Assessment of Cancer Therapy for Patients with 
Lymphoma (FACT‚ÄìLym) standardized measures of health status
 
&(/*(1(35235,(7$5<,1)250$7,21ed byd by the Euthe y
of Cancer Tf Cancer
ures of heres of h
535,235523352(3 5
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 33 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20194. OVERALL STUDY DESIGN
4.1. Study Design
This randomized, pl acebo-controlled study is designed to evaluate the efficacy and safety of R2-
CHOP chemotherapy versus placebo-R-CHOP ch emotherapy in subjects with previously 
untreated CD20+, ABC type DLBCL. Stratification fo r randomization will be employed to 
reduce bias related to subject IPI score, presence of bulky disease, and age. Rando mization in 
this parallel treatment design is in a 1:1 ratio to either R2-CHOP or placebo-R-CHOP.  Celgene, 
as well as the investigator and subject, will be blinded to treatment assignment.  
This study is divided into Screening ( 4.1.2 ), Treatment ( 4.1.3 ) and Follow-up Periods ( 4.1.7 ).  
Details of the study treatments are described in Section 8.
Approximately 560 subjects will be rando mized.  Sub jects who discontinue or withdraw from the 
study will not be replaced. There is one planned interim analysis for futility at 50% i nformation
level and one planned final analysis for superiority.  See Section 10for a detailed description of 
Statistical Analyses.
The study will be conducted in comp liance with Good Clin ical Practice (GCP).
 
 
 
  
 
 
 
4.1.2. Screening Period
Screening for eligibility determination may begin after the subject signs the informed consent
form.  All screening assessments must be completed within 28 days prior to Cycle 1 Day 1.  The 
only exceptions to the 28-day time period are for the lymph node/tumor biopsy and the bone marrow biopsy/optional aspirate, which may occ ur up to 8 weeks prior to C1D1; and the PET 
and CT scans, which may occur up to 6 weeks prior to C1D1.
During the Screening Period, subjects will undergo safety and other assessments to determine 
eligibility for the study as shown in Section 5Table of Events and as described in detail in 
Section 6Procedures.  If subject eligibility is confirmed, then rando mization via the inter active 
voice response system (IVRS) is the fi nal part of the Screening Peri od.  Pre-sp ecification of
optional therapies such as the extra two dos es of single agent rituximab or consolidation 
radiotherapy will also be registered in IVRS prior to randomization.
Key aspects of screening include Central Pathology assessment of disease diagnosis, typing by 
GEP, and CD20+ status; local assessmen t of bone marrow involvement by lymphoma; &(/*(1(35iodd
y y determindetermin
g assessmeng assessme
o the 28o the 28 --dd
y//optioptional onal
ans, which ns, which 
g the Screeng the Screen
ibilitibilit y yfofor trt
ectiectionon66PP
vovoice resice r
tiion5235,(7$5<,1)250$7,21ne, e, 
4.1.7.7).  ).  
itithdrhdraw faw frrfff
t t50%50 infoinfo
detailed desetailed des
tice (GCP)ce (GC
$5<7$5(7$,(75,(35,2352352
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 34 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019documentation of measurable disease by CT scan; co llection of a PET scan; and verification of 
adequate liver, renal, cardiac, and bone marrow function.  
4.1.3. Treatment Period
The Treatment Period begins with the first dose of lenalidomide/placebo or of the chemotherapy 
drugs as described in Section 8.  Subjects will receive protocol -specified treatments for 6 cy cles, 
and if standard of care per local practice, may  also receive two additional doses of single agent 
rituximab if pre-specified in IVRS prior to randomization.  Treatment will continue to completion, or until the outcome of the Midcyc le CT scan (once between Weeks 9 ‚Äì 12 which is 
after Cycle 3 but before Cycle 4) indicates a tr eatment change; diseas e progression; unacceptable 
toxicity; death; or withdrawal of consent, whichever occurs first. 
In order to manage toxicity and allow subjects  to complete 6 cycles of treatment, dose delay and 
modification rules will be followed (Section 8).  Key aspects of ongoing safety monitoring 
include physical exam, AE assessment, and hemato logy/chemistry laboratory testing prior to the 
initiation of every cycle, and at additional time points as shown in the Table of Events, Table 5 .
Key aspects of ongoing efficacy assessment include: CT scans at Screening, Midcycle (once 
between Weeks 9 ‚Äì 12 which is after Cycle 3 but before Cycle 4), once between 3 ‚Äì 4 weeks 
after completing Cycle 6, and in follow-up at specified time points; and PET scans at Screening 
and once 3 ‚Äì 4 weeks after completing Cycle 6.  A subject‚Äôs withdrawal from study treatment 
due to the outcome of the Midcycle CT scan or for disease progression will be based upon investigator assessment. However, the response evaluation 3 ‚Äì 4 weeks after completing cycle 6 
will be based on real time IRAC review per Section 4.1.5 .
4.1.4. Treatment Decisions Based on Midcycle CT Scan
Following the Midcycle CT scan, it is acceptable to  change therapies if the CT shows evidence 
of lack of response or progression.
Only a CT scan is required for the Midcycle assessment.  If a combined PET-CT is performed, 
measurements, response assessment, and treatment decisions should be based on the diagnostic 
quality CT portion of the PET-CT scan.  If a combined  PET-CT without contrast is performed, 
then progression may not be scored on PET positivity alone, but must be confirmed by CT with 
contrast or a biopsy of the PET positive lesio n.  As noted by the ICML Imaging Working Group, 
the positive predictive value of an interim PET in DLBCL is variable; therefore, the decision to 
change therapies solely on the basis of Midcycle PET is not recommended, unless there is clear 
evidence of progression ( Barrington, 2014 ).
4.1.5. Treatment Decisions Based on End of Treatment CT and PET Scans
After Cycle 6, response will be evaluated in real t ime by Central Radiology and this evaluation 
should guide immediate decisions regarding the subject‚Äôs next treatment.  The radiological 
assessment schedule is the same for all subjects , regardless of whether the optional two doses of 
single agent rituximab are administered.  Therefore, the CT and PET scans required at 3 ‚Äì 4 
weeks after completing Cycle 6 must be completed before the optional Cycle 7 dose of rituximab 
is administered.  The scans acquired 3 ‚Äì 4 weeks after Cycle 6 should be forwarded immediately 
to Central Radiology.  All prior scans should be  sent to Central Radiology at that time if for 
some reason they were not forwarded already.&(/*(1(35235,(7$5<,1)250$7,21h is h is
ceptable eptable 
dose delay aose delay a
mmonionitoringtoriii
yy testing pr testing pyy
le of Evenle of Even
eeningening , MidMid
once betweonce betw
ntsnts; and PE; and PE
withdrawalwithdrawa
e progressiprogressi
atatioion n 3 ‚Äì 4 3 ‚Äì 4 
4.1.54.1.5 .
idcdcycle CTycle CT
eptable to ceptable to c
Mididcycle aycle a
ment, and trment, and tr
-CT scanCT scan
e scored oscored o
hhe PETe PET pop
eevalue ofvalue o
oolely on thlely on th
ogressionogression (B
TreatmeTreatme
Cycle 6, reCycle 6, 
oululd guide d guide 
assessmenssessmen
ingle aingle a
k
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 35 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019If a combined PET-CT is performed, measurements, response assessment, and treatment 
decisions should be based on the diagnostic qu ality CT portion of the PET-CT scan. If a 
combined PET-CT without contrast is performe d, then progression may not be scored on PET
positivity alone, but must be confirmed by CT with contrast or a biopsy of the PET positive
lesion.  The same modality should be used throughout all post-baseline assessment time-points
for a given subject if possible.
4.1.6. End of Treatment Date
The End of Lenalidomide/Placebo Date is defined as the date of Cycle 6 Day 21 for subjects who 
complete 6 full cycles of lenalidomid e/placebo treatment per protocol; or  it is the date either the 
investigator or subject decided to permanentl y discontinue lenalidomid e/placebo treatment. The 
End of R-CHOP Date is defined as the date of Cycle 6 Day 21 for subjects who complete 6 full 
cycles of R-CHOP treatment per protocol; or it is the date either the investigator or subject 
decided to permanently discontinue R-CHOP treatmen t. The optional, extra 2 doses of rituximab 
do not extend the End of R-CHOP Date.  Study treatment includes both lenalidomide/placebo 
and R-CHOP, and these may be completed or discontinued at different times.  Therefore, the End 
of Treatment Date is defined as the later d ate of either End of Lenalidomide/Placebo or End of 
R-CHOP.  
4.1.7. Follow-up Period  
The Follow-up Period for each subject begins immediately after their End of Treatment Date; 
this rule applies to allsubjects.  This includes subjects who complete the full course of treatment,
who complete the full course of treatment plus the 2 extra dose of rituximab, who discontinue treatment due to progression or toxicity, as well as  those who discontinue before progression to 
pursue a new antilymphoma/salvage therapy (chemo therapy, SCT, radiotherapy, etc.).  Note that 
a subject receiving the 2 extra doses of rituximab would be in the Follow-up period during receipt of the last 2 rituximab doses.  Subjects  will be followed for fi rst and sec ond progressions,
subsequent antilymphoma therapies, develop ment of SPMs, and overall survival according to the 
schedule described in Table 5 . CT scans continue at the protocol specified time points until first 
progression and must be submitted to Central Radiology.  
If a combined PET-CT is performed, measurements, response assessment, and treatment 
decisions should be based on the diagnostic quality CT portion of the combin ed PET-CT scan.  If 
a combined PET-CT without contrast is performed, then progression may not be scored on PET
positivity alone, but must be confirmed by CT with contrast or a biopsy of the PET positive
lesion.  
After the 12 Apr 2019 primary analysis, subjects will only be followed for SPM and OS data 
collection.
 
 
 
 &(/*(1(35235,(7$5<,1)250$7,21 who wh
her the er the 
mmenten. The The
mplete 6 fulmplete 6 fu
or subject or subject 
2 doses of rdoses of r
alidoalido mide/mide
imes.  Themes.  T
oomide/Plamide/Pla
ely aftery after tht
s who comps who com
2 extra dos2 extra dos
as those was those 
(chem(chem othothee
uximab wouximab wo
ubjects wilbjects wi
develdevel opmopm
T scans conT scans co
itted to ted to CCen
performed,rformed,
ed on ed on thhe de
T without cowithout c
but mbut m ust beust bemm
12 Apr 201 Apr 201
oon.n
&((/&(&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 36 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20194.1.9. Independent and Central Assessment Committees
A Data Monitoring Committee (DMC) composed of oncologists and a biostatistician, who are all 
independent of and external to Celgene, will review ongoing safety data throughout the study
according to the DMC charter, and may review interim efficacy data for fut ility.  The DMC w ill 
make recommendations regarding the continuation of the study, potential amendments, or 
necessary safety measures.  
An IRAC will review all CT and PET scans and relevant clinical data for efficacy assessment 
using the IWG Response Criteria for NHL ( Cheson, 2014 ).  Their retrospective, batched review 
will be the basis for efficacy e ndpoint calculations.  Addition ally, the IRAC will perform a real 
time review of scans collected 3 ‚Äì 4 weeks after Cycle 6.  Otherwise, eligibility assessment for 
inclusion criterion number 4for measurable disease and response assessment will also be 
performed locally by the invest igator and will guide enrollment and treatment decisions.  
A Central Pathology laboratory will perform sc reening testing of lymph node / tumor biopsy 
samples to determine disease diagnosis, ABC versus GCB type, and CD20+ status.  Their review 
will serve as the basis for determining eligibility for inclusion criterion number 1and exclusion 
criterion number 2.
A Central Laboratory will perform hematology and chemistry testing of screening and on-study 
subject blood samples.  Their results will be the basis for safety endpoint calculations.  Central 
safety laboratory data will also be the primary guide for eligibility and subject management.  However, local laboratory results may be used to guide clinical decisions and dose 
modifications, and if used, those data will also be collected.  
4.2. Study Design Rationale
The worldwide standard of care in front line, advanced stage DLBCL is R-CHOP on a 21 dayschedule for 6 ‚Äì 8 cycles; this includes such countries as the US ( NCCN, 2013 ), Canada 
(Cheung, 2007 ), Japan ( Ishizawa, 2007 ), China ( Lin, 2005 ), and countries in Europe ( Feugier, 
2005 ; Ghielmini, 2013 ; Tilly, 2012 ).  Therefore, R-CHOP is the control arm drug selection.
The local standard practice in some countries / investig ative sites is to give a total of 8 cycles of 
rituximab.  Therefore in order to accommodate local practice in this global study, investigators may choose to give two additional doses of single agent rituximab at the end of the 6 cycles of 
R2-CHOP or placebo-R-CHOP induction therapy. However, to minimize bias, investigators are 
required to pre-specify this opt ion in IVRS be fore rando mization. 
As discussed in Section 1.5, the PFS data from the REAL07 and Mayo Clinic studies, both in 
front line DLBCL GCB and non-GCB subtypes, are the basis for evaluating R2-CHOP in the 
present study ( Chiappella, 2012; Nowakowski, 2015 ).  The 3-year PFS rate of 65% for non-GCB 
subjects treated with R2-CHOP shown by th e Mayo Clinic suggests that R2-CHOP is 
particularly active in the non-GCB subject group ( Nowakowski, 2015 ), and is the basis for 
selecting only the ABC type of DLBCL for this study.
The REAL07 study in subjects aged 60 - 80 years tested lenalidomide at 15 mg on Days 1 ‚Äì 14 
per 21-day cycle whereas the Mayo Clinic study in subjects 18 or older tested lenalidomide at 25 
mg on Days 1- 10 per 21-day cycle.  Both studies  treated s ubjects for 6 cycles and required 
pegfilgrastim prophylaxis for neutropenia and also required DVT prophylaxis.  A comparison of &(/*(1(35235,(7$5<,1)250$7,21w w
real real 
ent tfofor r
o be o be 
isiosions.  ns.  
/ tumor bio/ tumor bi
+ status.  T+ status.  T
numbermber 1a
ting ongi f sscrec
ty endpoty endpo int
gibiliibilitytyiiananyyd
clinical decinical de
ected.  ected.  
e, advanced, advance
uch countruch coun
0707), China (), Chi
)).  Therefo Therefo
soome me councou
der to accomer to acco
additad ioional dna
-R-R-CHOP CHO
ecify this cify this opop
nnSectSectioonn1
LBCL LBCL GCGC
studydy((ChiaChi
ctcts treated ws treated 
rtiicularly accularly a
selectelec ing oing o
he heRERE
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 37 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019the most common, Grade 3 and 4 hematological toxicities of neutropenia, thrombocytopenia, 
anemia, and febrile neutropenia suggests that the 15 mg schedule is better tolerated ( Chiappella,
2012 ;Nowakowski, 2015 ) and is the basis for the lenalid omide dose and schedule selected for 
this study.
Progression-free survival was selected as the study primary endpoint because it is a measure of 
clinical benefit most acceptable to regulatory authorities.  PFS in the ITT population will be
assessed by independent, centralized review.
Event free survival was selected as a key seconda ry endpoint because it is a measure of clinical 
benefit well accepted by clinicians in this diseas e setting. EFS captures information on what is 
considered failure of frontline chemotherapy (ie., R-CHOP), namely inadequate response such as stable disease or failure to achieve PET-negativity that often requires change in therapy and start 
of salvage therapy.  On the other hand, the PFS endpoint does not capture such change in therapy 
as a PFS event. Depending on the exact defini tion of PFS, a subject who has inadequate 
response to front line therapy and thus changes to salvage therapy would either be censored or be 
recorded as not having a progression, requiring continued follow-up through subsequent lines of 
therapy until an actual progression of  disease (tumor enlargement) is recorded.  It is of note that 
in a recent meta-analysis of several clinical trials , both 3-year PFS and 3-year EFS were highly 
correlated with difference in 5-year OS (r
sof 0.90 [95% CI 0.73 ‚Äì 0.96] ( Lee, 2011 ). 
The IWG response criteria were selected to provide an international standard for the assessment 
of lymphoma ( Cheson, 2014 ).  The use of this established tool and an IRAC will ensure that data 
across centers are evaluated consistently and will also allow for comparison to historical data.  
&(/*(1(35235,(7$5<,1)250$7,21al 
at iis s 
se such ase such a s 
apypyand starand sta
ange in thenge in th
nadequate adequate
hher be censer be cen
ugh subseqgh sub
ecorded.  ecorded.  ItI
and 3and 3 -year yea
‚Äì0.96] (0.96] ( LeL
natnatioional stanal st
tool and atool and a
allow forallow for c
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 38 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Figure 3: Overall Study Design
Screening Period    Treatment Period Follow Up Period
Day -28 to -1
Informed 
Consent
Central 
Pathology 
assessment of 
disease and 
subtype; 
eligibility 
review; 
stratification 
(IPI, bulky 
disease, age); 
and
randomizationLenalidomide + R-CHOP21
x 6 cycles*Follow for first 
and second 
progressions, 
OS, subsequent 
antilymphoma 
therapy, and 
SPM**Placebo + R-CHOP21
x 6 cycles*ABC
GCB, 
unclassifiable
Ineligible
IPI= international prognostic index, ABC= activated B-cell, GCB= germinal center B-cell, OS=overall survival, SPM= second 
primary malignancy*It is permissible to administer an additional two dose s (1 dose per 21-day cycle) of single agent rituximab 
after the 6 cycles of study treatment are complete if it is considered standard of care per local practice.  
However, the decision to administer these extra two doses must be pre-specified in IVRS prior to 
randomization.   
Study treatment will continue until 6 cycles of treatment are complete; or until unacceptable toxicity; or until 
the outcome of the CT scan conducted once between weeks 9-12 (after Cycle 3 but before Cycle) indicates a 
treatment change based on response assessment; disease progression; or withdrawal of consent; whichever 
occurs first.
** All subjects who discontinue treatment and who maintain consent, will proceed directly to the Follow-up 
Period.  This includes subjects who complete the full course of treatment, who discontinue treatment due to 
progression or toxicity, as well as those who discontinue before progression to pursue a new antilymphoma 
therapy (chemotherapy, SCT, radiotherapy, etc.).  During the Follow-up Period scans continue at protocol specified time points until first progression and are submitted to central radiology.   
Subjects who are alive after the 12 Apr 2019 primary analysis will still be followed exclusively for second 
primary malignancies and survival for up to 5 years from the date the last subject is randomized.5235,(7$5<,1)250$7,211)2)250)250ollow fwor ff
and s
prog
1)
<, 1<, 1
523552355252
&(/*(1(35252r an additi
atme
to administe
t will continu
of the CT s
t change bas
st
subjects who
Period.  This
progress
herap
spe
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 39 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20194.3. Study Duration
The primary analysis will occur when the requi red 192 PFS events (progressions / deaths) in the 
ITT population have occurred, which is approximately 42 months from the start of enrollment.  
After the primary analysis, those subjects who are alive will st ill be followed exclusively for 
second primary malignancies and survival for up to  5 years from the date the last subject is 
randomized. Therefore, the study duration is approximately 8 years (34 month accrual period + 5 
years SPM follow-up).  See Section 10.3.
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
study, or the date of receipt of the last data point from the last subject that is required for 
primary, secondary  analysis, as pre -specified in the protocol and/or the 
Statistical Analysis Plan, whichever is the later date.
&(/*(1(35235,(7$5<,1)250$7,21e 
the 
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 40 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20195. TABLE OF EVENTS
Table 5: Table of Events
Screening Period Treatment Period Follow-up Period
Day -28 to Day -1Cycles 1-6
Day 1
(+/- 3 days)Cycles 1-2 
Day 8
(+/- 3 days)End of Treatment Visit
(+/- 3 days)Weeks 34,46, 58, 70, 82, 
94, 106, 118, 130, 142, 154 
(¬± 1 week);  180, 206, 258, 
310 (¬± 2 weeks) until first 
progression
Informed Consent X
Complete Medical History X
Central Nervous System (CNS) Lymphoma EvaluationX
Hepatitis B Virus (HBV) Testing X
Hepatitis C Virus (HCV) Testing X
Creatinine Clearance (CrCl) X
Body surface Area (BSA) 
CalculationX
Electrocardiogram (ECG) X
Multiple Gated-Acquisition Scan 
(MUGA) / EchocardiographyXX
Saliva Sample X
Lymph Node / Tumor BiopsyWithin 8 weeks
prior to C1D1
Submit Lymph Node / Tumor 
Biopsy to Central PathologyX
Inclusion / Exclusion Criteria 
Review X
Detailed information for each row, if applicable, is provided in Section 6.
&(/(/*(1(35235,(7$5<,1)250$7,21CelCelgene Cgene C
21
0$0$0$0$
Treatmentreatment VV
(+/(+/--3 days3 da50
1
<,5<$5$5$5$5$57$$$$
(75,3523333
5235(3eekseks
C1D11D1(3(3(3(3
XX1(
X*(
(/(/(/(/*w, if applicaw, if applica
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 41 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 5: Table of Events (Continued)
Screening Period Treatment Period Follow-up Period
Day -28 to Day -1Cycles 1-6
Day 1
(+/- 3 days)Cycles 1-2 
Day 8
(+/- 3 days)End of Treatment Visit
(+/- 3 days)Weeks 34,46, 58, 70, 82, 94, 
106, 118, 130, 142, 154 (¬± 1 
week);  180, 206, 258, 310 
(¬± 2 weeks) until first 
progression
Pre-specify Optional 
Consolidation Radiotherapy
and/or Additional RituximabX
Randomization X
Modified Cumulative Illness 
Rating Scale (subjects >80 years)X
Physical Examination X X  X X
X
Required until the            
12 Apr 2019 primary 
analysisVital Signs X X X X
Complete Blood Count (CBC) 
with DifferentialXX X X
Lactate Dehydrogenase (LDH) X X X X
Serum Chemistry X X X X
Thyroid Stimulating Hormone 
(TSH)XX
Serum Immunoglobulin X X
Lenalidomide Counselling X X
Pregnancy Testing - for FCBP 
with Regular or No Menstrual 
Cycles24 hours prior to 
lenalidomide/placebo 
dosing, and once 
during day -10 to -14Weekly during first 28 days; 
every cycle on Day 1 thereafterAt End of Lenalidomide/Placebo
and at 28 Days after End of 
Lenalidomide/Placebo
Pregnancy Testing- for FCBP 
with Irregular Menstrual Cycles24 hours prior to 
lenalidomide/placebo 
dosing, and once 
during day -10 to -14Weekly during first 28 days; 
every cycle on Days 1 and 14 
thereafterAt End of Lenalidomide/Placebo 
and at both 14 and 28 days after 
End of Lenalidomide/Placebo
Detailed information for each row, if applicable, is provided in Section 6.
&(/(/*(1(35235,(7$5<,1)250$7,21CelCelgene Cgene C
21
FollowFollow7,2
VisitVisit
s)s)Weeks Weeks
106, 10
ww$70$
25
1),1
5<$5$5$5$5$5 XX7$$$$
XX(7XX5,(353535353523333
XX523to o 
lacebo lacebo
nd dononce ce 
ayy--yy10 to 10 to -14-143335(3
hours prior thours prio
nalidomide/pnalidomide/p
dosingdosing , anan
during dauring d(1
(//(/(/*ow, if applicow, if applic
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 42 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 5: Table of Events (Continued)
Screening Period Treatment  Period Follow-Up Period
Day -28 to Day -1Cycles 1-6
Day 1
(+/- 3 days)Cycles 1-2 
Day 8
(+/- 3 days)End of Treatment Visit
(+/- 3 days)Weeks 34,46, 58, 70, 82, 
94, 106, 118, 130, 142, 154 
(¬± 1 week);  180, 206, 258, 
310 (¬± 2 weeks) until first 
progression
Quality of Life Assessment X Once between Weeks 9‚Äì12, 
(after Cycle 3 but before Cycle 
4) 
Once 3 ‚Äì 4 weeks after 
completing Cycle 6
(Prior to optional Cycle 7 
rituximab)X
Required until the 12 Apr 
2019 primary analysisPerformance Status X
At Midcycle 
Computed Tomography (CT) 
Neck, Chest, Abdomen, PelvisWithin 6 weeks prior 
to C1D1
Response Assessment (Cheson, 2014 )
Positron Emission 
Tomography (PET) of Neck, 
Chest, Abdomen, PelvisWithin 6 weeks prior 
to C1D1
Bone Marrow BiopsyWithin 8 weeks prior 
to C1D1Procedure is dependent on the 
post Cycle 6 PET scan results and 
is required only if Bone Marrow 
Biopsy is positive at Screening, 
and there is an equivocal post 
Cycle 6 PET scan finding in the 
bone marrow
Bone Marrow Aspirate (optional)Within 8 weeks prior 
to C1D1
Detailed information for each row, if applicable, is provided in Section 6.
&(/*(1(35235,(7$5<,1)250$7,21CelCelgene Cgene C
21
FollowFollow -UU7,2
isitsit
))Weeks 3Weeks 
94, 1094, 1
(¬± 1(¬± 1
3$70
Once 3ce 
coco
(P(25
$$7$77
5,(35
r 2333
(33
n n 8 weeks8 week pr
to to C1D1C1D11
*(
row, if applicrow, if applic(/*(
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 43 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 5: Table of Events (Continued)
Screening Period Treatment  Period Follow-Up Period
Day -28 to Day -1Cycles 1-6
Day 1
(+/- 3 days)Cycles 1-2 
Day 8
(+/- 3 days)End of Treatment Visit
(+/- 3 days)Weeks 34,46, 58, 70, 82, 
94, 106, 118, 130, 142, 154 
(¬± 1 week);  180, 206, 258, 
310 (¬± 2 weeks) until first 
progression
Administer Investigational Product (IP) ‚Äì Start CycleX
(¬± 1 day)
IP Accountability and
ComplianceXX
Administer Mandatory 
Primary Neutropenia 
Prophylaxis(1-3 days after 
chemotherapy
or per local 
practice;
details in 
Section 8.2.3 )
Tumor Lysis Syndrome (TLS) 
AssessmentCycles 1 - 2
(same day as 
dosing)X
(¬± 1 day)
Adverse Event
After signing the informed consent document through 28 days after last dose, which includes the 
optional two additional doses of single agent rituximab, if administered. Concomitant Medications / Procedures
Subsequent Antilymphoma therapy and Progression After signing the informed consent document until the subject has died, revokes consent, or until the 12 Apr 2019 primary 
analysis, whichever occurs first.
Assessment of Second Primary 
Malignancy (SPM)After signing the informed consent document until the subject has died, revokes consent, or for up to 5 years from the date the  
last subject is randomized, whichever occurs first.
Survival Information
Detailed information for each row, if applicable, is provided in Section 6.
&(/**(1(ng the informthe inform( 35235,(7$5<,1)250$7,21CelCelgene Cgene C
21
FollowFollo U7,2
VisitVisit
s)s)WeeksWeek
94, 194, 
(¬±(¬±$70$
25
XX1)
<,
$5
XX
(¬± 1 da(¬± 1 da(7
3ent documenent docum
itional dosesitional dos3335
nformed conformed co5
(
*(f applicable, applicable, 
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 44 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20196. PROCEDURES
Informed Consent must be obtained prior to performing any procedures specifically for this 
study that are beyond standard of care.  The s ubject may withdraw consent at any time for all or 
certain aspects of the study as follows:
1. Withdraw consent for study treatment, but allo w Follow-up Period assessments and data 
collection on subsequent antilymphoma  therapy, PFS , SPM, and survival 
information.
2. Withdraw consent for study treatment and Follow-up Period assessments, but allow data 
collection on subsequent antilymphoma  therapy, PFS , SPM, and survival 
information.
3. Withdraw all consent.
Central Nervous System (CNS) Lymphoma Evaluation will be performed at Screening.  CNS 
involvement should be considered if paranasal sinus, testicular, epidural, or bone marrow sites 
are involved, or if there are ‚â• 2 extra-nodal sites and elevated LDH.  If CNS lymphoma is 
deemed possible by the investigator, then the sub ject is required to have a negative cerebrospinal 
fluid (CSF) cytology examination, and a head CT or MRI during Screening.  Refer to Section 
9.3.1 for permitted, concomitant CNS prophylaxis treatment.
Hepatitis B Virus (HBV) Testing will be pe rformed at Screening by the Central Laboratory and 
includes hepatitis B surface antigen (HBsAg), antibody to the hepatitis B surface antigen (anti-
HBs), and antibody to the hepatitis B core antigen  (anti-HBc).  If a subject is anti-HBc positive 
the Central Laboratory will automatically perform a quantitative polymerase chain reaction test 
to measure viral DNA load. If Screening Central Laboratory results are not available and 
treatment needs to be urgently started, then local laboratory results may be used to c onfirm 
eligibility, however the Celgene medical monitor must be consulted.  Additionally, the data must 
be submitted to Celgene in the case report form (CRF) and the investigator must ensure that 
samples for the Central Laboratory are drawn before investigational product is administered and immediately sent to the Central Laboratory.
Hepatitis C Virus (HCV) Testing will be pe rformed at Screening by the Central Laboratory on 
all sub jects.  If Screening Central Laboratory results are not available and treatment needs to be 
urgently started, then local laboratory results may be used to confirm eligibility, however the 
Celgene medical monitor must be consulted.  Additionally, the data must be submitted to 
Celgene in the CRF and the investigator must ensure that samples for the Central Laboratory are drawn before investigational product is administered and immediately sent to the Central 
Laboratory.  
For those who are HCV positive, the investigator must confirm that the subject is an acceptable 
candidate for R-CHOP therapy and does not have  an active HCV infection or unacceptable liver 
damage as documented by one of the following options: FibroScan
¬Æ(liver ultrasound for 
fibrosis), liver biopsy, zero RNA viral load by local laboratory, or ot her local practice test.
Creatinine Clearance will be assessed at Screening by the Central Laboratory.  If Screening 
Central Laboratory results are not  available and treatment needs to be  urgently started, then local &(/*(1(35235,(7$5<,1)250$7,21llow datllow dat a a 
ival ival 
med at Scrmed at 
ral, or ral, or bonebone
H.  If CNS ly.  If CNS
to have a nto have a n
ring Screenring Scree
ent.nt.
at Screeninat Screenin
bodybody to the to they
en (anten (ant i-HBHB
rform a quaform a qua
Central LabCentral Lab
then local lahen local 
dical monitoical mon
se report fose report f
atoryoryare drare dryy
traltral LaboraLaboll
CV) TCV) T estingstin
ening Centrning Cent
hen local lahen local la
alalmmllonionitortoiii
the CRF anhe CRF an
fore investre invest
atoryatory .  
or those whr those wh
candidateandidate
amamagag
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 45 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019laboratory results may be used to confirm elig ibility, however the Celgene medical monitor must 
be consulted.  Additionally, the data must be submitted to Celgene in the CRF and the 
investigator must ensure that samples for the Central Laboratory are drawn before investigational 
product is administered and immediately sent to the Central Laboratory.  Creatinine clearance (CrCl) is estimated using the Cockcroft-Gau lt formula where CrCl (mL/min) = (140 ‚Äì age) 
(weight [kg]) / 72 (serum creatinine [mg/dL]; fo r females, the formula is multiplied by 0.85 
(Cockcroft, 1976 ).
Body Surface Area (BSA) will be calculated using the subject‚Äôs height and weight according to 
local pharmacy practice.  Height will be collected only at Screening; however, weight will be 
collected at the start of every cycle.  It is up to pharmacist and investigator discretion whether BSA will be recalculated prior to preparing eve ry cycle of chemotherapy from Cycle 2 onward, 
or whether the Screening / Cycle 1 BSA will be used throughout the study. If BSA is to be 
recalculated, the same calculation method should be used throughout the study per subject.  
Electrocardiogram (ECG) will be performed at Screening to assess heart electrical function.  If 
an ECG was performed as standard of care within 28 days of dosing, that data may be used to 
fulfill the eligibility requirement.  
Multiple Gated-Acquisition Scan (MUGA) / Echocardiography will be performed at 
Screening and End of Treatment Visit to assess left ventricular ejection fraction (LVEF).  If a 
MUGA/echocardi ography wa s performed as standard of care within 28 days of dosing, that data 
may be used to fulfill the eligib ility requirement.  Note that MUGA is  highly preferred, but if this 
testing modality is not available or is not standa rd local practice, then ec hocardiography will be 
acceptable.
Saliva Sample is to be collected in a 2 mL ORAgene kit tube during Screening.  The sample is 
for germline mutational analysis and the results do not impact subject eligibility.
Lymph Node/Tumor Biopsy specimen preserved as a formalin-fixed paraffin-embedded block
(FFPE) or unstained slides, and acquired within  8 weeks prior to C1D1, must be available.  If 
submitting unstained slides, 15-20 are highly recommend in order to complete all testing.  If an 
archival specimen is not available or is not acceptable, a re-biopsy is required prior to randomization.  This procedure s hould be performed before initiating the optional pre-phase 
corticosteroid treatment.  Refer to Inclusion Criterion 3for more details on specimen 
acceptability.  Refer to the la boratory manual for sample handling instructions.  
Submit Lymph Node/Tumor Biopsy to Central Pathology. The Screening biopsy sample is to
be submitted to Central Pathology during Screening with enough time planned to allow central 
confirmation of disease, subtype, and CD20 status.  Central Pathology will review and provide
biopsy results within three calendar days (includes Saturday and Sunday) of receiving a complete 
sample set, properly prepared and labeled, a nd accompanied by the correct paperwork.
Inclusion/Exclusion Criteria must be reviewed and cleared prior to randomization.  Celgene 
corporate policy does not allow waivers to any eligibility criteria. 
Pre-specify Optional Consolidation Radiotherapy and/or Additional Rituximab if 
applicable.  If the investigator intends to adminis ter optional consolidation radiotherapy (Section 
8.2.2 ) and / or an optional two additional doses of single agent rituximab (Section 8.2.6
Rituximab), these must be pre-specified prior to rando mization th rough the IVRS. &(/*(1(35235,(7$5<,1)250$7,21to o 
be e 
ether ther 
2 onward, onward, 
is to be is to be 
per subject. per subject.
lectrical fulectrical f
data may bdata m
ywill be pewill be p
ejecteject ioin fra
e within 28e within 28
atatMUGA MUGA 
al practal pract ice, ice
Agene kit tAgene kit 
ults do not ults do not 
preserved preserve
red red wiwithin thiii
are e highly ghly 
ble or is notle or is not
ure should ure should 
Refer to Infer to
the lthe laboratabora
ode/ode/TumoTumo
Central PaCentral Pa
oof f diseasedisease
ullts wits willl ththiiiinin
e set, properset, proper
clusion/usion/ ExEx
corporate porporate p
rere-spsp
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 46 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Randomization is accomplished through the IVRS, by a designated member of the 
investigator‚Äôs staff once all eligibility criteria have  been verified.  Randomization is part of the 
Screening Period and may be completed up to 7 days prior to Cycle 1 Day 1 dosing (to allow 
pharmacy preparations) however, the Screening Period must not exceed 28 days.  
Modified Cumulative Illness Rating Scale (CIRS) is to be assessed at Screening only for 
subjects >80 years of age.  The following organ specific categories are assessed: heart; 
hypertension; vascular-hematopoietic; respiratory;  eyes, ears, nose, throat, and larynx; upper 
gastrointestinal; lower gastrointestinal; liver and biliary trees; renal; genitourinary; 
musculoskeletal/integument; central and peripheral nervous system; endocrine-metabolic system 
and breast; psychiatric and behavioral diseases.  DLBCL illnesses or disease related organ damage should not be assessed as part of this rating scale. If there are two or more 
illnesses/impairments in one organ category, the illness/impairment with the highest severity will 
be evaluated.  Each organ category is scored separately according to Appendix 19.2 (Salvi,
2008a) .
Physical Examination includes assessment of lymphadenopathy, hepatomegaly and 
splenomegaly, as clinically indicated. The exam is performed at Screening, at every cycle on Day 1, during Cycles 1 - 2 on Day 8, and at End of Treatment Visit.  If the most recent protocol 
scheduled or unscheduled assessment was performed within 7 days prior to End of Treatment
Visit, the assessment does not need to be repeat ed again at End of Treatment Visit.  If a subject
has discontinued treatment for any reason other than disease progression or death, the exam is 
required to continue during the Follow-up Period at Weeks 34, 46, 58, 70, 82, 94, 106, 118, 130, 
142, 154 (¬± 1 week); 180, 206, 258, and 310 (¬± 2 weeks) until first progression or the 12 Apr 
2019 primary analysis, whichever occurs first.
Vital Signs include blood pressure, pulse, and temperature and will be measured at Screening, 
every cycle on Day 1, during Cycles 1 - 2 on Day 8, and at End of Treatment Visit. If the most 
recent protocol scheduled or unscheduled assessment was performed within 7 days prior to End 
of Treatment, the assessment does not need to be repeated again at End of Treatment Visit.  If a 
subject has discontinued treatment for any reason other than disease progression or death, the assessment is required to continue during the Follow-up Period at Weeks 34, 46, 58, 70, 82, 94, 
106, 118, 130, 142, 154 (¬± 1 week); 180, 206, 258, and 310 (¬± 2 weeks) until first progression or 
the 12 Apr 2019 primary analysis, whichever occurs first.
Complete Blood Count (CBC) with Differential includes hemoglobin, hematocrit, white blood 
cell count (WBC) with differential, absolute ne utrophil count (ANC), absolute lymphocyte count 
(ALC), and platelet count.  The test is performed at Screening, every cycle on Day 1, during Cycles 1-2 on Day 8, and at End of Treatment Visit.  If a subject has discontinued treatment for 
any reason other than disease progression or death, the assessment is required to continue during 
the Follow-up Period at Weeks 34, 46, 58, 70, 82, 94, 106, 118, 130, 142, 154 (¬± 1 week); 180, 
206, 258, and 310 (¬± 2 weeks) until first progression or the 12 Apr 2019 primary analysis,
whichever occurs first. 
At Screening, all CBC testing is performed by the Central Laboratory.  If the Screening test is
completed within 7 days of Cycle 1 Day 1 dosing, the test does not need to be repeated again on 
Cycle 1 Day 1.  If Screening Central Laboratory results are not available and treatment needs to 
be urgently started, then local laboratory results may be used to confirm eligibility, however the Celgene medical monitor must be consulted.  Additionally, the data must be submitted to stem tem 
n 
st severitt severit y y 
9.29.2((SalviSalvi
mmegalyegaly anyd
ening, ening, aat evt ev
 If the f the mom
ays ypripor toto
d of d of TreatmTrea
se progressprogres
eks ks 3434, , 4646
eeks) untks) unt il f
d temped tempe raturatu
on Day 8, an Day 8, a
ed assessmed assessm
ot need to bot need to
t for any ret for any 
nue during ue during 
 w weeeek);k);18
analysisanalysi ,w
unt (CBC)unt (CBC
wiwiththii differ differhh
telet countelet cou tn
on Dayon Day  8, an 8, ayy
n other thaother tha
lowow-up Pep Pe
, 258, and  258, and 
whichever owhichever o
AtAt Scre Scre
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 47 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Celgene in the CRF and the investigator must ensure that samples for the Central Laboratory are 
drawn before investigational product is administered and immediately sent to the Central 
Laboratory.
After the Screening Period, testing continues by the Central Laboratory.  However, in urgent 
cases, local laboratory results may be used to guide clinical decisions and dose modifications,
however, that data must be submitted to Celgene in the CRF, and whenever possible, a 
concurrent sample should be sent to the Central Laboratory.
If the most recent protocol scheduled or unschedu led test was performed within 7 days prior to 
End of Treatment Visit, the test does not need to be repeated again at End of Treatment Visit.
Lactate Dehydrogenase (LDH) is performed at Screening, every cycle on Days 1, during 
Cycles 1-2 on Day 8, and at End of Treatment Visi t.  If a subject has discontinued treatment for 
any reason other than disease progression or death, the assessment is required to continue during 
the Follow-up Period at Weeks 34, 46, 58, 70, 82, 94, 106, 118, 130, 142, 154 (¬± 1 week); 180, 
206, 258, and 310 (¬± 2 weeks) until first progression or the 12 Apr 2019 primary analysis,
whichever occurs first.  
At Screening, all testing is performed by the Central Laboratory.  If the Screening test is
completed within 7 days of Cycle 1 Day 1 dosing, the test does not need to be repeated again on 
Cycle 1 Day 1.  
If Screening Central Laboratory results are not available and treatment needs to be urgently 
started, then a local laboratory LDH result may be used. However, the data must be submitted to 
Celgene in the CRF and the investigator must ensure that samples for the Central Laboratory are 
drawn before investigational product is administered and immediately sent to the Central Laboratory.  
After the Screening Period, testing continues by the Central Laboratory.  However, in urgent 
cases, local laboratory results may be used to gui de clinical decisions and dose modifications, 
however, that data must be submitted to Celgene in the CRF, and whenever possible, a 
concurrent sample should be sent to the Central Laboratory.
If the most recent protocol scheduled or unschedu led test was performed within 7 days prior to 
End of Treatment Visit, the test does not need to be repeated again at End of Treatment Visit.
Serum Chemistry includes albumin, alkaline phosphatase, alanine aminotransferase (ALT), 
aspartate transaminase (AST), bilirubin (total), calcium, chloride, creatinine, glucose, phosphorous, potassium, sodium, total protein, blood urea nitrogen (BUN), and uric acid.  The 
test is performed at Screening, every cycle on Da ys 1, during Cycles 1-2 on Day 8, and at End of 
Treatment Visit.  Unscheduled tests may be ordered at any time.  
At Screening, all chemistry testing is performed by the Central Laboratory.  If the Screening test 
is completed within 7 days of Cycle 1 Day 1 dosi ng, the test does not need to be repeated again
on Cycle 1 Day 1.  If Screening Central Laboratory results are not available and treatment needs to be urgently started, then local laboratory result s may be used to confirm eligibility, however 
the Celgene medical monitor must be consulte d.  Additionally, the data must be submitted to 
Celgene in the CRF and the investigator must ensure that samples for the Central Laboratory are drawn before investigational product is administered and immediately sent to the Central 
Laboratory.&(/*(1(35235,(7$5<,1)250$7,21o 
it.i
ring ing 
reatment foreatment f
cocontntinue dinue d
(¬± 1 w¬± 1 w eeeekk
imaryimary  analanalyy
the Scrhe Scr eeneen
not need to bneed to
and treatmeand treatme
..HoHoweveweve
e that sampe that sam
ered and imred and im
ues by the Cues by the 
used to guied to gui d
d to Celgend to Celg
t to the Cento the Ce
cheduled orheduled or
e testtestdodes
cludes ludes albua
nase (nase ( ASTAST ))
otassium, sootassium, s
med at Screed at Scre
VisitVisit .  Uns.  Un
reening, areening, a llll
oompmpleted wleted w
on Cyon Cy cle 1 cle 1
to be urgo be u
C
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 48 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019After the Screening Period, testing continues by the Central Laboratory.  However, in urgent 
cases, local laboratory results may be used to gui de clinical decisions and dose modifications, 
however, that data must be submitted to Celgene in the CRF, and whenever possible, a 
concurrent sample should be sent to the Central Laboratory.
If the most recent protocol scheduled or unschedu led test was performed within 7 days prior to 
End of Treatment Visit, the test does not need to be repeated again at End of Treatment Visit.
Thyroid Stimulating Hormone (TSH) is tested at Screening and at the End of Treatment Visit; 
the blood serum samples are analy zed by the Central Laboratory.
Serum Immunoglobulin (Ig) measurement includes IgA, IgG, IgM and will be collected at 
Screening and at End of Treatment Visit.  Testi ng is performed by the Central Laboratory.
Lenalidomide Counseling is conducted for all subjects at the following times: once during 
Screening prior to Cycle 1 Day 1 dosing; and while on treatment, once per cycle prior to 
dispensing lenalidomide.   Please consult the Pregnancy Prevention Risk Management Plan for 
details.
Pregnancy Testing is applicable to all subjects who are females of childbearing potential 
(FCBP). FCBP is defined as a: sexually mature female who: 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical 
removal of both ovaries) or 2) has not been naturally postmenopausal (amenorrhea following 
cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months).
Prior to starting investigational product, two negative pregnancy tests are required (sensitivity of 
at least 25 mIU/mL).  The first test must be performed within 10 to 14 days prior to the start oflenalidomide/placebo dosing, and the second within 24 hours prior to the start of
lenalidomide/placebo dosing.  During the Treatment  Period testing is performed weekly for the 
first 28 days. Thereafter, FCBP with regular or no menstrual cycles continue testing at a 
minimum of every 28 days during the Treatment Period (Day 1 of every 21-day cycle is 
acceptable), at the Lenalidomide/Placebo End of Treatment, and 28 days following 
Lenalidomide/Placebo End of Treatment.  Thereafter, FCBP with irregular menstrual cycles
continue testing every 14 days during the Treatment Period, at Lenalidomide/Placebo End of 
Treatment, and at both 14 and 28 days fo llowing Lenalidomide/Place bo End of Treatment.  
Quality of Life Assessment will be completed using the EQ -5D and FACT-Lym questionnaires 
(Appendix 19.6 and 19.7).  These are required to be completed at the following time points: at 
Screening, Midcycle, once 3 ‚Äì 4 weeks after completing Cycle 6; Weeks 34, 46, 58, 70, 82, 94, 
106, 118, 130, 142, 154 (¬± 1 week); 180, 206, 258, a nd 310 (¬± 2 weeks) until first progression or 
the 12 Apr 2019 primary analysis, whichever occurs first. To the extent possible, collect this 
assessment the same day the CT scan is performed.  If an additional CT scan is performed earlier 
than the specified time points due to changes in the subject‚Äôs clinical status, please also collect an additional questionnaire set at that time.  Once a subject has progressed, no further 
questionnaires are required.
Performance Status will be scored according to Table 6 and will be measured at Screening;
Midcycle; and once 3 ‚Äì 4 weeks after completing Cycle 6.  If a subject has discontinued 
treatment for any reason other than disease progre ssion or death, the assessment is required to &(/*(1(35235,(7$5<,1)250$7,21at at
oryory.
ce e during during 
e prior to e prior to
nagementnagement P
hildbearinghildbearing
as not s not underunde
ophorectomphorectom
nopausalnopausal (a(ll
or atr atleleast 2ast 2
nsecutive mnsecutive m
ive pregnanive pregnan
formed withormed w
witwithin 24 hin 24 
Treatment Treatment 
egular or ngular or n
he Treatmee Treatm
Placebo EnPlacebo E
Treatmentreatmen
ays ys during during
4 and 28 4 and 28 d
essment ssment ww
nd nd 19.719.7).  T).  T
dcyclecycle , onon
30, 142, 1530, 142, 15
pr 2019 pri2019 p
sment the ssment the s
an the specithe speci
addiddititiionalonalll
questionuestio
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 49 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019continue during the Fo llow-up Period at Weeks 34, 46, 58, 70, 82, 94, 106, 118, 130, 142, 154 (¬± 
1 week); 180, 206, 258, and 310 (¬± 2 weeks)  until first progression or the 12 Apr 2019 primary 
analysis, whichever occurs first.To the extent possible, collect this assessment the same day the 
CT scan is performed. 
Table 6: Performance Status by Eastern Cooperative Oncology Group Scale
Score Description
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, eg, light housework, office work.
2 Ambulatory and capable of all self-care but unable to carry out any work activities.  
Up and about more than 50% of waking hours.
3 Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours.
4 Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or 
chair
5 Dead
(Oken, 1982 )
 
 
 
 
CT Scan of the Neck, Chest, Abdomen, and Pelvis is to be performed with contrast unless 
medically contraindicated ; in this case magnetic resonance imaging (MRI) or a CT without 
contrast is acceptable. It is acceptable to perform a combined PET-CT, however, the CT portion 
should be of diagnostic quality.  
If the local preference is to perform a combined PET-CT without contrast, this will be acceptable 
for post baseline assessments only (unless contrast is medically contra indicated at baseline): 
Midcycle (once between Weeks 9 ‚Äì 12 which is after Cycle 3 but before cycle 4); End of 
Treatment Visit; and for PET negative (CR) subjects only , also during the Follow-up Period.  If a 
combined PET-CT without contrast is performed, then progression may not be scored on PET
positivity alone, but must be confirmed by CT with contrast or a biopsy of the PET positive 
lesion. The same modality should be used t hroughout all post-baseline assessment time-points
for a given subject if possible. Consult the radiology manual for more detail.  
This procedure should be performed before in itiating the optional pre-phase corticosteroid 
treatment. All scans will be sent to Centr al Radiology on an ongoing basis for subsequent 
efficacy assessment. Lo cal interpretation of scans w ill determine eligibility and inform real-time 
treatment decisions during the study.  However, th e CT scans collected 3 ‚Äì 4 weeks after Cycle 6 &(/*(1(352bdomen, abdomen, a
this casethis case mm
s acceptableacceptabl
qualiqual tyi.  
nce is to pere is to per
assessmenassessme
ce betweene between
VisitVisit ;;and and 
ed PET-ET-CCTT
ivitvityy
&(/*(1(35235,(7$5<,1)250$7,21$7ut $7$7$7
ork activitieork activiti0$
e than 50% e than 50% 25
otally confinotally conf1)
<, 15<
alaloneone
siionon..The sThe s
foor a givenr a given
is pi7$5(7$,(75,(35,23523
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 50 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019should be forwarded immediately to Central Radiology for a real time assessment which will 
guide treatment decisions at the post Cycle 6 time point .
The CT scans are required at Screening, Midcyc le (once between Weeks 9 ‚Äì 12 which is after 
Cycle 3 but before Cycle 4); once 3 ‚Äì 4 weeks after completing Cycle 6; Weeks 34, 46, 58, 70, 82, 94, 106, 118, 130, 142, 154 (¬± 1 week); 180, 206, 258, and 310 (¬± 2 weeks) until first 
progression or the 12 Apr 2019 primary analysis, whichever occurs first. The radiological 
assessment schedule is the same for all subjects , regardless of whether the optional two doses of 
single agent rituximab are administered.  Ther efore, the scan required at 3 ‚Äì 4 weeks after 
completing Cycle 6 must be completed before the optional Cycle 7 dose of rituximab is 
administered.  If an additional scan is performed earlier than the specified time points due to changes in the subject‚Äôs clinical status, this extra scan should also be  submitted to Central 
Radiology.  Once a subject has experienced first progression, no further CT scans are required.  
Below is a bulleted summary:
!Screening 
‚àÄPET and CT with contrast to define lesions
!Once between Weeks 9 ‚Äì 12 
‚àÄCT with contrast, or PET-CT without contrast per local standard of care
!Once 3-4 weeks after completing Cycle 6 
‚àÄPET and CT with contrast or PET-CT without contrast per local standard of care
!If PET negative (CR), contrast CT not required
!If PET positive, contrast CT or biopsy required to confirm PD before changing 
therapy
!Follow-up for PET negative (CR) cases
‚àÄCT with contrast, or PET-CT without  contrast per lo cal standa rd of care
‚àÄProgression must be confirmed by contrast CT or biopsy
!Follow-up for PET positive cases (PR and SD)
‚àÄCT with contrast
Scans previously acquired as standard of care up to 6 weeks prior to Cycle 1 Day 1 may be 
submitted to fulfill the Screening requiremen t as long as they m eet the minimum technical 
standards specified by Central Radiology and in clude all required field s.  Fields missing from 
archival scans may be imaged separately during Screening and the complete set of scans may be 
submitted together to fulfill Screening requirements.
The scanning time points are the same for allsubjects, including those who complete the full 
course of protocol specified treatment, who discontinue  treatment early due to toxicity, as well as 
those who discontinue before progression to pursue a new antilymphoma/salvage therapy (chemotherapy, SCT, radiotherapy, etc.).  All scans are submitted to Central Radiology.  
However, in the case where a subject receives a new antilymphoma therapy before first e to to 
tralral
are requiredre required
er local r loca sta
wiwiththiiout conout con
CT not requCT not requ
T or biopsyT or biopsy
e (CR) case(CR) cas
r PETr PE -CT CT 
ust be confiust be conf
PET positPET po i
hh contrastcontrahh
acquacqu ired aired a
ulfilfilll l ththe Sce S
pecified bypecified by
scans may ns may
itted togethitted toget
he scanninhe scannin
course ofourse of
ose wose w
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 51 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019progression, and as part of another clinical trial, continue the scans to the extent possible and 
submit if possible to Central Radiology until first progression.   
Response Assessment includes review of current CT, PET, laboratory, and clinical data to 
determine the subject‚Äôs response status per the IWG Response criteria for NHL ( Cheson, 2014 ).  
The response assessments are required at: Midcycle; once between 3 ‚Äì 4 weeks after completing 
Cycle 6; Weeks 34, 46, 58, 70, 82, 94, 106, 118, 130, 142, 154 (¬± 1 week); 180, 206, 258, and 
310 (¬± 2 weeks) until first progression or the 12 Apr 2019 primary analysis, whichever occurs first. The response assessment schedule is the same for all subjects , regardless of whether the 
optional two doses of rituximab ar e administered.  If an additional CT scan is performed earlier 
than the specified time points due to changes in the subject‚Äôs clinical status, please also perform an additional response assessment at that time.  Once a subject has progressed, no further 
response assessments are required.
Bone Marrow Biopsy will be performed at Screening (before pre-phase corticosteroid 
treatment, if applicable) for all subjects; and at the End of Treatment only if the subject has an 
equivocal post Cycle 6 PET scan finding in the bone marrow, and had lymphomatous 
involvement of the bone marrow at Screening.  Therefore, if an EOT biopsy is required, the timing will be dependent on the post Cycle 6 PET scan results. Samples previously acquired as 
standard of care within 8 weeks prior to C1D1 may be used to fulfill the Screening bone marrow 
biopsy requirement.  Local pathology review of the Screening and End of Treatment Visit bone 
marrow samples is acceptable; Central Pathology does not review bone marrow biopsy samples.  
The Screening results do not impact study eligibility.  A unilateral biopsy is acceptable.
Bone Marrow Aspirate sample collection within 8 weeks prior to C1D1 is recommended, but is 
not required.  This procedure should be performed before initiating the optional pre-phase 
corticosteroid treatment.  Local pathology re view of the aspirate is acceptable.  If a subject 
develops an SPM post C1D1, and if a Screening aspirate was collected, sponsor review of the sample and/or of the local pathol ogy report may be requested.  
PET Scan of the neck, chest, abdomen, and pelvis is required once during Screening before 
receipt of investigational products (also before pre-phase corticosteroid treatment, if applicable);and once between 3 ‚Äì 4 weeks after completing Cycle 6.  The radiological assessment schedule 
is the same for all subjects , regardless of whether the optional two doses of single agent 
rituximab are administered. Therefore the scan required at 3 ‚Äì 4 weeks after completing Cycle 6 must be completed before the optional Cycle 7 dose of rituximab is administered.   
Scan interpretation is according to the Deauville Criteria with a score of 1 ‚Äì 2 being negative, 
and score of 3 ‚Äì 5 being positive ( Itti, 2013; Meignan, 2013) , (Appendix 19.3).  Although local 
interpretation at Screening is acceptable, all scans will be sent to Central Radiology on an 
ongoing basis for subsequent efficacy assessment.  However, the PET scan collected 3 ‚Äì 4 weeks 
after Cycle 6 should be forwarded immediately to Ce ntral Radiology for a real time assessment 
which will guide treatment decisions at the post Cycle 6 time point .
Scans previously acquired as standard of care within 6 weeks prior to Cycle 1 Day 1 may be 
submitted to fulfill the Screening requiremen t as long as they meet the minimum technical 
standards specified by Central Radiology and incl ude all required fields.  Screening PET scan 
results do not impact eligibility.
&(/*(1(35235,(7$5<,1)250$7,21rlier ier 
erform rform 
her er 
osteroid osteroid 
the subjectthe subjec
mphompho matmo
biopsy is rebiopsy is re
mples previmples pre
ulfill the Sculfill the Sc
g and End og and End
revieview bonew bo
unilateralnilatera l
8 weeks p weeks p rir
ed before ined before in
view of the iew of the 
ening aspirning aspi
port mort m ay beay b
omen, and men, and
ss((also also befbef
after after comcom
, regardlessregardles
ed. edThereher
efore the opefore the 
on is accordon is accord
‚Äì‚Äì5 being 5 being
on n at Screeat Scree
basisbasis fofor sr 
Cycle 6 shoCycle 6 s
hich will guhich will gu
Scans preScans pre
bmibmi
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 52 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Administer Investigational Product as described in Section 8.2. 
IP Accountability and Compliance is described in Sections 8.7and 8.8.
Administer Mandatory Primary Neutropenia Prophylaxis as described in Section 8.2.3
Tumor Lysis Syndrome (TLS) Assessment includes review of uric acid, potassium, 
phosphorous, calcium, and serum creatinine laboratory values; hydration status check; and 
clinical assessment / grading using the Cairo- Bishop Definition of TLS in Appendix 19.5.  
(CTCAE is not used to grade TLS in this study.)  TLS assessment is to be performed at Cycles 1-2 Days 1, 8, and thereafter as clinically indicated.  Note that the TLS assessment has a smaller 
window than the other assessments.  The Day 1 TLS assessment must always be performed on 
the same day as dosing; the Day 8 TLS assess ment must be performed within ¬± 1 day.  TLS 
prophylaxis treatment is discussed in Section 9.3.5 .
Adverse Events will be collected from signing of informed consent through 28 days after the 
last dose of investigational product, which include s the optional two additional doses of single 
agent rituximab, if administered.
Concomitant Medications / Procedures will be collected from signing of informed consent 
through 28 days after the last dose of investigational product, which includes the optional two additional doses of single agent rituximab, if administered.  These also include blood products 
transfused (packed red blood cells, platelets, etc.).
Subsequent Antilymphoma Treatment and Progression will be recorded, 
specifically the individual drug names, dates of treatment, and progression date, as long as the 
subject does not revoke consent, and the study remains open at the investigator‚Äôs center.  
 
 Data through first progression may be collected at scheduled protocol clinic 
visits,  
. After the 12 Apr 2019 primary analysis, this information will not be 
collected.
Second Primary Malignancy (SPM) will be monitored as an event of interest and must be 
reported as an SAE regardless of the treatment arm the subject is in.  This includes any SPM, regardless of causal relationship to IP, occurring at any time for the duration of the study, from 
the time of signing the ICD until the subject has died, revokes consent, or for up to 5 years from 
the date the last subject is randomized, whichever occurs first.  Events of SPM are to be reported using the SAE report form and must be considered an ‚ÄúImportant Medical Event‚Äù even if no 
other serious criteria apply; these events must also be documented in the appropriate page(s) of 
the CRF and subject‚Äôs source documents.  Documentation on the diagnosis of the SPM must be provided at the time of reporting as an SAE (eg, any confir matory histology or cytology results, 
x-rays, CT scans, etc.).  If a tissue biopsy is collected related to an SPM, sponsor review of the 
sample and/or a local pathology report may be requested. For this particular study, SPM will include cases of DLBCL transformation to acute lymphoblastic leukemia (ALL).
As part of the SPM follow-up on all subjects, regardless of whether the subject actually 
experiences an SPM, information about subsequent antilymphoma therapies, first and second progression, and survival will also be collected.  This is described in the Table of Events
(Table 5 ) and earlier in Section 6.
&(/*(1(352352019 primar19 prima
SPM)SPM) willwill
s os of f ththe tree tre
onship to IPship to IP
ICD untICD u il til
ect is randoct is rand
port form aport form a
riteria apiteria ap plp
d subject‚Äôsd subject‚Äôs
d at the timethe tim
s, CT scanss, CT scan
mple aple a nd/nd/oo
include casnclude cas
s parsp a r5,(on may be cn may be c7$5onn
mentent, and prand p
mains open aains open $5<,1)250$7,2111--
er er 
ed on d on 
TLS TLS 
 daydays after s aft
nal doses ofnal doses 
ing of inforng of infor
ch includes h include
ese also incse also inc
7$5
5,(735,
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 53 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Survival Information will be collected on all subjects at scheduled protocol clinic visits until 
first progression.  Thereafter, information will be collected via subject contact (phone, email, 
visit, etc.) as long as the subject does not revoke consent, and the study remains open at the 
investigator‚Äôs center.
&(/*(1(35235,(7$5<,1)250$7,21
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 54 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20197. STUDY POPULATION
7.1. Number of Subjects and Sites
This study will enroll approximately 560 subjects in  the ITT population which are anticipated to 
come from the regions of North America, Europe, and Asia.
7.2. Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Histologically confirmed CD20+ DLBCL of the below World Health Organization 
(WHO) sub-classifications as assessed by Central Pathology.  In the rare case that local 
and Central pathology disagree on DLBCL diagnosis and/or CD20+ status, and if ABC 
type is confirmed by Central Pathology (inclusion criterion 2), then the subject may st ill 
be enrolled on the basis of a local DLBCL diagnosis and/or CD20+ status at investigator 
discretion.  A retrospective adjudication will be performed by a second Central Pathologist.
a. Not otherwise specified (NOS)
b. Associated with chronic inflammation
c. Epstein-Barr virus positive (EBV+) of the elderly
2. ABC type determined using a validated GEP assay performed on  
 as assessed by Central Pathology.  (ABC type subjects 
are reported by the GEP assay as eligible for this inclusion criterion, whereas subjects 
with an indeterminate, unclassifiable, or GCB type are not eligible).
3. Adequate lymph node or tumor biopsy specimen available for Central Pathology review 
and GEP profiling by the .  A formalin fixed 
paraffin embedded lymph node or tumor biopsy acquired by a surgical incision or 
excision biopsy is strongly preferred.  Core n eedle biopsy is allowe d, and typ ically 3 ‚Äì 4 
passes embedded in two FFPE blocks are adequate for both local and Central Pathology 
evaluation (one block for local and one block for Central Pathology).  Other commonly 
used devices (e.g. endoscopy forceps or grasp biopsy) are also acceptable provided they yield an equivalent amount of tissue.  Material from a fine needle aspiration is not 
acceptable.  If an archival specimen is not available or is not acceptable, a re-biopsy is 
required prior to randomization.
4. Measurable disease on cross section imaging by CT that is at least 1.5 cm in the longest 
diameter and measurable in two perpendicular dimensions.
5. Ann Arbor stage II-IV disease.6. No prior treatment for DLBCL , except as allowed in Section 8.2.1 .
7. Appropriate candidate for 6 cycles of R-CHOP21. 
8. International Prognostic Index score of 2 or greater.9. Performance status < 2 on the Eastern Coope rative Oncology Group (ECO G) scale. &(/*(1(3523ode or tumode or tum
yy preferred preferredyy
wo FFPE bloo FFPE b
ck for localk for loca
g. endoscopg. endosc
valalent ament am ou
  If an arch If an arch
d prid prior to raor to ra
asurable dissurable dis
iameter anmeter an
..Ann ArAnn Ar
6.6No No 5,(7$5<,1)250$7,21n n
hat local hat local 
and ifand if ABCAB
ubjectubject may
atusatusat inveinve
ond Centraond Centra
lyy
ssay performsay perform
bybyCentralCentrayy l
for this incfor this inc
or GCB or GCB tytypy
opsyopsy specimspecimyy
7.7235
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 55 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201910. Must be between the ages of 18 and 80 years on the date of the informed consent 
document signature.  At the discretion of the investigator, subjects over 80 years may be 
included if their ECOG performance status is ‚â§ 1; each of their individual organ system 
scores is ‚â§ 2 using the Modified Cumulative Illness Rating Scale (CIRS) for co-morbidity
(Salvi, 2008 ; Salvi, 2008a ); and if they would otherwise be eligible for full-dose R-
CHOP per local practice.
11. Must fulfill the following laboratory requirements:
a. Absolute neutrophil count (ANC) ‚â• 1,500 cells/mm3(1.5 x 109/L) unless secondary to 
bone marrow or spleen involvement by lym phoma; in th is case the limit is ‚â• 1,000 
cells/mm3(1.0 x 109/L). Bone marrow involvement by lymphoma is demonstrated by 
recent bone marrow aspiration, bone marrow biopsy, or PET scan finding.  Spleen 
involvement by lymphoma is demonstrated by splenomegaly.
b. Platelet count ‚â• 75,000/mm3 (75 x 109/L) unless secondary to bone marrow or spleen 
involvement by lymphoma; in  this case the limit is ‚â•50,000/ mm3 (50 x 109/L). Bone 
marrow involvement by lymphoma is demonstrated by recent bone marrow 
aspiration, bone marrow biopsy, or PET scan finding.  Spleen involvement by 
lymphoma is demonstrated by splenomegaly.
c. Hemoglobin ‚â• 7.5 g/dL (4.7 mmol/L)
d. Serum aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ‚â§
3.0 x upper limit of normal (ULN).  In the case of documented liver involvement by 
lymphoma, the requirement is ‚â§ 5.0 x ULN.
e. Serum total bilirubin ‚â§2.0 mg/dl (34 Œºmol/L).  In the case of Gilberts Syndrome, or 
documented liver or pancreatic involv ement by lymphoma, the requirement is ‚â§ 5.0 
mg/dl (86 Œºmol/L).
f. Calculated creatinine clearance (Cockcroft-Gault formula) of ‚â•30 mL/min
12. Understand and voluntarily sign an informed consent document prior to conducting study 
assessments or procedures. 
13. Able to adhere to the study visit schedule and other protocol requirements.
14. Females of childbearing potential (FCBP) must:
a. Have two negative pregnancy tests as verified by the study doctor prior to starting 
study therapy. She must agree to ongoing pregnancy testing during the course of the 
study, and after end of study therapy. This applies even if the subject practices 
complete abstinence 1from heterosexual contact.
b. Either commit to complete abstinence1from heterosexual contact (which must be 
reviewed on a monthly basis) or agree to use, and be able to comply with, effective 
contraception without interruption, 28 days pri or to starting study therapy, during the 
study therapy (including dose interruptions), and for 12 months after discontinuation of study therapy. 
                                               
1True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic 
abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.&(/*(1(35235,(7$5<,1)250$7,21y to to
000 0 
strated byated b
.  .Spleen Spleen
marrow marrow or o
mm(50 x 10(50 x 109
bone marrbone m
een involveeen involve
alanine tranalanine tra
e of e of documdocum
.
mmolol/L)/L)ll.  . Inn
vement byvement b
e (e (CockcroCockcro
gn an inforgn an in
tudytudy visivisiy t st ii
earing potenring poten
negategative prive pr
erapyerapy . SheShe
yy, and after , and after
mplete absplete absmm
EiEither comher comi
revieweview
concon
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 56 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201915. Male subjects must:
a. Practice comp lete abstinence1or agree to use a condom during sexual contact with a 
pregnant female or a female of childbearing potential while participating in the study, 
during dose interruptions and for at least 28 days following investigational productdiscontinuation, even if he has undergone a successful vasectomy. 
b. Agree to not donate semen during investigational product therapy and for 28 days 
after discontinuation of investigational product therapy. 
16. All subjects must:
a. Have an understanding that the invest igational product could have a potential 
teratogenic risk.  
b. Agree to abstain from donating blood while taking investigational product therapy 
and for 28 days after discontinuation of investigational product therapy. 
c. Agree not to share investigational product with another person.d. Agree to be counseled about pregnancy precautions and risk of fetal exposure.
e. Females must agree to abstain from breastfeeding during study participation and for 
at least 12 months after investigational product discontinuation.
7.3. Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. The following WHO subcategories of DLBCL:
a. Active CNS or meningeal lymphoma
b. Primary cutaneous, leg typec. Primary mediastinal (thymic)d. Lymphomatoid granulomatosise. ALK-positive lymphomaf. Plasmablastic lymphomag. Large B-cell lymphoma arising in HHV8 a ssociated multicentric Castleman disease
h. Primary effusion lymphomai. Intravascular large B-cellj. B-cell unclassifiable cases with features intermediate between DLBCL and Burkitt
k. Unclassifiable cases with features intermediate between DLBCL and classical 
Hodgkin‚Äôs lymphoma
l. T cell / histiocyte rich.
2. Post-transplant Lymphoproliferative Disorde r (PTLPD) cases, even  if they  are B-cell 
type and ABC subtype, are excluded.
3. Histology other than DLBCL. Evidence of composite DLBCL and FL, or of 
transformed NHL.
&(/*(1(35235,(7$5<,1)250$7,21uctuctththerapyerap
pypy. . 
of fetal expf fetal 
study partictudy partic
nuatnuioion.n.
ect froct fro m m en
BCL:BCL:
tositosiss
ma
hoomama
mphophoma arma a
usiosion lymphmp
cular large lar large B
l uunclassifinclassif
nclassifiablassifiab
Hodgkin‚ÄôsHodgkin‚Äô
l.l.T cell T cell
2.2.PosPos
tt
33
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 57 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20194. Seropositive for or active viral infection with hepatitis B virus (HBV): 
a. HBV surface antigen (HBsAg) positive
b. HBV surface antigen (HBsAg) negative, HBV surface antibody (anti-HBs) positive 
and/or HBV core antibody (anti-HBc) positive, and detectable viral DNA
Notes:
c. Subjects who are seropositive because of a successfully treated, prior infection are 
eligible (HBsAg negative, anti-HBs positive, and/or anti-HBc positive, but viral DNA negative)
d. Subjects who are seropositive because of HBV vaccination are eligible (anti-HBs
positive, anti-HBc negative, and HBsAg negative)
5. Hepatitis C virus (HCV) positive subjects w ith chronic hepatitis C, or subjects with an 
active hepatitis C infection requiring anti-v iral medication (at time of ra ndomization).  
Note: 
a. HCV positive subjects who do not have active hepatitis C, and who are otherwise 
acceptable candidates for R-CHOP chemotherapy, as documented by the investigator, 
are eligible.  
6. Known seropositive for or active viral infection with human immunodeficiency virus 
(HIV).
7. Contraindication to any drug in the chemotherapy regimen, and specifically:
a. LVEF < 45% as assessed by MUGA, or LVEF < local institutional normal limits for 
R-CHOP administration as assessed by echocardiography
b. Peripheral neuropathy ‚â• Grade 2 
8. Major surgery (excluding lymph node or bone marrow biopsy) within 28 days from 
signing the informed consent document, unless the subject is recovered
9. Life expectancy < 6 months
10. History of other malignancies, unless the subject has been free of the disease for ‚â• 5
years.  Exceptions to the ‚â• 5-year time limit include history of the following:
a. Localized non-melanoma skin cancer
b. Carcinoma in situ of the cervix
11. Prior use of lenalidomide12. Known allergy to thalidomide
13. Known sensitivity or allergy to murine products 14. Use of any investigational agent within 28 days or five half lives, whichever is longer, 
of Cycle 1 Day 1
15. Subjects who are unwilling to take VTE prophylaxis16. Pregnant or lactating females
17. Uncontrolled intercurrent illness&(/*(1(35235,(7$5<,1)250$7,21NA NA 
HBsBs
ubjects withjects with
f randorando mizamiz
and nd who who ara
ocumentcument ed e
th human ith human i
herapyherapy  regimrey
or LVEF <or LVEF <
d by echocd by echoc
2 
mph node orph node o
ntntdocumedocum
onthsonths
aalignancieslignanci
ns to the ns to th‚â•
nonnon--memelanla
ooma ma in in sisittii
r use of lr use of l en
Known allnown a
13.13KnowKnow
14.14.UU
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 58 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201918. Any significant medical condition, laboratory a bnormality, or psychiatric illness that 
would prevent the subject from si gning the informed consent form
19. Any condition, such as an active, seve re infection, or the presence of laboratory 
abnormalities, which places the sub ject at unacceptable risk if he/she were to participate 
in the study
20. Any condition that confounds the ab ility to interpret data from the study
&(/*(1(35235,(7$5<,1)250$7,21
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 59 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20198. DESCRIPTION OF STUDY TREATMENTS
8.1. Description of Investigational Products
Celgene will provide lena lidomide 2.5 mg, 5 mg, 10 mg, and 15 mg capsules and the respective 
matching placebo capsules for oral administration.  
Celgene will provide commercial supplies, for c ountries where rituximab, cyclophosphamide, 
doxorubicin, vincris tine, and prednisone or prednisolone are designated as investigational 
product, labeled appropriately for investigational use as per the regulations of the relevant 
country health authority.  Subjects enrolled in countries where rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisone or prednisolone are designated as non-investigational, 
should obtain commercially available product through their local hospital pharmacy or licensed 
distributer.  
Required medications for neutropenia will be selected by the investigator according to local 
practice and provided by the investigative site.
Recommended medications such as aspirin and allopurinol, if used, will be selected by the 
investigator according to local practice and provided by the investigative site.
8.2. Treatment Schedule and Administration
Please see Section 9.3for information about recommended prophylactic treatments related to 
CNS lymphoma, infections, nausea, rituximab infusion reactions, HBV reactivation, TLS, and VTE.  There is a ¬± 1 day window for Day 1 dosing during Cycles 2-6.  However, no window is 
applicable to Cycle 1 Day 1 dosing.
8.2.1. Optional Prephase Treatment
For elderly subjects or for subjects with bulky disease, systemic symptoms, compressive disease, 
elevated bilirubin due to lymphoma, or ra pidly progressing adenopathies, prephase treatment 
with corticosteroids according to local pract ice is per mitted prior to beginning the Treatment 
Period, at the discretion of the investigator ( Pfreundschuh, 2010 ).  It is recommended to limit the 
prephase treatment to up to 100 mg / day prednisone or equivalent for 10 days.  In the case of 
prephase corticosteroid treatment, there is no protocol specified definition of bulky disease.  A washout period is not required; prephase treatment may be given, immediately followed by the 
prednisone as part of R-CHOP, and then a corticosteroid taper is allowed.  However, the 
Screening PET, CT, lymph node biopsy, and bone marrow biopsy (and if applicable, also the 
bone marrow aspirate) should be completed before initiating corticosteroids.  
In cases of medical emergencies (e.g., superior vena cava or spinal cord compression) in which 
prephase treatment with corticosteroids is not c onsidered adequate, it may be acceptable for local 
radiation to be administered; however, the Celgene medical monitor must be consulted.  In such 
case, the radiated lesion(s) cannot be used as measurable (target) lesion(s).
Prephase treatment with vincristine or any other chemotherapy is prohibited.&(/*(1(35235,(7$5<,1)250$7,21dede, 
ational, ational, 
or licensedor licensed
ording to loording to lo
ll be l be selectselec
gatgive site.ive site
ed prophylad prophyla
n reactn react ioions,ns
during Cycduring Cy
hbbhulkyulky disedisy
,or rapidlyor rapidl
local practlocal prac
investigatoinvestiga
100 mg / d100 mg /
treatment, treatment
rrequired; pequired
of Rof R--CHOCHO
CTCT, lymph, lymphT
w aspirate) w aspirate)
of medicalmedica
ase treatmease treatm
iatatioion to bn to b
casase,ththe rae ra
rerephapha
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 60 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20198.2.2. Optional Consolidation Treatment (Pre-Specified)
The investigator may prospectively choose to give local radiotherapy after study chemotherapy 
per local practice, such as for the treatment of a pa rticular site of bulky disease or a large mass, 
or in subjects at higher risk for CNS lymphoma.  In the case of consolidation treatment, bulky disease is defined as ‚â• 7.0 cm.  However, the decision to treat and the location to be treated must 
be determined during the Screening Period and registered in the IVRS.  In this case, the 
consolidation radiotherapy will not count as a treatment event for the EFS endpoint.  
If the investigator should decide at anytime after Cycle 1 Day 1 to give consolidation treatment, 
or to switch treatment to a different lesion, recei pt of consolidation treatment will count as an 
EFS event.  
8.2.3. Mandatory Primary Neutropenia Prophylaxis
Primary neutropenia prophylaxis with either granulocyte-colony stimulating factor (G-CSF) or 
granulocyte macrophage-colony stimulating factor (GM-CSF) is required for all subjects at every 
cycle during Cycles 1 ‚Äì 6.  The selection of a par ticular drug, for example filgrastim, 
pegfilgrastim, lenograstim, sargramostim, molgr amostim, is per local practice.  The dose and 
schedule of the selected drug is also determined per local pract ice. However, it is reco mmended
that investigators follow either of the below schedules, at every cycle:
!Pegfilgrastim (or equivalent biosimilar product) once per cycle, starting on Day 2-4 (i.e. 
1-3 days after chemotherapy)
OR
!Filgrastim (or equivalent biosimilar product) for at least 7 days in each cycle, starting on 
Day 2-4 (i.e. 1-3 days after chemotherapy)
8.2.4. Lenalidomide/Placebo-R-CHOP Regimen
The R2-CHOP or placebo-R-CHOP regimen will be administered over a 21-day cycle (with the 
possible exception of Cycle 1, whic h may last 22 days; see Section 8.2.6 Rituximab).  
Treatment will continue until the R2-CHOP or p lacebo-R-CHOP regimen of 6 cy cles is 
complete, or until unacceptable toxicity, inadequate response to treatment is determined, disease 
progression, or withdrawal of consent, whichever occurs first.  
&(/*(1(35235,(7$5<,1)250$7,21nt, 
an n
actor (ctor ( G-G-CSC
or all subjer all subje
le filgrastfilgra im
practpract ice.  Tice.  T
However, However
cyclecycle :
ce per cyclee per cycle
duct) for at duct) for a
rapy)rapy)
HOPHOP RegRe
regimen wregimen 
hich may lhich may l
l ththe e R2-R2CH
ptable toxicptable t
awal of conawal of con
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 61 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 7: Lenalidomide/Placebo-R-CHOP Regimen
Drug DoseDosing Days
(21-day cycle)
Lenalidomide / Placebo PO 15 mg 1-14
Rituximab IV 375 mg/m2-1 OR 1
Cyclophosphamide IV 750 mg/m21
Doxorubicin IV 50 mg/m21
Vincristine IV 1.4 mg/m2 (max of 2.0 mg total) 1
Prednisone / Prednisolone PO
(Day 1 IV administration is acceptable)100 mg 1-5
IV=intravenous, PO= per os, oral administration
8.2.5. Lenalidomide / Placebo 
Lenalidomide is initiated on Day 1 of Cycle 1 at a dose of 15 mg (oral administration) PO once 
daily for 14 days in each 21-day cycle. 
On Day 1 of every cycle, lenalidomide will be administered in the clinic.  For subsequent dosing 
days, subjects should be instructed to take lenalidomide / placebo at approximately the same time
each day as the Day 1 dosing for that cycle. Th ere is no requirement for taking lenalidomide / 
placebo with or without food, or with or without certain types of foods or liquids.
A 7-day rest period following the 14 days of dosing is required, unless the allowed -1 day visit 
window around Day 1 is used; in this case the minimum rest period is 6 days.  A rest period may 
be extended for toxicit y as needed (Section 8.2.12 ).
If a subject misses a dose of len alidomide / placeb o and it is within 12 hours of their normal 
dosing time, the subject should be instructed to mak e up the missed dose, and to then take their 
next dose according to their regular schedule. Lenalidomide concentration is low at 12 hours post dose, therefore making up a missed dose and then resuming regular dosing with a greater 
than or equal to ( ‚â•) 12 hour interval between the two doses will not cause considerable drug 
accumulation.  
Dose modifications are per Table 8. The dose may also be interrupted and/or reduced for 
reasons in addition to those listed in Table 8 per investigator discretion.  If a dose is reduced, re-
escalation is not permitted.
8.2.6. Rituximab
The investigator may choose whether to administer rituximab on Day 1 of the cycle or one day 
prior to the start of the cycle.  During Cycle 1, if rituximab is administered one day prior to the start of the other chemotherapy drugs, then Cycle 1 may last 22 days instead of the usual 21 (Day 
-1 plus Days 1 ‚Äì 21); and first receipt of rituximab will mark the beginning of the Treatment 
Period.  Additionally, the investigator may choose to administer rituximab over two days at the &(/*(1(35235,(7$5<,1)250$7,21$7$7$7$70$$$
11-5550
)2
(oraloradminadminl
d in the clinin the cl
/ pl/ placebo acebo
 no requireno requ
ertaiertain tyn typepyyy
dosing is dosing is rere
the minimuhe minim
tion on8.2.128.2.1 )
omidemide / pl/ pla
e instructede instructe
egular scheegular sche
g up a missup a mis
hour intervahour interv
ns are perns are per
ittioion to thn to th
is not perms not perm
Rituxitu
he he investinvest igig
priprior to thto th
art ofart of
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 62 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019beginning of each cycle per local practice (for example Day -1 and Day 1; or Day 1 and Day 2; 
or Day 2 and Day 3).
It is permissible to administer an additional two doses (1 dose per 21-day cycle) of single agent 
rituximab after the 6 cycles of study treatment are complete if it is considered standard of care 
per local practice.  However, the decision to administer these extra two doses must be pre-
specified in IVRS prior to randomization.  The radiological and response assessment schedule is 
the same for all subjects regardless of whether the optional two doses of rituximab are 
administered.  Therefore, the scan required at 3 ‚Äì 4 weeks after completing Cycle 6 must be 
completed before the optional Cycle 7 dose of rituximab is administered.  
Preparation, infusion rate, dose modification, and guidance on pregnancy prevention s hould be 
performed according to the locally approved ritux imab prescribing infor mation or your local 
institutional practice.
8.2.7. Cyclophosphamide
Preparation and infusion rate are according to the package insert and local pract ice.  
Recommended dose modifications are provided in Table 10 and may be applied at investigator 
discretion.  For tox icities not covered by Table 10 it is recommended to follow the package insert 
and local practice.  
8.2.8. Doxorubicin
No other anthracycline may be substituted for doxorubicin.  Liposomal doxorubicin is not 
permitted.  
Preparation and infusion rate are according to the package insert and local pract ice.  
Recommended dose modifications are provided in Table 10 and may be applied at investigator 
discretion.  For tox icities not covered by Table 10 , it is recommended to follow the package 
insert and local practice.  
8.2.9. Vincristine
Preparation and infusion rate are according to the package insert and local pract ice.  
Recommended dose modifications are provided in Table 11 and may be applied at investigator 
discretion.  For tox icities not covered by Table 11 , it is recommended to follow the package 
insert and local practice.  
8.2.10. Prednisone
The prednisone start dose is a flat 100 mg PO or intravenous (IV) dose ( Moreno, 2000 ).
Subsequent doses may be reduced for medical reasons at investigator discretion.
Subjects should be instructed to take prednisone in the morning on scheduled dosing days.  
In countries where prednisone is not available it will be acceptable to substitute prednisolone on 
a 1:1 basis for prednisone. It is also acceptable to administer the prednisone or prednisolone by IV rather than PO on Day 1 of the cycle for convenience.  In countries where local pract ice is to 
use an IV formulation on Day 1, it will be acceptab le to substitute an equivalent (80 mg) or local &(/*(1(35235,(7$5<,1)250$7,21oulld be d be 
ur lur localocal
al practpract ice.
ybbye appliede applie
ded to foed to fo llollo
ubiubicin.c LipL
the packagthe packag
ovided inovided in TT
byTableTabl 1010
ate are accoe are acco
mododificatific io
citieies snot cnot c
practpract ice.  ice.  
PrednisonPrednison
ednisone ednisone ss
sequent dosequent do
&SubjectSubject s shs s
coucou
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 63 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019practice dose of IV methylprednisone on Day 1 only of each cycle.  It will also be acceptable to 
substitute with a local practice dose of IV dexamethasone on Day 1 only of each cycle.  
8.2.11. Lenalidomide/Placebo-R-CHOP Regimen Modifications
Recommended regimen modifications are provided in Table 12 and may be applied at 
investigator discretion.  For toxicities not covered by Table 12 , it is recommended to follow the 
respective package inserts and local practice.  
8.2.12. Requalification Criteria For Subsequent Treatment Cycles
The next cycle of treatment may begin on the ne xt scheduled Day 1 if all of the following 
Requalification Criteria are met:
!ANC ‚â•1,000 cells/mm¬≥ (1.0 x 109/L), unless secondary to lymphoma bone marrow 
or spleen involvement per investigator assessment
!Platelet count ‚â• 75,000 cells/mm¬≥ (75 x 109/L), unless secondary to lymphoma bone 
marrow or spleen involvement per investigator assessment
!All other non-hematological toxicities have resolved to ‚â§ Grade 2 
!A 7-day rest period has elapsed following the last dose of lenalidomide/placebo (a
6-day rest period applies if the early rituximab dosing option is used; Section 8.2.6 )
If the Requalification Criteria are not met (after the rest period has elapsed) on Day 1 of the new 
cycle, the subject will be evalu ated again within 7 days.  If the requalification criteria are still not 
met after 7 days delay, the subject will be evaluated again in another 7 days.  If the 
requalification criteria are again not met after 14 days total delay, hold lenalidomide/placebo, 
and if clinically appropriate, continue R-CHOP alone (c ontinue in the Treatment and Follow-up 
Periods per Table 5 ).  Lenalidomide/pl acebo may be resumed later if the requalification criteria 
are met; however, skipped doses of lenalidomide/ placebo may not be made up, and rest periods 
must be observed.
Other toxicity delays for any of the individual chemotherapy drugs rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) are allowed.  Other 
toxicity delays for R-CHOP as a unit are allowed t o a maximum of two 14-day delays over all 6 
cycles.  At investigator discretion, lenalidomide/placebo may be continued alone if R-CHOP is 
discontinued, provided the above re-qu alification criteria are otherwise met, and rest periods are 
observed.
If the requalification criteria are fulfilled, but the subject develops toxicity as described in
Table 8 due to lenalidomide / placebo, the R-CHOP drugs  should continue even if lenalidomide / 
placebo is held.  There is no maximum delay limit for lenalidomide / placebo.  Lenalidomide / 
placebo may be resumed later if the requalification criteria are met; however, skipped doses of 
lenalidomide/ placebo may not be made up and rest periods must be observed. &(/*(1(35235,(7$5<,1)250$7,21g 
bone marroone marr
ryryto to yylymphlymph
‚â§ ‚â§GradeGrade 2 2
ose of lse of ena
osing optiosing opti o
period hasperiod ha
aysys.  If.   the thf
ed again ined again i
14 days tota4 days tot
OP alOP a one one((
ebo mebo m ayay bby
nalidonalido midemide
fththe individindivi
icin, icin, vincrivinc
OP as a uniOP as a 
rdiscretdiscr ion
deddththe aboe abo
ificatificat ioion crn cr
ue to lto lenalienal
oois isheld.ld
ebo mebo m ay bay b
enalidoenalido midmid
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 64 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 8: Dose Modification Rules ‚Äì Lenalidomide / Placebo
NCI CTCAE (v 4.03)
Toxicity Grade Action Required
Neutropenia*
Sustained ( ‚â• 7 days) Grade 4 
(neutrophil count < 500 
cells/mm¬≥ [0.5x109/L])
*unless secondary to lymphoma 
bone marrow or spleeninvolvement per investigator assessment!Withhold dose for the remainder of the cycle
!Monitor CBC at least every seven days
!At the next cycle, when the Requalification Criteria For 
Subsequent Treatment Cycles (Section 8.2.12 ) are met, restart at 
the same dose level
Febrile Neutropenia*
Grade 3 or 4
*unless secondary to lymphoma 
bone marrow or spleen 
involvement per investigator 
assessment!Withhold dose for the remainder of the cycle
!Monitor CBC at least every seven days
!At the next cycle, when the Requalification Criteria For 
Subsequent Treatment Cycles (Section 8.2.12 ) are met, restart at 
the next lower dose level
Thrombocytopenia*
Grade 4 (platelet count < 25,000 
cells/mm¬≥ [25x109/L]) 
*unless secondary to lymphoma 
bone marrow or spleen
involvement per investigator 
assessment!Withhold dose for the remainder of the cycle
!Monitor CBC at least every seven days
!If at Day 1 of the next cycle, the Requalification Criteria For 
Subsequent Treatment Cycles (Section 8.2.12 ) are met, restart at 
the same dose level
!If at Day 1 of the next cycle, the Requalification Criteria For 
Subsequent Treatment Cycles (Section 8.2.12 ) are not met, restart 
at the next lower dose level when Requalification Criteria are met
Rash
Grade 2 or 3 non-desquamating 
(blistering)
------------
Desquamating (blistering) ‚â•
Grade 3 
ORNon-desquamating Grade 4!Determine causative investigational product and if attributable to 
lenalidomide then: 
-Hold dose; administer antihistamines or short course of ‚â§ 20 
mg prednisone (or equivalent)
-When toxicity resolves to ‚â§ Grade 1, restart at the same dose 
level-----------------
!Determine causative investigational product and if attributable to 
lenalidomide then: 
-Discontinue lenalidomide / placebo
Allergic reaction or 
hypersensitivity
Grade 2
------------
Grade 3‚Äì 4!Determine causative investigational product and if attributable to 
lenalidomide then: 
-Withhold dose.  Follow at least every seven days
-When the toxicity resolves to ‚â§ Grade 1, restart lenalidomide / 
placebo at next lower dose level-----------------
-Discontinue lenalidomide &(/*rgic reactiorgic react
ypersensitivpersensitiv
GradGra/*(1(35235,(7$5<,1)250$7,21t at t at 7,2
cation Criteration Criter
ion 8.2.128.2.1 )50
mainder of thmainder 
every sevenvery sev
next cycle, next cycle,
eaeatment Cyctment C
se levele level
y 1 of the ne1 of the n
equent Treaequent Trea
he next lowhe next low<,
blistering) blistering) ‚â•‚â•
esquamatinquamatinDetDeterermin
lenalidnalid
--35
35
/*
&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 65 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 8: Dose Modification Rules ‚Äì Lenalidomide / Placebo (Continued)
NCI CTCAE (v 4.03)
Toxicity Grade Action Required
Constipation
Grade 1‚Äì2
-----------------
‚â• Grade 3!Initiate bowel regimen and maintain dose level
-----------------
!Withhold dose.  Follow at least every seven days 
!When the toxicity resolves to ‚â§ Grade 2, restart at same dose level
Venous thrombosis/embolism
‚â• Grade 3!Withhold dose and start therapeutic anticoagulation; restart at 
investigator‚Äôs discretion (maintain dose level)
Tumor Lysis Syndrome (TLS)
Grading is per Cairo-Bishop, and
not per NCI CTCAE, for TLS 
only
Lab TLS or Grade 1 TLS
-----------------
Grade 2 ‚Äì 4!Continue lenalidomide (maintain dose), or at the investigator‚Äôs 
discretion, continue lenalidomide and reduce dose by one level
!Provide vigorous IV hydration and appropriate medical 
management according to the local standard of care, until electrolyte abnormalities are corrected.  Rasburicase therapy is appropriate (if approved by the local Health Authority) as needed 
to reduce hyperuricemia
!Hospitalization will be at investigator‚Äôs discretion
-----------------
!Withhold dose
!When symptoms resolve to Grade 0, restart at same dose level
!If lenalidomide is resumed prior to the start of the subsequent 
cycle, a chemistry test should be performed every other day for the first week following re-initiation of lenalidomide
AST or ALT > 3 x ULN !Withhold lenalidomide dose; re-test at least weekly until AST or 
ALT < 2.5 x ULN or return to baseline
!If the event is considered related to lenalidomide, restart 
lenalidomide at next lower dose level
!If the event is considered NOT related to lenalidomide, restart the 
same dose level of lenalidomide
!For subjects with Gilbert‚Äôs syndrome or liver involvement, consult
the Celgene medical monitor regarding dose reductions 
Bilirubin > 3 x ULN !Withhold lenalidomide dose; re-test at least weekly until bilirubin 
< 1.5 x ULN
!If the event is considered related to lenalidomide, restart 
lenalidomide at next lower dose level
!If the event is considered NOT related to lenalidomide, restart the 
same dose of lenalidomide
!For subjects with Gilbert‚Äôs syndrome or liver involvement, consult
the Celgene medical monitor regarding dose reductions&(/*(13 3 x ULNx ULN(1(35235WithholdWithh
ALT <LT <
!!IIff35,(7$5<,1)250t the investit the investi
uce dose byuce dose by
propriate mpropriate m
standard ofstandard 
rrectedected .  Ras.  Ra
he local Heae local He
e at investigaat investig
ptoms resolvptoms reso
domide is redomide is r50$7,21osose e levellevel7,2
restart at restart at 0$
e, a chemistr, a chemistr
e first weeke first week50
35
35
(1
&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 66 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 8: Dose Modification Rules ‚Äì Lenalidomide / Placebo (Continued)
NCI CTCAE (v 4.03)
Toxicity Grade Action Required
Other lenalidomide related non-
hematologic AEs ‚â• Grade 3!Withhold dose
!When the AE resolves to ‚â§ Grade 2, restart at the same or next 
lower dose level per the investigator‚Äôs discretion
AE= adverse event, ALT= alanine transaminase; AST= aspartate transaminase CBC= complete blood count, NCI 
CTCAE=National Cancer Institute Common Terminology Criteria for AE, Lab = laboratory, ULN= upper limit of 
normal
Table 9: Dose Reduction Levels ‚Äì Lenalidomide
Starting Dose 15 mg Daily on Days 1-14, Every 21 Days
Level ‚Äì1 Dose 10 mg daily on Days 1‚Äì14, every 21 days
Level ‚Äì2 Dose 5 mg daily on Days 1‚Äì 14, every 21 days
Level ‚Äì3 Dose 2.5 mg daily on Days 1‚Äì14, every 21 days
Table 10: Recommended Dose Modification Rules ‚Äì Cyclophosphamide and/or
Doxorubicin
NCI CTCAE (v 4.03)
Toxicity Grade Action Required
Neutropenia
Sustained ( ‚â• 7 days) Grade 4!If toxicity occurs after discontinuing lenalidomide, decrease both 
cyclophosphamide and doxorubicin by 25% and follow standard dosing guidelines
Thrombocytopenia
Sustained ( ‚â• 7 days) Grade 4
OR‚â§10,000 cells/mm
3or 10 x109
cells/L) at any time!If toxicity occurs after discontinuing lenalidomide, decrease both 
cyclophosphamide and doxorubicin by 25% and follow standard 
dosing guidelines
Cystitis, noninfective
Grade 2!Withhold cyclophosphamide for the current cycle and until 
resolution of cystitis
!At next cycle decrease current cyclophosphamide dose by 50%  
!For subsequent cycles, if all renal / genitourinary toxicity is Grade 
< 2, re-escalate to the previous cyclophosphamide dose
Left ventricular systolic 
dysfunction
‚â• Grade 3!Discontinue doxorubicin&(/*(nn
*(1(35235,(7$5<,1)250$7,217,27,27,2mit of it of
ry 21y 21 DaysDay5
ysys2
daysdays)2
ery 2ery 2 11daysday1
<, CyclophoCyclopho
AcA7$
ty occurs afty occurs aft
phosphamidphosphamid
sing guidelising guide,(
10 x1010 x9!!If toxicIf toxi
cyclcy
d23
35
infectiveinfective
21(
Left ventrLeft ventr
dysfuncdysfun
‚â•G(/&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 67 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 10: Recommended Dose Modification Rules ‚Äì Cyclophosphamide and/or 
Doxorubicin (Continued)
NCI CTCAE (v 4.03)
Toxicity Grade Action Required
Mucositis / Stomatitis
‚â• Grade 2!At next cycle decrease current doxorubicin dose by 25%
!For subsequent cycles, if toxicity resolves to < Grade 2, re-
escalate to the previous doxorubicin dose
NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.
Table 11: Recommended Dose Modification Rules ‚Äì Vincristine
NCI CTCAE
Toxicity Grade (v 4.03) Action Required
Peripheral ne uropath y- motor
Grade 2
-----------------Grade 3!Withhold vincristine for the current cycle and until toxicity 
improves to < Grade 2 
!At next cycle decrease current dose by 50%  
-----------------
!Discontinue vincristine
Peripheral neuropathy- sensory
Grade 3
-----------------Grade 4!Withhold vincristine for the current cycle and until toxicity 
improves to < Grade 2
!At next cycle decrease current dose by 50%  
-----------------
!Discontinue vincristine
NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.
Table 12: Recommended Dose Modification Rules ‚Äì Lenalidomide/Placebo R-CHOP 
Regimen 
NCI CTCAE (v 4.03)
Toxicity Grade (as applicable) Action Required
Nausea / Vomiting 
Grade 3!Maximize anti-emetic therapy; if anti-emetic therapy is 
ineffective, discontinue lenalidomide/placebo or entire regimen at 
investigator discretion 
Infection 
with ANC ‚â• 1000/mm3 and 
requiring IV antibiotics or 
hospitalization 
------------
with ANC < 1000/mm3 and 
requiring IV antibiotics or 
hospitalization !Withhold regimen; restart at the same dose level when infection is 
controlled.  
!If AE reoccurs on subsequent cycles, decrease 
lenalidomide/placebo to next lower dose level and consider prophylactic antibiotics
------------
!Withhold regimen; restart when infection is controlled, decrease 
lenalidomide/placebo to the next lower dose level. &(/*(ANC C‚â• 1000‚â• 100
quiring IV aquiring IV
hospitalizathospitalizat(1(35235,(7$5<,1)250$7,217,7,7,
50
cycle cycle and and
nt dose by 5dose by 5
ee2
ine infor the for the 
Grade 2Grade 2
cle decreasecle decreas
-----
continue vicontinue vi5<
5,TerminologyTerminolog
e ModificaModific
cable)cable)33353(333
--------(
&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 68 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Table 12: Recommended Dose Modification Rules ‚Äì Lenalidomide/Placebo R-CHOP 
Regimen (Continued)
NCI CTCAE (v 4.03)
Toxicity Grade (as applicable) Action Required
!If AE reoccurs despite discontinuation of lenalidomide/placebo, 
then on subsequent cycles reduce cyclophosphamide by 25% and 
doxorubicin by 25%; consider prophylactic antibiotics.
Viral Hepatitis B, C
new infection, or reactivation !Discontinue regimen; treat hepatitis 
Other non-hematologic 
toxicity
Grade 3!Withhold regimen until toxicity resolves to ‚â§ Grade 2 or baseline, 
then restart
8.2.13. Overdose
Overdose, as defined for this protocol, refers to lenalidomide / placebo, rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone / prednisolone.  On a per-dose basis, 
an overdose is defined as the following amount over the protocol-specified dose of these drug(s) 
assigned to a given subject, regardless of any associated AEs or sequelae:
PO any amount over the protocol-specified dose
IV 10% over the protocol-specified dose
On a schedule or frequency basis, an overdose is defined as anything more frequent than the 
protocol required schedule or frequency.  On an infusion rate basis, an overdose is defined as any 
rate faster than the protocol-specified rate.
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the CRF.  See Section 11for the 
reporting of AEs associated with overdose.  
8.2.14. Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from study 
treatment:
!Treatment was completed per protocol
!Adverse event(s)
!Locally assessed outcome of the Midc ycle CT scan indicates a treatment change
!Disease progression
!Protocol violation
!Withdrawal of consent
!Lost to follow up&(/*(1(35235,(7$5<,1)250$7,217,$7,7,7,
 2 or baselin2 or basel0$
)2
ebo, rituximo, rituxim
ednisonilone.ne.
colcol-specifiespec
s or seques or sequ
is defined s defined
n an infusion an infusio
e.e.
ation, includtion, inc
oonal, shounal, sho
hh overdose overdoshh
on
are considare cons
eatment waatment w
AdAdverse verse 
!!LocaLoc
!D
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 69 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019!Death
The following events are considered sufficient reasons for discontinuing a subject from the 
overall study:
!Withdrawal of consent
!Lost to follow up
!Death
The reasons for both treatment and study disconti nuation should be recorded in the CRF and in 
the source documents.
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
&(/*(1(35235,(7$5<,1)250$7,21in in 
25)251)21)
<, 1<, 15<$5<
(7$,(75,(35,2352352352(3 5(31(
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 70 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019&(/*(1(35235,(7$5<,1)250$7,21&(/*(1(35235,(7$5<,1)250$7,2
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 71 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20198.5. Method of Treatment Assignment
An IVRS will be employed to accomplish rando mization, to record pre-specification of optional 
consolidation radiotherapy, and to manage subject medications.  
Subjects will be typed as GCB, ABC, or unclassi fiable by the Central Pathology laboratory as 
part of screening.  Disease diagnosis, subtype , and CD20 status will be entered by the Central 
Pathology laboratory into the IVRS.  
Once the subject is determined eligible, the investigator or designee will access the IVRS within 
the 28-day Screening Period to obtain the randomized treatment assignment for the subject.  
Subjects will be stratified as follows: 
!IPI score:  2 / ‚â• 3 
!Age: < 65 / ‚â• 65
!Presence of bulky disease: ‚â• 7.0 cm (bulky) / < 7.0 cm (non-bulky)
Subjects will be ra ndomized in  a 1:1 ratio to either R2-CHOP or placebo-R-CHOP.  The subject 
identification number (s ubject ID) assigned by the IVRS will id entify the subject for all aspects 
of the study, including drug re-supply requests,  result reporting from all central laboratories, 
central radiology data submission, and CRF data.  The ra ndomization schedule w ill be generated 
by the IVRS vendor.
8.6. Packaging and Labeling
Lenalidomide / placebo will be packaged in bottles, and each bottle will contain 14 capsules.  
The label(s) for IP will include sponsor name, address and telephone number, the protocol 
number, IP name, dosage form and strength (where applicable), amount of IP per container, lot &(/*(1(35235,(7$5<n, to to recordreco
edicatedic ioionsn
ifiablefiable by ytht
, and CD20 and CD20
e, ththe ie invesnves
ain the randn the ran
loowsws: :
3 3
‚â• ‚â• 6565
ce of bulky e of bulky
e randoe rando mizm
nnnumber number 
udy, includ, inclu
llradiradologo
the IVRS vhe IVRS v
8.6.8.6.7,21
< ,1)250$7,2
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 72 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019number, expiry date (where applicable), medication identification/kit number, dosing 
instructions, storage conditions, and required caution statements and/or re gulatory statements as 
applicable. Additional information may be included on the label as applicable per local 
regulations.
8.7. Investigational Product Accountability and Disposal
The investigator(s) or designee is responsible for taking an inventory of each shipment of 
investigational product received and compar ing it with the accompanying shipping 
order/packaging slip.  The investigator(s) will verify the accuracy of the information on the shipping order/packaging slip and call IVRS to register receipt at the site of the investigational 
product.  
At the study site, investigational product will be stored in a locked, safe area to prevent 
unauthorized access and should be stored as directed on the product label.
An accurate accounting of the dispensing and return of investigational product for each study 
subject will be main tained in source documents on an ongoi ng basis by a member of the study 
site staff.  Additionally, if any investigational product is lost or damaged or if the study subject
misses a dose, this informatio n should be documented in the study subject‚Äôs CRF and source 
documents.  
Celgene will instruct the investigator on the return, disposal, and/or destruction of unused
investigational product.   
8.8. Investigational Product Compliance
For the oral medications of prednisone (or prednisolone) and lenalidomide / placebo, study 
personnel will review the dosing instructions with  the subject prior to dispensing investigational 
product. The subject will be instructed to return the investigational pr oduct bottles, including 
any unused investigational product, to the site at the end of the applicable treatment cycle. To 
monitor treatment compliance, the subject w ill be interviewed at each applicable visit regarding 
whether they took their medication, and a r econciliation of capsules will be done upon bottle 
return.  Subject compliance will be noted in the source records and on the appropriate CRFs based upon the interview and capsule count.
For the IV medications of rituximab, cyclophosphamide, doxorubicin, and vincristine, the 
planned and administered dosage will be recorded in the source records and on the appropriate   CRFs.
&(/*(1(35235,(7$5<,1)250$7,21ioonal nal 
event vent 
ductuctfofor eacr eac
a mmember oembe
ged or if thged or if t
ysubjectsubject ‚Äôs ‚Äôs C
al,and/or deand/or d
ianceianc
dnisolone) dnisolone)
ns wits wit h the h the
o return tho return 
o the site o the sit at
subjectsubject wii
ioion, and a n, and a 
will be notwill be not
anddcapsulcap
ns of rituximns of ritux
nistered dosistered dos
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 73 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20199. CONCOMITANT MEDICATIONS AND PROCEDURES
9.1. Prohibited Concomitant Medications 
Anticancer therapy other than R-CHOP plus le nalidomide or placebo is prohibited during the 
entire Treatment Period of the study.  
Other investigational therapy (drug or otherwise) is prohibited 28 days prior to Day 1 dosing and 
during the entire Treatment Period of the study.  
9.2. Permitted Concomitant Medications 
9.2.1. Hematopoietic Growth Factors and Transfusions
Growth factors (eg erythropoietin, platelet growth  factors) and blood product transfusions 
(packed red blood cells, platelets, etc.) may be pr escribed during the Treatment and Follow-up 
Periods at the investigator‚Äôs discretion and should be used in accordance with the American 
Society of Clinical Oncology‚Äôs (ASCO) guidelines or the European Society for Medical Oncology (ESMO) guidelines.  With the exception of packed red blood cells, which may be 
administered at any time as needed, including during Screening; other growth factors or blood 
product transfusions should not  be administered during the Screening Period to increase a 
subject‚Äôs blood values in order to meet entry criteria.  Note that primary neutropenia prophylaxis 
during the Treatment Period is mandatory (Section 8.2.3 ).  
9.2.2. Pneumocystis Pneumonia Prophylaxis
Pneumocystis prophylaxis is permitted for all subjects according to local pract ice.
9.3. Recommended Concomitant Medications 
9.3.1. CNS Lymphoma Prophylaxis
Subjects at risk for CNS involvement may receive CNS lymphoma prophylaxis treatment.  The 
following may be considered by the investigator: 4 ‚Äì 8 doses of intrathecal methotrexate and/or 
cytarabine administered during the R2-CHOP or placebo-R-CHOP induction treatment.  CNS prophylaxis with IV drugs is not permitted.
9.3.2. Nausea Prophylaxis
Premedication with an antiemetic is recommended according to local pract ice.
9.3.3. Rituximab Infusion Reaction Prophylaxis
Premedication with acetaminophen and diphenhydramine to prevent a rituximab infusion 
reaction is recommended according to local practice.  It is acceptable to use glucocorticoid 
steroids to treat an active rituximab infusion reaction as per local practice.&(/*(1(35235,(7$5<,1)250$7,21nsfusionsfusio nsns
t and Foand Fo lloll
ith the Amth the Am
ietty y fofor Mer 
od cells, wod cells, w
ther gher g rowthrowt
eening Periening
hat phat p rimaryrimar
.   
ubjectbject s accos ac
ant ant MedMed
ylaxisylaxis
ment may rment may 
by the by the iinvenv
uring the R2ing the R
ugs is not pugs is not 
a ProphylaProphyla
wiwiththii an anan ahh
RituximRituxim
mmedicedicatatioion wn 
actiaction is reon is re
&steroiteds tods to
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 74 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20199.3.4. HBV Reactivation Prophylaxis
Subjects who are HBsAg negative, anti-HBs posit ive, and or anti-HBc positive, but viral DNA 
negative are eligible.  For these subjects, DNA monitoring and prophylactic medication for HBV 
reactivation are recommended per local practice.
9.3.5. TLS Prophylaxis
It is recommended that subjects receive TLS prophylaxis (allopurinol, rasrubricase or equivalent 
as per institutional guidelines) and be well hydrated (orally) during the first week of treatment 
administration in the first cycle, or as clinically indicated.  Hydration levels should be adjusted 
according to age and clinical status.  To monito r for TLS, the subjects will have blood samples 
drawn for serum chemistry on Days 1, and 8 of the first 2 cycles and additionally as clinically 
indicated.  TLS will be assessed by the Cairo-Bishop Grading system (not by CTCAE) and the 
assessment includes both laboratory tumor lysis syndrome (LTLS) criteria and clinical TLS criteria. If a subject develops LTLS (defined by the presence of two or more serum value 
abnormalities of uric acid, po tassium, phosphorous , or calcium) or ‚â• Grade 1 TLS (defined by 
the presence of laboratory TLS and one or more of the following criteria: creatinine ‚â• 1.5 x ULN, 
arrhythmia, or seizures), appropriate medical ma nagement should be initiated according to the 
local standard of care in each in stitution, along with vigorous IV hydration.  Rasburicase 
treatment is considered appropriate if it is approved by the local Health Authority.
Refer to Table 8 for further instructions and dose modifications for TLS. 
9.3.6. Venous Thromboembolism Prophylaxis
It is not known whether prophy lactic anticoagulation or antip latelet therapy prescribed in 
conjunction with lenalidomide may lessen the potential for venous thromboembolism. In this 
double-b lind placebo-controlled clinical trial, in which the investigator does not know the 
subject‚Äôs treatment arm assignment, the decision to take prophylactic measures should be madecarefully after an assessment of an individual subject‚Äôs underlying risk factors.
As reference information, for subjects receiving lenalidomide in open-label trials, it is strongly 
recommended that subjects at risk for VTE receiv e either aspirin (70 ‚Äì 325 mg PO daily) or 
another prophylaxis agent while on lenalidomide. In t hose subjects with a high risk of VTE, it is 
strongly recommended that the subject receive prophylactic anticoagulation therapy with low 
molecular weight (LMW) heparin, or heparin (dose recommended for the prophylaxis of DVT/PE per the package insert), or warfarin (to maintain an INR of 2.0). These prophylactic 
agents should be considered for subjects enrolli ng in this blinded, placebo-controlled clinical 
trial. The choice of VTE prophylaxis agent relies upon the investigator‚Äôs discretion and should be tailored to the subject‚Äôs individual risk/benefit profile by taking into account the individual 
thrombotic risk, bleeding risk, and the quality of compliance with the VTE prophylaxis.
The use of clopidogrel or ticlopidine alone is not recommended as VTE prophylaxis in this trial.
9.4. Mandatory Concomitant Medication
9.4.1. Primary Neutropenia Prophylaxis
Please refer to Section 8.2.3 .&(/*(1(35235,(7atii(7$5<,1)250$7,21sted ed 
mples ples mmm
linicallylinically
AE) AE) and and thth
linical TLSlinical T
serum valuserum va
ee1 TLS (d1 TLS (d
iaa::creatinincreatin
e ininititiiiated aated a
hyydratdioonn
alal Heal Healll thtllAh
ations for Ttions for T
iss
on or anton or ant
e potente potent ial ial f
ial, in whicial, in whic
decision todecision 
dividualdividual su
bjects receibjects rece
t risk for VTrisk for V
while on lehile on le
that the subthat the su
MW) heparMW) hepa
package insackage ins
be considere consid
hohoicice ofe of VT VTff
ed to the subo the su
botibotic risk, bc risk, b
heeuse of cluse of cl
9.4..4.
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 75 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201910. STATISTICAL ANALYSES
The objectives of the statistical analyses are to investigate the effi cacy and safety of R2-CHOP 
versus placebo-R-CHOP in subjects with previous ly untreated, ABC type DLBCL.  One interim 
analysis at 50% information level for fut ility and one final analysis for superiority are 
pre-planned for the primary efficacy endpoint.
10.1. Overview
Eligible subjects will be randomized to either  the R2-CHOP or placebo-R-CHOP regimen in a 
1:1 ratio.  Treatment will continue until 6 cycles of treatment are completed, or un til 
unacceptable toxicity, or the outcome of the Midcycle CT scan indicates a treatment change, disease progression, or withdrawal of consent, whichever occurs first.  Upon treatment 
completion or premature discontinuation, subjects will be followed for progression, subsequent 
antilymphoma therapies, and overall survival.
The efficacy analyses will be based on subjects‚Äô response to treatment evaluated by the 
investigator and by the IRAC using the IWG Response Criteria for NHL ( Cheson, 2014 ).   
The safety analyses will include AEs, physical examinations, vital signs, and laboratory tests.
All statist ical analyses specified in this protocol will be conducted using SAS
¬Æversion 9.2 or 
higher. 
10.2. Study Population Definitions
In this study the following three populations w ill be defined for the analysis and used in 
presentation of the data.
Intent-to-Treat (ITT) Population: The ITT population is defined as all subjects who are 
randomized into the trial, regardless of wheth er they received study treatment or not.  
Modified Intent-to-Treat (mITT) Population: The mITT population is defined as all
subjects who satisfy the following conditions: 
!are randomized
!have received at least one dose of investigational product
!are CD20+, ABC type DLBCL as determined by Central Pathology 
!are previously untreated
!have measurable disease at baseline
!have at least one post-baseline tumor assessment or died after randomization but 
before the assessment
Safety Population: The safety population is defined as all subjects who have received at 
least one dose of investigational product. 
 
 &(/*(1(35235,(7$5<,1)250$7,21a 
angeange , ,
ent nt 
n, subsequsubsequ
luated by uated by thth
L ((Cheson,Cheso
signs, and lsigns, and
ted using ed usi S
e defined e defined f
he ITT pope ITT pop
oof f whetherwheth
TT) T) PopulaPopu
wing condiwing cond
at laeast onast 
0+,+,ABCABC tyty
previously upreviously u
have have measumeasu
!!have athave a
befobef
Safety Safety 
leasteas&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 76 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019The ITT population will be used for the primary efficacy analysis. Subjects will be analyzed 
according to the treatment arm to which  they are initially assigned. 
The mITT population will be used as supportive analysis for efficacy.  Subjects will be analyzed 
according to the treatment arm to which  they are initially assigned.  
The safety population will be  used for all safety analyses.  Subjects will be analyzed according to 
the treatment which they actually received.
 
10.3. Sample Size and Power Considerations
The sample size of this study is determined to  provide adequate power to evaluate the treatment 
effect on PFS, the primary endpoint.    
Accrual
This study will accrue a total of 560 sub jects over approximately a 34-month accrual period.  
However, if the actual number of PFS events toward the end of the accrual period is far less than expected or if the subject dropout rate is unusually high, an additional number of subjects may be 
enrolled.
Sample Size for the PFS Analysis
The PFS endpoint will be analyzed after a total of 192 PFS events in the ITT population have 
been observed.  This sample size will have 90% power to detect a hazard ratio (HR) of 0.625, 
i.e., a 37.5% reduction in the PFS hazard rate, at a two-sided 0.05 significance level, with an interim analysis for fut ility at 50% of the information pre-planned.   In case the event rate falls 
below 2 events per month before reaching 192 events, the final analysis will be performed when 
at least 170 events have occurred.  The power of the study will be at least 86%.    
With an adequate enrollment rate and the assumption that the median PFS in the control arm is 
about 24 months, it is estimated that the requi red 50% information, or 96 PFS events, for the 
interim PFS futility analysis w ill be available approximately 28 months from the start of 
enrollment, and the required 192 PFS events for th e final PFS analysis will be available in about 
42 months from the start of enrollment.
This sample size is calculated using the software EAST 5.4 with a Œ≤-spending function of 
Gamma(-4).  Since there is no intention to declare efficacy at the interim PFS analysis, no 
Œ±-spending function is specified.  For a detailed description of stopping boundaries please refer 
to Section 10.8 Interim Analysis.
The treatment effect assumption for the sample size determination is based on limited 
information available from two investigator initiated studies (Section 1.5.2.1 study MC078E and 
Section 1.5.2.2 study REAL07). In the event that new d ata from an external, randomized study 
suggests a substantially different effect from the assumptions made in this protocol, the sample 
size or analysis plan of the present study may be  adjusted.  However, th e adjustment should be 
made prior to any un-blinded analysis.ththe treatme treatm
momontnth accrh acc
accrual pericrual peri
onalnanlumbumbn
PFSPFS eventeven
wer to detewer to det
a atwtwo-osideside
rmatrmation prion pr
192 events192 events
power of thpower of 
nd d thte assuassu
that the that the reqreq
will be avaiwill be ava
d 192192PFSFS
t of enrot of enro llml
calculated calculated 
ncnce there ie there i ss
unction is spnction is s
10.80.8InterimInterim
eatment effeatment eff
rmrmatatioion avn av
Sectiectionon1.51.5
suggestsugges
eo$
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 77 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201910.4. Background and Demographic Characteristics
Subjects‚Äô age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics, while gender, race and other categorical variables will be provided using frequency 
tabulations.  Medical history data will be summarized using frequency tabulations by system 
organ class and preferred term.
10.5. Subject Disposition
Subject disposition (analysis population allocatio n, randomization status,  discontinued treatment,
primary reason for early treatment discontinu ation, discontinued the study, primary reason for 
early study discontinuation) will be summarized using frequency and percent for both treatmentarms.  A summary of subjects randomized by c ountry/site will be provided. Protocol 
deviations/violations will be summarized using frequency tabulations.
10.6. Efficacy Analysis
10.6.1. Primary Efficacy Endpoint Definition
The primary efficacy endpoint of this study is PFS, which is defined as the time from 
randomization to objective disease progression or death from any cause, whichever occurs first.
The PFS events will be determined by the IRAC using the Revised Response Criteria for 
Malignant Lymphoma ( Cheson, 2014 ).  The PFS analysis based on the IRAC assessment will 
serve as the primary analysis.  The PFS analysis based on the local investigator‚Äôs assessment will serve as the sensitivity analysis. 
Subjects who did not experience disease progression and who did not die before the clinical data 
cut-off date will be censored at the time of the last visit with adequate response assessment.
In addition, the following two sets of censoring rules will be applied to the PFS analysis.  
The first set of censoring rules will follow FDA‚Äôs ‚ÄúGuidance for industry: Clinical trial endpoints 
for the approval of cancer drugs and biologics‚Äù ( FDA, 2007 ).  Specifically, subjects who 
received new anticancer therapy without object ive disease progression will be censored at the 
date of the last radiological assessment prior to the new anticancer therapy.  The analysis with 
this set of censoring rules will serve as the primary analysis for PFS. 
In order to avoid possible informative censoring, e.g. the administration of new anticancer 
therapy may be related to factors associated with  the actual survival time, a sensitivity analysis 
for PFS will be performed using the second set of censoring rules that follows EMA‚Äôs guideline ‚ÄúAppendix 1 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man‚Äù 
(EMA, 2012 ).  Specifically, outcome data will be collected according to the intended schedule of 
assessment and the date of progression or recurrence will be assigned based on the time of the first evidence of objective progression or recurrence re gardless of violations, discontinuation of 
investigational product or change of therapy.  Detailed censoring rules for PFS analysis will be 
provided in the Statist ical Analysis Plan (SAP).
&(/*(1(35235,(7$5<,1)250$7,21entnt,
for for 
reatmentreatment
ll
ed as the tid as the t
nyycause, cauyy w
Revised Reevised R
is based onis based o
d on d on thhe elo
ession andession and
thhe elast vislast vi
ensoring runsoring ru
follolfow FDw FD
and bioand bio lolo
apy witapy wit houhou
al assessmeassessme
les will servles will ser
ossible infoossible info
related to frelated to f
be performbe perform
x 1 1 to the Gto the G
20122012 ).  Sp).  Sp
ssment andssment and
rst evirst evi dencden
investigatnvestigat
oviovidd
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 78 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201910.6.2. Secondary Efficacy Endpoint Definitions
Key Secondary Endpoint
The key secondary efficacy endpoint of the st udy is EFS, which is defined as the time from 
randomization until occurrence of one of the following events, whichever occurs first: 
!Disease progression 
!Relapse from CR 
!Initiation of subsequent systemic antilymphoma therapy
!Death due to any cause 
Pre-specified consolidation radiotherapy after study chemotherapy per local practice, such as for 
the treatment of a particular site of bulky disease or a large mass, or in subjects at higher risk for 
CNS lymphoma as described in Section 8.2.2 will not count as subsequent systemic 
antilymphoma therapy or an EFS event if the decis ion to treat and the location to be treated is 
determined during the Screening Period.  Similarly, pre-specified additional two doses of single 
agent rituximab as described in Section 8.2.6 will be handled in the s ame way.
Subjects who did not experience any of these events defined in the four categories above before 
the clinical data cutoff date will be censored at the last time known to be alive and without these 
events.
Other Secondary Endpoints
Overall Survival
The OS is defined as the time between rando mization and d eath from any cause.  Subjects who 
complete the study and ar e still alive at the time of the clinical data cutoff date will be censored
at the last visit date or the last contact date, which ever is later.  Subjects who were lost to follow-
up prior to the clinical data cut-off date will also be censored at the time of the last contact.
CR Rate by IWG (Cheson, 2014 )
The CR rate is calculated as the proportion of subjects who have achieved CR prior to any 
treatment change.
Duration of CR
Duration of CR is defined only for the subjects who have achieved CR prior to any treatment 
change.  It is calculated as the time from the first CR prior to treatment change to the first event of disease progression or death.  Subjects who have not progressed or died at the time of the 
clinical data cutoff date will be censored at the last assessment showing no progression.  Subjects 
who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change.  
Time to Next Lymphoma Treatment
The TTNLT is defined as the time from randomization to the time of treatment change for the 
next lymphoma treatment.  Subjects without treatment change will be censored at the last visit. &(/*(1(35235,(7$5<,1)250$7,21such as uch as foforr
higher risk higher risk 
mic mic 
n to be trean to be trea
al two dosel two dose
me way.me way.
four categofour cate
wn to be alwn to be al
attion and dion and d
mme ofe of the cl the clff
whicheverwhicheve
will also bewill also 
proportionproportion
efined onlyfined only
ulated as thulated as th
gression or ression o
cutcutoff datoff dat
nge treatme treatm
sment showsment show
ime to ime to NexNe
The TTNThe TT
xt l
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 79 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Objective Response Rate
The ORR is defined as the proportion of subjects who have achieved either CR or PR prior to 
any treatment change.
Health Related Quality of Life 
Data on health related quality of life will be collected using the standardized EQ-5D and FACT-
Lym health measurement instruments.
EQ-5D is a standardized measure of health status developed by the EuroQol Group. The EQ-
5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual 
activities, pain/discomfort, a nd anxiety/depression. Each dimension has 3 levels: no problems, 
some problems, extreme problems. The respondent is  asked to indicate his/her health state by 
ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 
dimensions. The EQ visual anal og scale records the respondent‚Äôs self-rated health on a vertical, 
visual analogue scale where the endpoints are labeled ‚ÄúBest imaginable health state‚Äù and ‚ÄúWorst imaginable health s tate.‚Äù This i nformation can be used as a quantitative measure of health 
outcome as judged by the individual respondents. It should be noted that the numerals 1-3 have 
no arithmetic properties and should not be used as a cardinal score.
The FACT-Lym questionnaire was developed as part of the FACIT measurement system to 
address HRQL issues for NHL patients. The FACT-Lym questionnaire is a validated and reliable 
self-report instrument for assessing the impact of lymphoma on HRQL and a useful targeted endpoint in NHL clinical research ( Hlubocky, 2012 ).
It contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-
effects, and consists of five general HRQL subscales ( Cella, 2005 ). It begins with the Functional 
Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four 
core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing 
(6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to a ssess NHL-related symptoms such as pain, itching, night sweats, 
trouble sleeping, fatigue and trouble concentrating. The FACT-Lym also asks patients about their 
concerns regarding lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment.  All questions are answered on a 5-point scale ranging from ‚Äúnot at all‚Äù (0) to 
‚Äúvery much‚Äù (4).
Both HRQoL instruments (EQ-5D and Fact ‚Äì Lym) will be examined as secondary endpoints to 
identify changes in HRQoL measures relative to the comparator arm. The analysis of these 
HRQoL instruments will be predefine d in the SAP prior to database lock.
 
 
 
 (/*(1(35235,(7$5<,1)250$7,21blems, ems, 
h state byh state by
h of the 5 h of the 5
llththll on a veon a hh
h stateh sta ‚Äù an‚Äù a
measure of measure of 
hat the numat the num
CIT measuCIT measu
estestioionnaire nnaire
ma on HRQma on HRQ
momon nlymphoymph
calescales ((CellCe
ACTACT -G)-G), w,w
ms), Social/ms), Social/
FACTFACT -LymLy
ss NHLs NHL --relr
ble concenble concen
swelling, fswelling,
s are answs are answ
ments (EQments (EQ
in HRQoL in HRQoL 
ments will ments wil
/*((/*&(&(&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 80 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019 
 
 
  
 
 
 
 
 
 
 
 
 
 
10.6.4. Analysis Method
Demographics and Baseline CharacteristicsSubjects‚Äô demographics and baseline characteristics will be summarized for the ITT population, 
mITT population, and Safety population.
Subjects‚Äô age, weight, and baseline characteristics  will be summarized using descriptive statistics 
(mean, standard deviation, median, minimum and maximum), while gender, race, and other 
categorical variables will be provided using frequenc y tabulations. Medical history data will be 
summarized using frequency tabulations by system organ class and preferred term.
Subject disposition (analysis population allocation, randomized, premature treatment 
discontinuation along with primary reason for treatment discontinuation, premature study discontinuation along with primary reason for study discontinuation) will be summarized using 
frequency and percentage for both treatment arms.  Protocol deviations and violations will be 
summarized using frequency tabulations.
Time-to-Event Endpoints
The efficacy analysis will be performed on both ITT and mITT populations where the analysis 
on ITT population is the primary analysis a nd analysis on mITT population is supportive.
For the time-to event endpoints, the Kaplan-Meier estimates of the survival function will be 
calculated and graphically presented.  The stratif ied log-rank test will be performed to evaluate &(/*(1(35235,(7eristicsristics
ne charactercharacte
pulpulatatioion.n.
aseline charaseline cha
, m,ediedian, man m
will be proviill be prov
frequencyquency tatyy
ioion n(analys(analys
oon n alalonog wg w
attioion alon alo ngn
ncncy y and pernd per
mmarized usmarized us
TimeTime -< ,1)250$7,21
toto--EE
he efhe ef0$5
)2
<,5<$5<7$5(7$
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 81 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019treatment efficacy.  The stratification factors for analysis include subject disease severity (IPI 
score 2 vs 3 or above), presence of bulky disease (tumor diameter ‚â• 7.0 cm vs < 7.0 cm), and age 
category (< 65 vs 65 or older).  The experimental ar m will be declared superior if the 2-sided p-
value from the stratified log-rank test is ‚â§ 0.05 in favor of the experimental arm. The un-
stratified log-rank test will be performed as sensitivity analysis.  
Conventionally, hazard ratio with two-sided 95% confidence interval (CI) will be estimated 
using the Cox proportional hazards model. But the treatment effect will be determined by the p-value from the stratified log-rank test, not by  this 95% CI for the hazard ratio. Subgroup analysis 
for EFS and PFS will be performed as appropriate. 
Binary Endpoints
The binary endpoints such as CR rate will be summarized in frequency and percent by treatment 
arm.  The stratified Cochran-Mantel-Haenszel (CMH) test w ill be pe rformed to evaluate 
treatment efficacy.  The stratificatio n factors include subject diseas e severity (IPI score 2 vs 3 or 
above), presence of bulky disease (tumor diameter ‚â• 7.0 cm vs < 7.0 cm), and age category (< 65
vs 65 or older).  The un-stratified CMH test will be performed as sensitivity analysis.  
10.7. Safety Analysis
Safety analysis will include all s ubjects in the Sa fety population. 
Investigational product exposure will be summarized for each treatment arm including duration 
of investigational product, total dose taken, and dose reductions.  
Adverse events, vital sign measurements , clinical laboratory measuremen ts, physical 
examination and concomitant medications will be summarized by tr eatment arm. 
Adverse Events
AEs will be coded according to Medical Dictionary for Drug Regulatory Activities (MedDRA) 
and classified using the NCI CTCAE. The incidence rates of AEs will be tabulated by system 
organ class and preferred term. The incidence of AEs will also be tabulated by severity within 
each system organ class and preferred term.  The most severe grade of each preferred term for a subject will be u tilized for summaries of AEs by NCI CTCAE grade.
Subsets of AEs to be summarized include SAEs, suspected treatment-related AEs, and AEs that 
resulted in withdrawal of investigational product. 
All AEs with corresponding attributes will be di splayed in a by-subject listing. AEs leading to 
death or to discontinuation from treatment, events classified as NCI CTCAE grade 3 or higher, 
suspected treatment-related events, and SAEs will also be displayed in separate by-subject
listings.  
Laboratory Tests
Laboratory data will be graded according to NCI CTCAE severity grade. The frequencies of the 
worst severity grade observed during treatment will be displayed in cross-tabulations by baseline 
status for each treatment arm. &(/*(1(35235,(7$5<,1)250$7,21sis sis 
by treatmeby treatm
valvaluate uate lll
(IPI score 2(IPI score 
and age catnd age cat
vitty y analysana
on. n. 
each treatmeach treatm
eductions.  eductions.  
aboratoryaboratory y
be summarbe summa
l DictDictionana
. . The inciThe in
he incidenhe incide
referred termferred ter
ummaries oummarie
mmarizemmarize dd
al of l of investinves
rrespondingrrespondin
contontinuatinuat i
treatmenteatment --r
  
boratory oratory TT
LaboratoryLaborator
worst sworst s
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 82 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019For variables for which an NCI CTCAE scale does not exist, the frequency of subjects with 
values below, within, and above the normal ra nges pretreatment and during treatment will be 
summarized by  treatment.
Change from baseline will be descriptively summarized at each post-baseline visit by treatment 
arm.
Lab shift tables will be produced by treatment arm.Physical Examination and Vital Signs
Physical examination data will be tabulated by treatment.  Vital signs data w ill be descriptively 
summarized by tr eatment in terms of means, medians,  standard deviations, minimum, and 
maximum.
10.8. Interim Analysis
Interim Analysis for PFS
An interim analysis for futility only is planned for the PFS at 50% information level, ie, when 96
PFS events among the enrolled ITT subjects have  been developed acro ss all treatment arms.  
According to the projected enrollment rate and the hypothesized treatment effect, it is estimated 
that the required 96 PFS events will be observe d in about 28 months after the first subj ect is 
randomized.  
The boundary for declaring fut ility of the exper imental arm over the control arm is based on a 
√ü-spending function of Gamma(-4) with overall Œ≤ = 90%.  A normalized log-rank statistic will be 
calculated and compared with the fut ility boundary.  
If the 1-sided p-value is ‚â•0.478 at the interim PFS analysis, the alternative hypothesis may be 
rejected, and the DMC may r ecommend stopping the trial for fut ility.  However, this fu tility 
boundary is a non-binding boundary, which means th at the study does not have to stop if the 
futility boundary is crossed at the interim analysis.  Th e study may continue, if so desired by the 
sponsor, to the final analysis for efficacy without inflating the Type 1 error or losing power.
Since there is no intention to declare efficacy at the interim PFS analysis, no penalty in Œ± should 
be imposed.  Treatment efficacy will be declared at the final PFS analysis if the 1-sided p-value is ‚â§ 0.025 in favor of the experimental arm, after the required 192 PFS events in the ITT 
population are observed.
&(/*(1(35235,(7$5<,1)250$7,21vely ely 
d 
matatioionnlevl
ross all treaoss all tre
reatment efeatment e
ontnthshsafter f
arm over thm over t
0%.0%  A norA nor
yy.  . 
PFS FS analysanaly
pping the tpping the t
ich mich m eans eans 
rim analysirim analys
ficacy witcacy wit hh
eclare efficclare effic
cacy will becacy will
experimenexperim
d.d.
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 83 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201911. ADVERSE EVENTS
11.1. Monitoring, Recording, and Reporting of Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a 
worsening concomitant illness, an injury, or an y concomitant impairment of the subject‚Äôs health, 
including laboratory test values (as specified by the criteria in Section 11.3), regardless of 
etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or 
intensity of a pre-existing condition) should be  considered an AE.  A diagnosis or syndrome 
should be recorded on the AE page of the CRF rather than the individual signs or symptoms of the diagnosis or syndrome.
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be reported on the overdos e CRF. (See Section 8.2.13 for the definition of overdose.) Any sequela 
of an accidental or intentional overdose of an investigational product should be reported as an 
AE on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be 
identified as the cause of the event on the SAE  report form and CRF but should not be reported 
as an SAE itself.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject‚Äôs clinical symptoms, laboratory, 
pathological, radiological or surgical findings , physical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by the investigator from the time the subject si gns informed consent 
until 28 days after the last dose of IP and those SAEs made known to the investigator at any time thereafter that are suspected of being related to IP.  AEs and SAEs will be recorded on the AE 
page of the CRF and in the subject‚Äôs source docu ments.  All SAEs must be reported to Celgene 
Drug Safety within 24 hours of the investigat or‚Äôs knowledge of the event by facsimile, or other 
appropriate method, using the SAE Report Form, or approved equivalent form.
11.2. Evaluation of Adverse Events
A qualified investigator will evaluate all adverse events as to: 
11.2.1. Seriousness 
A serious adverse event (SAE) is any AE occurring at any dose that:
!Results in death;
!Is life-threatening (i.e., in the opinion of the investigator, the subject is at immediate 
risk of death from the AE);
!Requires inpatient hospitalization or prolongation of ex isting hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);oms of ms of 
reported aseported as
n AE shoulAE shou
erdose.)erdose.) AnA
ould be repould be 
e sequela m sequela m
g g in the SAn the S
CRF bCRF ut shh
AssessmenAssessm
s clinical ss clinical s
sical examisical exam
r from r from the tthe t
those SAEthose SAE
related to IPrelated to IP
s source dosource d
he ihe investnvest igig
e SAE Repoe SAE Rep
n of An of A dvedv
gator will evgator will e
riousness iousness 
adverse evdverse ev
!!Resues
!I
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 84 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019!Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject‚Äôs ability to conduct normal life functions);
!Is a congenital anomaly/birth defect;
!Constitutes an important medical event.
Important medical events are defined as thos e occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Second primary malignancies will be monitored as events of interest and must be reported as 
serious adverse events regardless of the treatment arm the subject is in (see Section 11.5).  This 
includes any second primary malignancy, regardless of causal relationship to IP (lenalidomide / 
placebo or control), occurring at any time for the duration of the study, from the time of signing 
the ICD through follow-up for overall survival.  For this particular study, SPM will include cases 
of DLBCL transformation to ALL.  The Follow-up Period involves subject contact per Table 5 , 
until the subject dies, revokes consent, or until 5 years from the date the last subject is 
randomized, whichever occurs first.  Events of sec ond primary malignancy are to be reported 
using the SAE report form and must be considered an ‚ÄúImportant Medical Event‚Äù if no other serious criteria apply; these events must also be documented in the appropriate page(s) of the 
CRF (i.e., AE and SPM CRF) and subject‚Äôs source documents.  Documentation on the diagnosis 
of the second primary malignancy must be provide d at the time of report ing as an SAE (e.g., any 
confirmatory histology or cytology results, X-rays, CT scans, etc.).
Events not considered to be SAEs are hospitalizations for:
!A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospi talization for a comp lication of therapy administration will be 
reported as an SAE.
!Routine treatment or monitoring of the studied indication not asso ciated with any 
deterioration in condition.
!The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.
!A procedure for protocol/disease-related investigations (e.g., surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, hospitalization or prolonged hosp italization for a complication of such procedures 
remains a reportable SAE.
!Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.
!A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the CRF.  Hospitalization or 
prolonge d hospitalization for a complication remains a reportable SAE.&(/*(1(35235,(7$5<,1)250$7,21d be be 
ported as orted as 
n 11.511.5).  ).  ThT
P ( (lenalidolenalid
 the time othe time 
SPM willSPM w l
bject contabject cont
e the last sue the last 
malignancymalignancy
tant Medictant Med
ed in the apin the a
uments.  Douments.  D
at the timat the tim e
s, CT scanss, CT scan
alizatilizati onons fs f
ocol therapocol therap
n ffor a comor a comfff
r mmonionitorintorinii
onditondit ioion.n
tration of btration of 
n.  However  Howev
h transfusiotransfusio
procedure frocedure
endoscopyendoscopy
hospihospi taltaii
remem
!!H
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 85 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019!An elective treatment of or an elective procedure for a pre-existing condition 
unrelated to the studied indication. 
!Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
11.2.2. Severity / Intensity
For both AEs and SAEs, the investigator must assess the severity / intensity of the event. 
The severity / intensity of AEs will be grade d based upon the subject‚Äôs symptoms according to 
the current active minor version of the Common Terminology Criteria for Adverse Events 
(CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
AEs that are not defined in the CTCAE should be evaluated for severity / intensity according to 
the following scale:
!Grade 1 = Mild ‚Äì transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!Grade 2 = Moderate ‚Äì mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!Grade 3 = Severe ‚Äì marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible
!Grade 4 = Life threatening ‚Äì extreme limita tion in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice 
care probable
!Grade 5 = Death - the event results in death
The term ‚Äúsevere‚Äù is often used to describe th e intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is notthe same as ‚Äúserious‚Äù which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject‚Äôs life or functioning.  
Seriousness, not severity, serves as a gui de for defining regulatory obligations.
&(/*(1(35235,(7$5<,1)250$7,21event. event
oms accordims accord
Adverse Evdverse Ev
ctc.htm#ctctc.htm#ctc
veritey / int/ int
no limitatno limitat i
limitatlimitat ioionn
ventventioion/then/the
atatioion nin acn ac
required, hrequired, h
gg‚Äì‚Äìextremextre
medical intemedical int
h --ththe eveee v e
ften used tften used t
al infarctinfarct ioio
ch as severech as sever
ect/event ect/event o
ife or functe or funct
sness, not ssness, not s
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 86 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201911.2.3. Causality 
The investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: Means a causal relationship of the adverse event to IP
administration is unlikely or remote , or other medications, 
therapeutic interventions, or underlying conditions provide a 
sufficient explanation for the observed event.
Suspected: Means there is a reasonable possibility that the administration 
of IP caused the adverse event.  ‚ÄòReasonable possibility‚Äô means 
there is evidence to suggest a causal relationship between the IP and the adverse event.
Causality s hould be a ssessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP
that has not been manufactured or provided by Celgene, please provide the name of the manufacturer when reporting the event.
11.2.4. Duration
For both AEs and SAEs, the investigator will provide a record of the start and stop dates of the 
event.
11.2.5. Action Taken
The investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(e.g., discontinuation, interruption, or reduction of IP, as appropriate) and report if concomitant 
and/or additional treatments were given for the event. 
11.2.6. Outcome
The investigator will report the outcome of the event for both AEs and SAEs.  All SAEs that 
have not resolved upon discontinuation of the subject‚Äôs participation in the study must be 
followed until recovered, recovered with sequelae, not recovered or death (due to the SAE). 
11.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!results in discontinuation from the study;
!requires treatment, modification/ interrup tion of IP dose, or any other therapeutic 
intervention; or
!is judged to be of significant clinical importance.&(/*(1(35235,(7$5<,1)250$7,21ans an
n the IP n the IP 
ently availaently avai
ormrmatatioion b
or, ancillarr, ancillar
 provide thprovid
ide a recoride a recor
taken witaken w thhi
or reductior reducti
re given forre given for
eport the oueport the o
pon disconon discon
covered, recovered, r
AbnormAbnorm
normal labonormal labo
!!rree
!
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 87 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a part of a diagnosis or syndrome, then the labor atory abnormality should be recorded as the AE. If 
possible, the laboratory abnormality should be r ecorded as a medical term and not simply as an 
abnormal laboratory result (e.g., record throm bocytopenia rather than decreased platelets).
11.4. Pregnancy
All pregnancies or suspected pregnancies occurring in either a female subject or partner of a 
male subject are immediately reportable events .
11.4.1. Females of Childbearing Potential:
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 28 days of the subject‚Äôs last dose of IP, are considered immediately reportable events.  IP is to be discontinued 
immediately and the subject instructed to return any unus ed portion of the IP to the Investigator.  
The pregnancy, suspected pregnancy, or positive pregnancy test must be reported to CelgeneDrug Safety immediately by facsimile, or other appropri ate method, using the Pregnancy Init ial 
Report Form, or approved equivalent form.  The exposure of any pregnant female (e.g., caregiver 
or pharmacist) to lenalidomide is also an immediately reportable event.  The female subject 
should be referred to an obstetrician-gynecologist, preferably one experienced in reproductive 
toxicity for further evaluation and counseling.  
The investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outco me of the pregnancy (e ither normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (e.g., spontaneous abortion), the investigator 
should report the abnormal outcome as an AE. If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate 
method, within 24 hours of the investigator‚Äôs knowledge of the event using the SAE Report Form, or approved equivalent form.
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant d eath after 28 days that the investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
facsimile, or other appropri ate method, within 24 hours of the investigator‚Äôs knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2. Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant, the male 
subject taking IP should notify the investigator, and the pregnant female partner should be advised to call their healthcare provider immediately.   of a of a 
t regardlt regardl esses
witwithinhin28 d
s.  . IPIPis to bis to b
n ofn  the IP the IPf
must be remust be re
mmethod,etho usius
e of any pre of any pre
rereportablportabl e ee 
preferably oreferably
ct until coct until co
boutbout ththe oueo u
yFFyolollolow-w-u
as abnormaabnorma
ome as an Aome as an 
s an SAEs an SAE tot
f the he iinvesnves
ivalent formivalent for
s that occur that occur
Es.  In addEs.  In add
in utero exin utero ex
or other apr other ap
sing the SAsing the SA
.4.2..4.2. MM
If a femaf a fem
bjecbj
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 88 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201911.5. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF.  All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the investigator‚Äôs knowledge of the event by facsimile, 
or other appropriate method, using the SAE Report Form, or approved equivalent form. This instruction pertains to initial SAE report s as well as any follow-up reports.
Second primary malignancies will be monitored as events of interest and must be reported as 
serious adverse events regardless of the treatment arm the subject is in (see Section 11.2.1 ).  This 
includes any second primary malignancy, re gardless of causa l relations hip to IP (len alidomide / 
placebo or control), occurring at any time for the duration of the study, from the time of signing 
the ICD through follow-up for overall survival.  Fo r this particular study, SPM will include cases 
of DLBCL transformation to ALL.  The Follow-up Period involves subject contact per Table 5 ,
until the subject dies, revokes consent, or until 5 years from the date the last subject is 
randomized, whichever occurs first.  Events of second primary malignancy are to be reported using the SAE report form and must be consider ed an ‚ÄúImportant Medical Event‚Äù if no other 
serious criteria apply; these events must also be documented in the appropriate page(s) of the 
CRF (i.e., AE and SPM CRF) and sub ject‚Äôs s ource documents.  Documen tation on the diagnosis 
of the second primary malignancy must be provide d at the time of report ing as an SAE (e.g., any 
confirmatory histology or cytology results, X-rays, CT scans, etc.).
The investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
(from the time the sub ject signs informed consent until 28 days after the last dose of IP) and any 
SPM occurring at any time during the study including the follow-up period, or any SAE made known to the investigator at anytime thereafter that are suspected of being related to IP.  SAEs
occurring prior to treatment (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include a concise summary
of hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and deat h certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data should be detailed in a subsequent SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the investigator is responsible for informing the IRB/EC of 
the SAE and providing them with all relevant initial and follow-up information about the event. The investigator must keep copies of all SAE information on file including correspondence with 
Celgene and the IRB/EC.
11.5.1. Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business days.  Urgent queries (e.g., missing causali ty assessment) may be handled by phone.
11.6. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to lenalidomide based on the Investigator Brochure.&(/riri(/*(1(35235,(7$5<,1)250$7,21This This
midmie / e / 
f signing f signing 
nclude casenclude cas
ct perperTablTabl
ubject is bject is 
are to be reare to be r
al EventEvenl ‚Äù if
propriate ppropriate p
cumcumentatientat o
ofof reporti ref ni
, etc.). etc.
se forms ise forms
atatioinship tnship 
ntntil 28 dayil 28 day
uding the fuding the f
er that are ser that are s
the ICF) wthe ICF) w
iled descripiled descrip
nt document docume
yyreport andreport andyy
me avame ava ilableilabl
oved equivved equiv
alalllllegislategisl ioi
ding them wding them w
must keepmust keep
he IRB/ECe IRB/EC
Safety QSafety 
es pertaines pertain
acsimile oracsimile or
days.  Urdays.  Ur
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 89 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019In the United States, all suspected unexpected serious adverse reactions (SUSARs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
For countries within the European Econo mic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Au thorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arisi ng from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.  
Adverse events such as disease progression, death related to disease progression (in the absence 
of serious IP-related events) and serious events due to the relapse of the studied indication will not be subject to expedited reporting by the sponsor to regulatory authorities.
Celgene or its authorized repres entative shall notify the investigator of the following information 
(In Japan, Celgene KK shall notify the Heads of the Institutes in addition to the investigators):
!Any AE suspected of being related to the use of IP in this study or in other studies
that is both serious and unexpected (i.e., SUSAR);
!Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
!In Japan, measures taken in foreign countries to ensure subject safety, study reports 
that indicates potential risk of cancer, etc.,  or biannual SAE report according to the 
local regulations.
Where required by local legislation, the invest igator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 15.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Celgene Drug Safety con tact informatio n, please refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pr egnancy Report Form Completion Guidelines.
&(/*(1(35235,(7$5<,1)250$7,21sence sence 
on willwill
wing informwing inform
e iinvestiganvestig
dyyor ior iyy n otheno t hiii
ests a signifsts a signi
eratogeniratoge ci
ensure ensure subsu
bibiannualannual Sl
ator shalltor shal nnl
gnificant risgnificant ri
ertertinent safinent saf
RB/ECRB/EC .  ((S
InformatioInformatio
ntact intact i nfornfoii
lines or to tlines or t
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 90 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201912. DISCONTINUATIONS
Discontinuation may be from the investigational product or from the overall study.  Since this 
study includes overall survival as an endpoint, the reasons for discontinuing both investigational 
product and the study will be collected for all subjects, as long as the study remain open at an 
investigator‚Äôs site. The reasons for discontinuation should be recorded in the CRF and in the source documents.
12.1. Discontinuation of Investigational Product
The following events are considered sufficient reasons for discontinuing a subject from investigational product:
!Completed investigational product regimen per protocol
!Locally assessed outcome of the Midcycle CT scan indicates a treatment change
!Progression
!Adverse event(s)
!Protocol violation
!Withdrawal of consent
!Death
!Lost to follow up
12.2. Discontinuation from the Study
The following events are considered sufficient reasons for discontinuing a subject from the 
overall study: 
!Withdrawal of consent
!Death
!Lost to follow up
&(/*(1(35235,(7$5<,1)250$7,21tment changment cha
udydy
ient reasonent reason
up
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 91 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201913. EMERGENCY PROCEDURES
13.1. Emergency Contact
In emergency situations, the investigator should contact the responsible Medical Monitor or 
designee by telephone at the number(s) listed on the Emergency Contact Information page of the 
protocol (after title page).
In the unlikely event that the Medical Monitor or designee cannot be reached, please contact the 
global Emergency Call Center by telephone at the number listed on the Emergency Contact 
Information page of the protocol (after title page).  This global Emergency Call Center is 
available 24 hours a day and 7 days a week. Th e representatives are responsible for obtaining 
your call-back information and contacting the on call Celgene/CRO Medical Monitor, who will 
then contact you promptly.
Note: The back-up 24 hour global emergency contact call center should only be used if you are 
not able to reach the Medical Monitor or designee for emergency calls. 
13.2. Emergency Identification of Investigational Products
The blind must not be broken during the course of the study unless in the opinion of the investigator, it is absolutely necessary to saf ely treat the subject.  If it is medically imperative to 
know what IP the subject is receiving, IP should be  temporarily discontinued, if, in the opinion 
of the investigator, continuing IP can negatively affect the outcome of the subject‚Äôs treatment.  The investigator or authorized person may call  the IVRS for unblinded dose information.  The 
reason for breaking the blind must be documented in the source documents.
&(/*(1(35235,(7$5<,1)250$7,21taining taining 
r, who willr, who will
bbe used if ye used if y
roductsoducts
ess in the opess in the o
ect.  If it is mct.  If it i
rarily discorily disc
the outcomhe outcom
VRS for unbVRS for u
d in the soud in the so
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 92 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201914. REGULATORY CONSIDERATIONS 
14.1. Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ens ure that Celgene, its authorized representative,
and investigator abide by Good Clinical Practice (GCP ), as described in International Conference 
on Harmonization (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declaration of Helsinki. The study  will receive approval from an IRB/EC prior to 
commencement. The investigator will conduct all aspects of this study in accordance with 
applicable national, state, and local laws of the pertinent regulatory authorities.
14.2. Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in the local regulations.  Celgene staff or an authorized representative will evaluate and approve all investigators who in turn will select their staff.
The investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions. The investigator should maintain a list of sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.
The investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject‚Äôs source documents.
The investigator, or a designated member of the investigator‚Äôs staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (e.g., 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The investigator must ensure timely and accurate completion of CRFs and queries.
At the time results of this study are made available to the public, Celgene will provide
Investigators with a summary of the results that is written for the lay person. The Investigator is 
responsible for sharing these results with the subject and/or their caregiver as agreed by the subject.
14.3. Subject Information and Informed Consent
The investigator must obtain informed consent of a legal representative prior to any study related procedures.
Documentation that informed consen t occurred prior to the study subject‚Äôs entry into the study 
and of the informed consent process should be recorded in the study subject‚Äôs source documents 
including the date.  The original informed consent document signed and dated by the study subject and by the person consenting the study subj ect prior to the study subject‚Äôs entry into the 
study, must be maintained in the investigator‚Äôs study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the informed consent document must be revised.  St udy subjects participating in the study when the 
amended protocol is implemented must be re-conse nted with the revised version of the informed &(/*(1(35235,(7$5<,1)250$7,21to to 
Practice anPractice 
luate and aluate and a
dyyare adeqare adeq
y--related drelated d
d other apprd other a
elelated dutiated duti
all subjects all subjects
Subjects wSubjects 
ents.nts.
he he iinvestignvestig
ueries and aeries and 
charts, and harts, an
nsure timensure tim
re mre made avade a
oof f ththe resuer e s u
se results we results w
ect Informect Inform
tor mr must obust obmm
entatientati on thon th
of the infoof the info
ncluding thncluding th
subject aubject a
udy,d
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 93 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019consent document.  The revised informed consent document signed and dated by the study 
subject and by the person consenting the study s ubject must be maintained in the investigator‚Äôs 
study files and a copy given to the study subject.  
14.4. Confidentiality
Celgene affirms the subject's right to protecti on against invasion of privacy and to be in 
compliance with ICH and other local regulations (w hichever is most stringent). Celgene requires 
the investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy an y medical records relevant to the study in 
accordance with local laws.
Should direct access to medical r ecords require a waiver or authorization separate from the 
subject‚Äôs signed informed consent document, it is the responsibility of the investigator to obtain such permission in writing from the appropriate individual.
14.5. Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  Written approval must be obtained before implementation of the amended vers ion occurs.  The written signed approval 
from the IRB/EC should specifically reference the investigator name, protocol number, study 
title and amendment number(s) that is applicable. Amendments that are administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC for information purposes.
14.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol , informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought.  If applicable, the documents will also be submitted to the authorities in accordance with local legal requirements.
IP can only be supplied to an investigator by Celgene or its authorized representative after 
documentation on all ethical a nd legal requirements for starting the study has been received by 
Celgene or its authorized represe ntative.  This documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications.  If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue a statement confirming that the composition of the committee is in accordance with GCP.  For 
example, the IRB General Assurance Number may be accepted as a substitute for this list.  
Formal approval by the IRB/EC should mention the protocol title, number, amendment number (if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed.  It must mention the date on which the decision was made and must be 
officially signed by a commi ttee memb er.  Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requi rements.  Amendments must be evaluated to &(/*(1(35235,(7$5<,1)250$7,21om the om the 
gator to obtator to ob
edicaledical  MonMoll
l.  Written .  Written
.  The writt The 
tor namor nam e, pp
dments thatdments tha
d to the d to the IRBIRB
dependendependen
otocolotocol , info, info
ted to the IRted to the I
f issue, andssue, and
s sought.  Is sought.  I
witwith h lolocalcallll
o an io an i nvestnv i
ethical and thical and 
orized rzed r epreepre
IRB/EC anIRB/EC an
cupations acupations 
t confirminconfirmin
e, the IRB e, the IRB 
mal approvamal approv
fapplicableapplicable
documdocum entent
fficialfficia
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 94 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019determine whether formal approval must be sought and whether the informed consent document 
should also be revised.
The investigator must keep a record of all comm unication with the IRB/EC  and, if applicable, 
between a Coordinating investigator and the IRB /EC. This statement also applies to any 
communication between the investigator (or coordinating investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
14.7. Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the investigator must submit to the IRB/EC:
!Information on serious or unexpected adverse events as soon as possible 
!Periodic reports on the progress of the study
!Deviations from the protocol or anything that may involve added risk to subjects
14.8. Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons.  Any premature discontinuation will be appropriately documented 
according to local requirements (e.g., IRB/EC, regulatory authorities).
In addition, the investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!Unsatisfactory enrollment
!GCP noncompliance
!Inaccurate or incomplete data collection
!Falsification of records
!Failure to adhere to the study protocol
&(/*(1(35235,(7$5<,1)250$7,21B/EC:B/EC:
possible possible 
ve added rive added
me mefofor rear rea
n will be apn will be ap
ulatoryulatory authautyy
right to disight to di
e reasons se reasons s
pplete data clete data c
recordsecord
dhere to thedhere to th
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 95 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201915. DATA HANDLING AND RECORDKEEPING
15.1. Data/Documents
The investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigat ional product are complete, accurate, filed and 
retained.  Examples of source documents include: hospital records; clinic and office charts; 
laboratory notes; memoranda; subject‚Äôs diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; x-ray film and re ports; and records kept at the pharmacy, and 
the laboratories, as well as copies of CRFs or CD-ROM.
15.2. Data Management
Data will be collected via CRF and entered into the clinical database per Celgene SOPs.  This data will be electronically verified through use of programmed edit checks specified by the clinical team.  Discrepancies in the data will be brought to the attention of the clinical team, and 
investigational site personnel, if necessary.  Resolutions to these issues will be reflected in the 
database.  An audit trail within the sy stem will track all changes made to the data.
15.3. Record Retention
Essential documents must be retained by the investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketi ng applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IP.  The investigator must retain these 
documents for the time period described above or according to local laws or requirements, 
whichever is longer.  Essential documents include, but are not limited to, the following:
!Signed informed consent documents for all subjects
!Subject identification code list, screening log (if applicable), and enrollment log
!Record of all communications between the Investigator and the IRB/EC
!Composition of the IRB/EC
!Record of all communications between the investigator, Celgene, and their authorized 
representative(s)
!List of Sub-investigators and other appropriately qualified persons to whom the 
investigator has delegated significant study-related duties, together with their roles in the study, curriculum vitae, and their signatures
!IP accountability records
!Record of any body fluids or tissue samples retained
!All other source documents (subject records, hospital records, laboratory records, 
etc.) 
!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).&(/*(1(35235,(7$5<,1)250$7,21s s 
, and and 
ene SOPs.  ne SOPs.
specified byspecified b
of the clinicf the cl
s will be res will be re
ade to the dade to the
for a minimfor a mi
and untand unt il thil th
gion, or at lion, or at l
of the IP.  Tof the IP.  T
ve or accordve or accor
include, include, bubu
documents fdocuments f
code list, sccode list, 
mumunicatinicati onon
ofof the IRB/e IRf
f all coall co mmmm
entative(s)entative(s)
st of Subof Sub -ini
investinvesti gatogato
thhe stude stu
!!IP IP 
!!
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 96 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019The investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The investigator must obtain approval in writing from Celgene prior to destruction of any 
records.  If the investigator is unable to meet this  obligation, the investigator must ask Celgene 
for permission to make alternative arrangemen ts.  Details of these arrangements should be 
documented. 
All study documents should be made available if  required by relevant health authorities.  
investigator/institution should take measures to  prevent accidental or premature destruction of 
these documents.
&(/*(1(35235,(7$5<,1)250$7,21
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 97 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201916. QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully moni tored by Celgene or its authorized representative
for compliance with applicable government regulations with respect to current GCP and standard 
operating procedures.
16.1. Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  Before the study is initiated at a s ite visit or at an investigator meeting, all aspects of 
the study are reviewed with the investigator and the staff.  Prior to enrolling subjects into the 
study, a Celgene representative will review th e protocol, CRFs, procedures for obtaining 
informed consent, record keeping, and reporting of AEs/SAEs with the investigator.  Monitoring 
will include on-site visits with the investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  At each monitoring visit, the facilities, investigational product storage area, CRFs, subject‚Äôs source documents, and all other study 
documentation will be inspected/reviewed by the Ce lgene representative for accuracy, adherence 
to the protocol and Good Clinical Pract ice.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the investigator and/or his/her staff.  Any necessary corrections will be made directly to the CRFs or via queries by the investigator and/or his/her 
staff.  Monitoring procedures require that info rmed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2. Audits and Inspections
In addition to the routine monitoring proce dures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Pract ice 
guidelines and regulations.
The investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (e .g., FDA, EMA, Health Canada) 
and company authorized representatives.  The investigator should make every effort to be 
available for the audits and/or inspections.  If the investigator is contacted by any regulatory 
authority regarding an inspection, he/she should contact Celgene immediately.
&(/*(1(35235,(7$5<,1)250$7,21of of 
the h
g g
 Monitorin Monitorin
propriate opriate 
he facilite facilit iesie
d all other sd all other 
fofor accurar acc
that ihas a dia diii
documentadocume
his/her stafhis/her staf
ies byes by the ithyy
nsents, adhnsents, adh
er recordinger recordin
specific mspecific m
procedureprocedu s
entatives ofntatives o
lgene SOPslgene SOP
ed to permed to pe
RFs and appFs and app
ns by IRBns by IRB
hhoriorized rezed re
he audie aud ts ats ai
egarding angarding an
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 98 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201917. PUBLICATIONS
The results of this study will be submitted for publication in a peer reviewed, scientific journal. 
Study results may also be presented at one or more medical congresses, and may be used for 
teaching purposes.  Additionally, this study and its results may be submitte d for inclus ion in all 
appropriate health authority study registries, as well as publication on health authority study registry websites, as required by local health authority regulations.  Eligibility for external 
authorship, as well as selection of first authorship, will be based on several considerations, 
including, but not limited to, contribution to protoc ol development, study recruitment, data 
quality, participation in d ata analysis, participation in study steering committee (when 
applicable) and contribution to abstract, presentation and/or publication development. 
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 99 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201918. REFERENCES
Ahmadi T, Chong EA, Gordon A, Aqui NA, Xu YY, Svoboda J, et al. Phase II trial of 
lenalidomide - rituximab +/- dexamethasone in r elapsed or refractory indolent B-cell or mantle 
cell lymphomas resistant to rituximab [a bstract]. Blood (A merican Society of Hematology
Annual Meeting Abstracts) 2011;118:266.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of 
diffuse large B-cell lymphoma identified by gene expression profiling. Nature 
2000;403(6769):503-11.
Armitage JO, Weisenburger DD. New approach to classifying non-hodgkin‚Äôs lymphomas: 
clinical features of the major histologic Subtypes. Non-Hodgkin's Lymphoma Classification 
Project. J Clin Oncol 1998;16(8):2780-95.
Barrington S, Mikhaeel N, Kostakoglu L, Meignan M, Hutchings M, M√ºeller S, et al. Role of 
imaging in the staging and response assessment of lymphoma: consensus of the international 
conference on malignant lymphomas imaging working group. J Clin Oncol 2014;32(27):3048-58.
Bottero V, Busuttil V, Loubat A, Magne N, Fischel JL, Milano G, et al. Activation of nuclear 
factor kappa B through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001;61(21):7785-91.
Cairo MS, Bishop M. Tumour lysis syndrome: ne w therapeutic strategies and classification. Br J 
Haematol. 2004; 127 :3-11.
Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and 
prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an 
expert TLS panel consensus. British J Haemat .2010; 149: 578-586.
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, 
Version 3.0, DCTD, NCI, NIH, DHHS, Pub lish Date: August 9, 2006.  Available from 
http://ctep.cancer.gov
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, 
Version 4.0, DCTD, NCI, NIH, DHHS, Publish Date: May 28, 2009 Available from 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40  
Cella D, Webster K, Cashy K, et al., Development of a measure of health-related quality of life 
for non-Hodgkin's lymphoma clinical research: the functional assessment of cancer therapy‚Äî
lymphoma (FACT-Lym). Blood 2005;106, Ab stracts, no. 11; ASH Annual Meeting.
Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin 
Oncol 2008a;26(9):1544-52.
Chanan-Khan AA, Whitworth A, Bangia N, Por ter CW, Lee K. Lenalidomide-associated tumor 
flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol
2008b;26(29):4851-2.
Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J, et.al. Report of an international 
workshop to standardize response criteria for non-Hodgkins‚Äôs lymphoma. J Clin Oncol. 
1999;17(4):1244-53. Erratum in: J Clin Oncol 2000;18(11):2351&(/*(1(35235,(7$5<,1)250$7,21s: 
catatioion n 
S, et al, et al . Rol. R
the internathe intern
ool l 2014;322014
et al. et al. ActActivi
poisons SNpoison
Res 2001;6Res 2001;6
apeutic straapeutic st
mmendatmmendat ioio
n adults ann adults an
matmat .2010; 2010;
Commomm on Teon T
HSHS, Publish, Publi
Program, CProgram, C
NIH, DHHIH, DHH
protocolDevprotocolDe
K, Cashy KK, Cashy K
n's lymphon's lympho
FACTFACT --LymLym
KhananAA, CAA, C
2008a200 ;26(;26(
hananhanan -KhaKha
flare reactlare react
008b;008b;
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 100 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Cheson B, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response 
criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579-86.
Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E, et al. Recommendations for 
initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32(27):3059-68.
Cheung M, Haynes A, Meyer R, Stevens A, Imrie K, et al. Rituximab in lymphoma: a systemic 
review and consensus practice guideline from Cancer Care Ontario.  Cancer Treat Rev 
2007;33(2)161076.
Chiappella A, Franceschetti S, Castellino A, Ca rella AM, Baldi I, Zanni M, et. al. Rituximab-
CHOP21 plus lenalidomide (LR-CHOP21) is effectiv e and feasible in elderly untreated diffuse 
large B-cell lymphoma (DLBCL): results of Phase II REAL07 study of the Fondazione Italiana 
Linfomi (FIL) [abstract]. Blood (ASH Annual Meeting Abstracts), 2012; 20:903.
Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, et al.. Lenalidomide plus 
cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in 
untreated elderly diffuse large B-cell lymphoma patients: phase I study by the Fondazione 
Italiana Linfomi. H aematologica 2013a; Epub ahead of print.
Chiappella A, Castellino A, Franceschetti S, Carella A, Baldi I, Zanni M, et al. Lenalidomide 
plus rituximab-CHOP21 in elderly untreated diffuse large B-cell lymphoma is promising: long 
term results of the phase II REAL07 study of  the fondazione italiana linfomi (FIL). European 
Hematology Association (poster) 2013b.
Cockcroft DW, Gault MH.  Prediction of creatinine clearance from serum creatinine.  Nephron 
1976;16:31-41.
Compagno M, Lim WK, Grunn A, Nandula SV, Bra hmachary M, Shen Q, et al. Mutations of 
multiple genes cause deregulation of NF- Œ∫B in diffuse large B-cell lymphoma. Nature 
2009;459(7247):717-21.
Corazzelli G, De Filippi R, Capobianco G, Frigeri F, De Rosa V, Iaccarino G, et al. Tumor flare 
reactions and response to lenalidomide in patien ts with refractory classic Hodgkin lymphoma.  
Am J Hematol 2010;85(1):87-90.
Costa LJ, Feldman AL, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, et al.  Germinal 
center B (GCB) and non-GCB cell-like diffuse large B- cell lymphomas have s imilar outcomes 
following autologous haematopoietic stem cell transplantation. Br J Haematol 2008;142(3):404-
12.
Czuczman M, Vose J, Zinzani PL, Reeder C, Buckstein R, Haioun C, et al.  Lenalidomide 
monotherapy is clinically active in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): A Pooled Analysis of  Data from 2 Phase II Studies (NHL-002/003)
[abstract] 15th Congress of the European Hematology Association, 2010. Hematological 
2010;95(Suppl 2):0574.
Czuczman M, Trneny M, Davies A, Rule S, Linton K, Wagner-Hohnston N et al.  A phase 2/3 
multicenter, randomized study comparing the efficacy and safety of lenalidomide versus 
investigator‚Äôs cho ice in r elapsed/refractory DLBCL.  Blood (A merican Society of  Hematology 
Annual Meeting Oral Presentation) 2014. &(/*(1(35235,(7$5<,1)250$7,21mabab-
d d ddiffuse iffuse 
one Italianone Italian
LenalidoLenalido mim
safe and efsafe and ef
y bybyy the Fonthe Foyy
Zanni M, eZanni M, e
cell lymphcell lymph
ne ine italianatalianaiii
e clearancee clearance
a SV, BrahmSV, Brahm
-Œ∫B in diffu-Œ∫B in diffu
bianco G, bianco G, F
idodomide inmide in
77-90.-90.
Micallef IMicallef N
nonnon--GCB cGCB
ous haemous haem aa
M, M, Vose JVose J
erapy is erapy is cclil
phohoma (DLma (DL
bstract]bstract] 1515
2010;95(S2010;95(S
ucz
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 101 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term 
follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide 
plus dexamethasone in patients with relapsed or refractory multiple myeloma .Leukemia 
2009;23(11):2147-52.
Ding H, Jin x, Ding N, Fu Z, Song Y, Zhu J.  Single nucleotide polymorphisms of CD20 gene 
and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell 
lymphoma. Cancer Cell Int 2013;13(1):58-65.
Dutia M, DeRoock I, Chee K, et al. Analysis of a Phase 2 study of lenalidomide and rituximab in
relapsed or refractory non-Hodgkin‚Äôs lymphoma. Haematologica 2010; 118, Abstract # 0295. 
European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (EU).  
Methodological consideration for using progression- free survival or disease-free survival (DFS) 
in confirmatory trials. EMA/CHMP/27994/2008/Rev.1; 2012.
Eve HE, Rule SA.  Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.  Br J 
Haematol 2010;151(4):402-12.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm√© C, et al. Long term 
results of the R-CHOP study in the treatment of elderly patients wi th diffuse large B-cell 
lymphoma: a study by the Groupe d‚ÄôEtude des Lymphomes de l‚ÄôAdulte. J Clin Oncol 
2005;23(18):4117-26. 
Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for 
Biologics Evaluation and Research (US). Guidance for industry: clinical trial endpoints for the 
approval of cancer drugs and biologics. Rockville, MD; 2007.
Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM , Shi X, et al.  Addition of rituximab to 
standard chemotherapy improves the survival of both the germinal center  B-cell‚Äìlik e and non‚Äì
germinal center B-cell‚Äìlike s ubtypes of diffuse la rge B-cell lymphoma. J Clin Oncol 
2008;26(28):4587-94.
Gaidarova S, Corral L, Glezer E, Schafer P,  Lopez-Girona A. Treatment of MCL cells with 
combined rituximab and lenalidomide enhances NK-mediated synapse formation and cell killing. 
Blood (American Society of Hematology  Annual Meeting Abstracts) 2009;1687.
Gandhi A, Kang J, Havens C, Conklin T, Ning Y, Wu L, et.al. Immunomodulatory agents 
lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors 
Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 CRBNBr J Haematol
2013;10(1111):12708-28.
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al. ESMO 
Guidelines consensus conference on malignant lymphoma 2011 part 1:  diffuse large B-cell 
lymphoma (DLBCL), follicular lymphoma (FL)  and chronic lymphocytic leukemia (CLL). 
Annals of Oncol 2013;24(3):561‚Äì76.
Gisselbrecht C.  TP53 mutations and rituximab-CHOP. Blood 2012;120(19):3867-9.Goy A, Sinha R, Williams ME, Besisik SK, Drach J, Ramchandren R, et al. Phase II multicenter 
study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or 
progressed after or were refractory to bortezomib: The MCL-001 ‚ÄúEMERGE‚Äù Study [abstract]. Blood (ASH Annual Meeting Abstracts), Nov 2012;120:905.&(/*(1(35235,(7$5<,1)250$7,21b inin
95. 95. 
se (EU).  e (EU).  
rvival (DFSrvival (DF
ell lympholl lympho m
Ferm√© C, etFerm√© C, et
thth diffuse liffuseh
‚ÄôAdulte‚ÄôAdu .J
Evaluatvaluat ioion
or industry:or industry:
MD; 2007MD; 2007
D, SmitSmit h LMh LM
al oal of f both tboth t
diffuse largdiffuse larg
Schafer P, Schafer P
doomide enhmide en
HematolHematoff o
ens C, Conens C, Co
mmalidomidalidomid
via mvia m odulodul
:1270812708 -28.-2
M, Vitolo M, Vitolo 
nes nconsenconsen
phohoma (DLma (DL
nnals onnals o f f OnOn
GiGisselbrsselb
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 102 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical 
double-hit score is a strong predict or of outcome in patients with diffuse large B-cell lymphoma 
treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin 
Oncol 2012;30(28):3460-7.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of 
the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a 
tissue microarray. Blood 2004;103(1):275-82.
Hernandez-Ilizali turri F, Deeb G, Zinzani PL, P ileri SA, Malik F, Macon WR, et al. Higher 
response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal 
center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117(22):5058-66.
Hernandez-Ilizali turri F, Reddy N, Hol kova B, Ottman E, Czuczman M. Immunomodulatory 
drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined 
immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11(16): 5984-92.
Hlubocky F, Webster K, Ca shy J, Beaumont J, Cella D; The development and validation of a 
measure of health-related quality of life for non-Hodgkin‚Äôs lymphoma: the Functional 
Assessment of Cancer Therapy- Lymphoma ( FACT-Lym). Lymphoma 2012; Article ID 147176, 
9 pages.
Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al; Ge rman High-Grade Non-
Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B- cell lymphoma. Blood 2013;121(12):2253-63.
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 
protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse 
large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The 
International DLBCL Rituximab-C HOP Consortium P rogram. Bl ood 2013; 121(20):4021-31.
Ishizawa K.  The Standard treatments for patients with hematological malignancies in Japan.  
[Article in Japanese]  Gan To Kagaku Ryoho 2007;34(5):709-12
Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target
of thalidomide teratogenicity. Science 2010; 327:1345-50.
Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen A, Vera P, et al. An International 
confirmatory study of the prognostic value of ear ly PET/CT in diffuse large B-cell lymphoma: 
comparison between Deauville criteria and ‚àÜSUVmax.  Eur J Nucl Med Mol Imaging 2013;40 
(9):1312-20.
Jardin F, Ruminy P, Kerckaert JP, Parmentier F, Picquenot JM, Quief S, et al. Detection of 
somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas. Haematologica 2008;93(4):543-50.
Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent 
expression of MYC and BCL2 in  diffuse large B-cell lym phoma treated with rituximab plus 
cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30(28):3452-9.
Ketterer N, Coiffier B, Thieblemont C, Ferm√© C, Bri √®re J, Casasnovas O, et al. Phase III study of 
ACVBP versus ACVBP plus rituximab for patients  with localized low-risk  diffuse large B-cell 
lymphoma (LNH03-1B). Annals of Oncol 2013;24(4):1032-7.&(/*(1(35235,(7$5<,1)250$7,21inal inal 
0588-66.-66.
ooduldulatoryatory
cocombined mbined 
84-92.-9
t and validaand valida
the Functthe Func i
ma 201ma 201 2;AA
AC, etAC, e all; G;G
witith BCLh BCL
ood 2013;1ood 2013;1
L, BalasubrL, Balasubr
urvivalurviva  ofol
hh--ririsk genesk gene
onsortionsorti umumiii
for patientfor pat
aku Ryu Ry ohohoo
ra T, Hotta T, Hotta
yy. Sci. Science enc
riiololo-oRiedinied
f the prognthe progff
een Deauvieen Deauvi
Ruminyuminy P, KP, Kyy
quantquant ititativativ
tcomtcom e in de in 
Johnson NAohnson NA
expressioxpress
cllop
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 103 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, Fisher RI, et al. Venous 
thromboembolism in patients with diffu se large B-cell lymphoma. Leuk Lymphoma 
2006;47(6):1029-33.
Kronke J, Udeshi N, Narla A, Grauman P, H urst S, McConkey M, et al.  Lenalidomide causes 
selective degradation of IKZF1 and IKZF3 in  multiple myeloma cells. Science 2013;10(1126):1-
3.
Lee L, Wang L, Crump M.  Identification of potential surrogate end points in randomized 
clinical trials of aggressive and indolent non-Hodgkin‚Äôs lymphoma: correlation of complete 
response, time-to-event and overall survival end points. Ann Oncol 2011;22(6):1392-403.
Leleu X, Daley L, Rodon P, Hulin C, Dauriac C, Hacini H, et al. Final analysis of MELISSE, a 
large multicentric observational study to deter mine risk factors of venous thromboembolism in 
patients with multiple myeloma treated with immunomodulator drugs. Presented at the Annual 
Meeting of ASH, 2011, Abst ract # 1235.
Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H, et al.  Stromal gene signatures in large-B 
cell lymphomas. N Engl  J Med 2008;359(22):2313-23.
Leonard J, Jung S-H, Johnson JL, et al. CALG B 50401: A randomized trial of lenalidomide 
alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: final 
results of a phase II study [abstract]. J Clin Oncol 2012;30(Suppl; abstr 8000).
Li Y, Gordon M, Xu-Monette Z, Visco C, Tzankov A, Zou D, et al. Single nucleotide variation 
in the TP53 3‚Äô untranslated region in diffuse large B-cell lymphoma treated with rituximab-
CHOP: a report from the International DLBCL  Rituximab-CHOP consortium Program.  Blood 
2013; 121(22):4529-40.
Lin T, Zhang H, Huang Y, Guan Z, Shen T, Shi Y, et al.  Comparison between R-CHOP regimen 
and CHOP regimen in treating naive diffuse large B-cell lymphoma in china‚Äîa multi-center 
randomized trial.  [Article in Chinese] Ai Zheng 2005;24(12):1421-6.
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct 
protein target for immunomodulatory and an tiproliferative activities of lenalidomide and 
pomalidomide. Leukemia 2012;26:2326-35.
Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. 
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N 
Engl J Med 2004;350(18):1828-37.
Lu G, Middleton R, Sun H, Naniong M, Ott C, Mitsiades C, et al. The myeloma drug 
lenalidomide promotes the cer eblon-dependent destruction of ikaros proteins. Science 
2013;10(1126):1-8.
Luo JL, Kamata H, Karin M. IKK/NF‚Äì Œ∫B signaling: balancing life and death ‚Äì a new approach 
to cancer therapy. J Clin Invest 2005;115(10):2625-32.
Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous 
thromboembolism prophylaxis and treatment in patients with cancer: American Society of 
Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-204.&(/*(1(35235,(7$5<,1)250$7,21ELISSE, a LISSE, a 
mbombolism lism ini
d at the Annat the An
ne signaturee signature
ized trial oized trial 
ent foent fo llicul
uppl; abstr uppl; abst
ou D, etu D, et al
cell lymphocell lympho
uximabuximab -CHCH
,Shi Y, etShi Y, et
fuse large Bfuse large B
] Ai Zheng ] Ai Zhe
, Miller K, , Miller K
ullatoryatory  andandyy
012;26:232012;26:23
DDKK, AlizadAliza
al in diffusein diffus
350350(18)(18):18:18
ton R, Sunon R, Sun
deepromromoteote
0(1126):10(1126):1 -8-8
JLJL, Kam, Kam aa
o o cancercancer thth
Lyman yman
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 104 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A.  Report on the 4th 
International Workshop on Positron Emission Tomography in Lymphoma held in Menton, 
France, 3 ‚Äì 5 October 2012. Leuk & Lym phoma 2013;55(1)31-7.
Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET 
scan in lymphoma.  Leu & Lym 2009;50(8):1257-60.
Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, et al.  
Epratuzumab with rituximab, cyclophosphamid e, doxorubicin, vincristin e, and prednisone 
chemotherapy in patients with previously untreated diffuse large  B-cell lym phoma. Blood 
2011;118(15):4053-61.
Mohren M, Markmann I, Jentsch-Ullrich K, Koenig smann M, Lutze G, Franke A. Increased risk 
of thromboembolism in patients with malignant  lymphoma: a single-centre analysis. Br J Cancer 
2005;92(8):1349-51.
Moreno A, Colon-Otero G, Solberg L. The prednisone dosage in the CHOP chemotherapy 
regimen for non-Hodgkin‚Äôs lymphomas (NHL): is there a standard? Oncologist 2000;5:238-49.
Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations 
altering EZH2 (Tyr641) in follicular and diffuse large B- cell lymphomas of germinal-center 
origin. Nat Genet 2010;42(2):181-5.
NCCN clinical practice guidelines in onc ology (NCCN Guidelin es¬Æ). Non-Hodgkins 
lymphomas. Version 1.2013. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim KH, et al.  Oncogenically active MYD88 
mutations in human lymphoma. Nature 2011;470(7332):115-9.
Nowakowski G, LaPlant B, Habermann T, Rivera C, Macon W, Inwards D, et al. Lenalidomide 
can be safely combined with R-CHOP (R2-CHOP) in the initial chemotherapy for aggressive B-
cell lymphomas: phase 1 study. Leukemia 2011;25:1877-81.
Nowakowski G, LaPlant B, Reeder C, Foran J, Porrata L, Macon W, et al. Combination of 
lenalidomide with R-CHOP (R2-CHOP) is well to lerated and effective as initial therapy for 
aggressive B-cell lymphomas ‚Äì a Phase II study [abstract]. Blood (ASH Annual Meeting 
Abstracts), Nov 2012;120:689.
Nowakowski G, Reeder C, Foran J, Porrata L, Macon W, Rivera C. Combination of 
lenalidomide with R-CHOP (R2-CHOP) ove rcomes negative prognostic impact of non-GCB 
phenotype in DLBCL: a phase 2 study [poster]. 12
thInternational Conference on Malignant 
Lymphoma, Lugano, Switzerland;19-22 June 2013.  Abstract No.213 Hematol Oncol 
2013;31(Suppl 1):168.  Available from: http://onlinelibrary.wiley.com/doi/10.1002/hon.2058/pdf
Nowakowski G, LaPlant B, Macon W, Reeder C, Foran J, Nelson G, et al. Lenalidomide 
combined with R-CHOP overcomes negati ve prognostic impact of non-germinal center B- cell 
phenotype in newly diagnosed diffuse large B- cell lymphoma: a phase II study. J Clin Oncol 
2015;33(3):251-7.
Oken MM Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative 
Oncology Group Am J Clin  Oncol 1982; 5: 649‚Äì55. &(/*(1(35235,(7$5<,1)250$7,21eased rieased ri sk sk
.Br J CancBr J Can
chemotherachemothe
lologist 2000gist 2000
t alal. Som. Som atat
hohomas of as of g
delines¬Æ).delines¬Æ).
/nhl.pdf.nhl.pdf.
Lim KH, etLim KH, e
470(7332):170(7332):
 Rivera C, Rivera C,
(R2R2-CHOPCHO
kemia 2011kemia 20
der C, Forader C, Fora
R2R2-CHOP)CHOP
mas as‚Äì‚Äìa PhaaP h a
20:689.20:689.
eder C, Foder C, Fo
h Rh R--CHOPCHO
DLBCL: aDLBCL: a
a, Lugano, , Lugano, 
1(Suppl 1):(Suppl 1):
wakowskiwakowski GGii
ombined wombined w
phenotyphenot
15;15
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 105 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Ottinger H, Belka C, Kozole G, Engelhard M, Me users P, Paar D, et al. Deep venous thrombosis 
and pulmonary artery embolism in high-grade non Hodgkin‚Äôs lympho ma: incidence, causes and 
prognostic relevance. Eur J Haematol 1995;54(3):186-94.
Park LC, Woo SY, Kim S, Jeon H, Ko YH, Kim SJ, et al. Incidence, risk factors and clinical 
features of venous thromboembolism in newly d iagnosed lymphoma patients: results from a 
prospective cohort study with Asian population. Thromb Res 2012;130(3):e6-e12.
Pfreundschuh M. How I treat elderly patients  with diffuse large B-cell lymphoma. Bl ood 
2010;116(24):5103-10.
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al; Eastern 
Cooperative Oncology Group.  Len alidomide pl us high-dose dexamethasone versus lenalidomide 
plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-
label randomised controlled trial. Lancet Oncol 2010;11(1):29-37.
Ramsay A, Clear A, Kelly G, Fatah R, Matthe ws J, MacDugall F, et al. Follicular lymphoma 
cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: 
implications for the tumor microenvironment and immunotherapy. Blood 2009; 114; 4713-20.
Ramsay A, Johnson A, Lee A, Gorgun G, LeDieu R, Blum W, et al; Chronic lymphocytic 
leukemia T cells show impaired immunological synapse formation that can be reversed with an 
immunomodulating drug. J of Clin Investigation 2008;118(7) 2427-37.
R√©cher C, Coiffier B, Haioun C, Molin TJ, Ferm√© C, Casasnovas O, et al. Intensified 
chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the 
treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 
trial. Lancet 2011;378(9806):1858-67.
Reddy N, Hernandez-Ilizaliturri F, Deeb G, Roth M, Vaughn M, Knight J, et al. 
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by
dendritic cells, and inhibit angiogenesis enhanci ng the anti-tumor activity of rituximab in vivo. 
Br J Haemat 2007; 140:36-45.
 
 
Rosenwald A, Wright G, Chan WC, Connor s JM, Campo E, Fisher RI, et al; 
Lymphoma/Leukemia Molecular Profiling Project.  The use of molecular profiling to predict 
survival after chemotherapy for diffuse large-B-cell lymphoma.  N Engl J Med 
2002;346(25):1937-47.
Salvi F, Miller M, Grilli A, Giorgi R, Towers A, Morichi V, et al; A manual of guidelines to 
score the modified cumulative illness rating scale and its validation in acute hospitalized elderly 
patients. J Am Geriatr Soc 2008;56(10):1926-31.
Salvi F, Miller M, Towers A, Grilli A, Morichi V, Giorgi R, et al; Manual of guidelines for 
scoring the modified cumulative illness rating scale (CIRS). J Am Geriatr Soc 2008a;56(10):
Appendix S1.&(/*(1(3right G, Chright G, Ch
ukemia Moukemia M
er chemother chemoth
6(25):19375):193
i F, Miller Mi F, Miller
core the mocore the mo5235,(7$5<,1)250$7,21ern ern
nalidomidenalidomid
ma: an opma: an op
cular lympcular lym
witwith h lelnall
od 2009; 1od 2009; 
l; Chronil; Chroni cc
on that canon that can
) 2427) 242 -37.37
sasnovas Oasnovas 
andard CHOndard CHO
0303--2B): an 2B): an 
Roth M, VRoth M, V
ural killer-ral killer c
sis enhancinsis enha
patipaents. Jnts. J
lvii35235(3
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 106 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Scott D, Wright G, Williams M, Lih C, Walsh W, Jaffe E, et al; Determining cell-of-origin 
subtypes of diffuse large B-cell lymphoma using ge ne expression in formalin-fixed paraffin 
embedded tissue.  Blood 2014;123(8):1214-7.
Schif B, Lennerz JK, Kohler CW, Bentink S, Kreuz M, Melzner I, et al.  SOCS1 mutation 
subtypes predict divergent outcomes in diffuse large B- cell lym phoma (DLBCL) patients. 
Oncotarget 2013;4(1):35-47.
Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierach S, et al. BCL2 mutations 
in diffuse large B-cell lymphoma. Leukemia 2012; 26(6):1383-90.
Tilly H, Vitolo U, Walewski J, da Silva MG, S hpillberg O, Andre M, et al. Diffuse large B-cell 
lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii,78-82.
Vitolo U, Chiappella A, Franceschetti S, Carella A, Baldi I, Inghirami G, et al. Lenalidomide 
plus R-CHOP21 in elderly patients with untreated  diffuse large B-cell lymphoma: results of the 
REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014;15(7):730-37.
Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide 
in combination with rituximab for patients with  relapsed or refractory mantle-cell lymphoma: a 
phase 1/2 clinical trial. Lancet Oncol 2012;13(7):716-23.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al; Multiple Myeloma 
(009) Study Investigators. Lenalidomide plus dex amethasone for relapsed multiple myeloma in 
North America. N Engl J Med 2007;357(21):2133-42.
Wiernik PH, Lossos IS, Tuscano JM, Justice G,  Vose JM, Cole CE, et al.  Lenalidomide 
monotherapy in relapsed or refractory aggre ssive non-Hodgkin‚Äôs lymphoma. J Clin Oncol
2008;26(30):4952-7.
Wilson WH, Dunleavy K, Pi ttaluga S, Hegde U, Grant N, S teinberg SM, et al.  Phase II study of 
dose-adjusted EPOCH and rituximab in untreated  diffuse large B-cell ly mphoma with analysis of 
germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26(16):2717-24. 
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international 
phase II trial of single-agent lenalidomid e for relapsed or refractory aggressive B-cell non-
Hodgkin's lymphoma. Ann Oncol 2011;22(7):1622-7.
Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, et al. Lenalidomide oral 
monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin‚Äôs lymphoma. J Clin Oncol 2009;27:5404-9. 
Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al.  Lenalidomide enhances natural 
killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.  Clin Cancer Res 2008;14(14):4650-7.
Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic 
lethality for the therapy of ABC diffuse large B cell lym phoma. Cancer C ell 2012;21(6):723-37.
Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett J, et al. Synergistic antitumor effects of 
lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 
2009;84(9):553-9BB--cellcell
fofollollow-w-
LenalidomLenalido
homhoma: resula: resu
730730-37.-37
apu SS, et aapu SS, et a
oryormmyantantlel
tmauer EAmauer EA
asone for reone for 
Vose JM, CVose JM, C
ive nonve non -HoHo
Hegde U, GHegde U, 
b in untreat in untre
l center biol center b
PPLL, Reede, Reede
nt llenalidoenalido
Ann OncoAnn Onco l
k PH, MoorH, Moor
oduces duraoduces dur
Clin Oncolin Onco l
dams M, Cams M, C
cell and mocell and mo
20+ tum20+ tum or or 
YangYa Y, SY, S
ethalitethalit
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 107 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Zhang LH, Losek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in 
activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and 
cereblon expression. Br J Haematol 2013;160(4):487-502.
Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, et al. Incidence and risk factors of 
venous thromboembolic events in lymphoma. Am J Med 2010 Oct;123(10):935-41.
Zhu YX, Braggio E, Shi CX, Bruins A, Schmidt J, Van Wier S, et al. Ce reblon expression is 
required for the antimyeloma activity of lenalidomide and pomalidomide.  Blood 2011;118:4771-79.
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 108 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201919. APPENDICES
19.1. Ann Arbor Staging System 
!Stage I:
‚àÄI: Involvement of a single lymph node region
‚àÄIE: Localized involvement of a single extralymphatic organ or site.
!Stage II:
‚àÄII: Involvement of 2 or more lymph node regions on the same side of the 
diaphragm
‚àÄIIE: Localized involvement of a single associated extralymphatic organ or site and 
its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm
!Stage III:
‚àÄIII: Involvement of lymph node regions on both sides of the diaphragm
‚àÄIIIE: Involvement of lymph node regions on both sides of the diaphragm 
accompanied by localized involvement of an extralymphatic organ or site
‚àÄIIIS: Involvement of lymph node regions on both sides of the diaphragm 
accompanied by involvement of the spleen
‚àÄIIIS+E: Both IIIS+IIIE
!Stage IV:
‚àÄIV: Disseminated (multifocal) involvement of 1 or more extralymphatic sites with 
or without associated lymph node involvement or isolated extralymphatic organ involvement with distant (non regional) nodal involvement
‚àÄIVE: Extranodal lymphoid malignancies arise in tissues separate from, but near, 
the major lymphatic aggregates.
Source: American Joint Committee on Cancer. Non Hodgkin‚Äôs lymphoma. In: AJCC Staging 
Manual. 5th ed. Philadelphia, PA: Lippincott-Raven;1997:289-94.
&(/*(1(35235,(7$5<,1)250$7,21organ or sitgan or sit
ons on the ns on the
es of the diaes of the d
th sides of tth sides
extralympextralymp
s on both sis on both s
pleenpleen
focal) invoocal) inv
lymph nodlymph n
distant (distant ( nonno
dal lymphoal lympho i
ymphatic agmphatic a
tt Committ Committ
ladelphia, Pdelphia, 
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 109 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201919.2. Modified Cumulative Illness Rating Scale ( Salvi, 2008a ) 
RATING SUGGESTIONS (GENERAL PRINCIPLES)
Every single disease must be classified in the appropriate system. If there are several problems in 
the same system, only the most severe is rated. Example: for a patient suffering from a well-controlled angina (Rated 2) and terminal heart failure (Rated 4), only the higher rated condition 
would be scored in the Cardiac system (e.g. rating is 4).
The spread of a cancer may lead to rate the condition in more than one category. For example, a 
lung cancer with bone metastases treated with nonsteroidal anti-inflammatory drugs (NSAID) is 
Rated 4 in Respiratory and 2 in Musculoskeletal.
General rules for severity rating:
0 - No problem affecting that system or past problem without clinical relevance.1 - Current mild problem or past significant problem.
2 - Moderate disability or morbidity and/or requires first line therapy.
3 - Severe problem and/or constant and significant disability and/or hard to control chronic 
problems (complex therapeutic reg imen).
4 - Extremely severe problem and/or immediate tr eatment required and/or organ failure and/or 
severe functional impairment.
LEVEL 0
No problem or healed minor injuries; past childhood illnesses (chickenpox); minor surgery 
(carpal tunnel completely healed, caesarean); uncomplicated healed fractures; other past problems h ealed without sequel, residual or complication (pneumonia).
LEVEL 1
Any current medical problem that causes mild disc omfort or disability, or has occasional 
exacerbations, having only minor impact on morbidity (asthma controlled with PRN 
bronchodilators, occasional heartburn relieved wi th PRN antiacids). Medical problems that are 
not currently active but were significant problems  in the past (passage of a kidney stone) or 
required major surgery (hysterectomy , cholecystectomy, appendectomy).
LEVEL 2
Medical conditions that require daily tr eatment or first line therapy (asthma contro lled with 
inhaled steroids, gastro-esophageal reflux treated with daily medication, osteoarthritis requiring 
daily NSAID, etc.) and/or have m oderate disabilit y or morbidity.
LEVEL 3
Chronic conditions that are not controlled with first line therapy (asthma needing continuous 
corticosteroid therapy, symptomatic angina desp ite medical regimes, heart failure with symptoms 
or uncontrolled hypertension despite complex therapeutic regimen) and/or constant significant 
disability, but not severe disability., a a
ID) is ID) is 
ard to contrard to cont
ired and/orred an
od illnessesod illnesses
ncomplicatcomplica
complicatiocomplicatio
causes milduses mild
or impact onor impact o
eartburn reeartburn re
re sie significagnific
(hysterecto(hysterect
tioions that rns that 
roids, gastroids, gastr
SAID, etc.)SAID, etc.
VEL 3VEL 3
&(Chronic cChronic c
ortiorticoco
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 110 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019LEVEL 4
Any acute condition that requires immediate treatment or hospitalization (unstable angina, acute 
myocardial infarction, stroke, but also bladder outlet obstruction) and/or extremely severe 
problems; organ failure (end-stage renal disease n eeding dialysis, oxygen-dependent chronic 
obstructive pulmonary disease, terminal heart f ailure); severe sensory impairment (almost 
complete blindness or deafness, being wheelchair bound) and/or severely affected quality of life, 
severe impairment in function; deli rium by medical (organic) conditions.
RATING MALIGNANCIES
Consistent scoring of severity ratings for various malignancies is a difficult problem. Each 
malignancy has its own rating system and prognostic indicators, the complexity of which would 
quickly exceed the aim of the intended simplicity and ease of use of CIRS.
The following general guidelines are intended to provide a reasonably accurate delineation of 
medical burden for cancer without excessive complexity.
Level 1: Cancer diagnosed in the remote past without evidence of recurrence or sequel in the past 
10 years or skin cancer excised in the past without major sequel (other than melanoma).
Level 2: No evidence of recurrence or sequel in the past 5 years.
Level 3: Required chemotherapy, radiation, hormonal therapy or surgical procedure for cancer in 
the past 5 years.
Level 4: Recurrent malignancy or metastasis (other than to lymph glands) or palliative treatment 
stage.
These ratings are to be made in the appropriate organ category for a given malignancy.
ORGAN SPECIFIC CATEGORIES
The following organ specific categories will attempt to provide guidelines for consistent rating of 
comparable severity. Common conditions will be stressed with the focus on the ‚Äújudgement strategy‚Äù that can be applied to other problems not listed. 
If there are several problems in the same system, only the most severe is rated.
HEART
In this category only heart and coronary disease ha ve to be considered (not vascular): coronary 
arteries disease, heart failure, valvular heart diseases, heart disease secondary to hypertension, endocardities, miocardities, pericardities, arrhy thmias (extrasystoles, bundle-branch blocks, atrial 
fibrillation, PMK placement), heart malignancies. Functional impact must be considered too, e.g. 
NYHA II heart failure has different value between dependent and independent persons.
0 - No problems
1 -Remote MI (>5 years ago); occasional [exer tion] angina; asymptomatic valvular disease
2 -CHF compensated with meds (NYHA I-II); daily anti-angina meds; left ventricular 
hypertrophy; atrial fibrillation, bundle branch bloc k, daily anti -arrhythmic drugs (even for 
prophylaxis); PMK placement for asymptomatic bradycardia (relieved by Holter EKG 
monitoring); valvular disease requiring medical treatmentch h
hich would hich would
e delineatdelineat ioi
rrence or serrence or 
her than mer than me
pyy or surgi or surgiyy
han to lymphan to ly
te organ cate organ cat
ries will atties will a
ndindititiions wons w
o othero other probpro
ms in the sas in the sa
only heart aonly heart 
se, heart fai, heart fa
ees, miocars, miocar
on, PMK pPMK 
A II hA II h eart eart
--No probNo prob
1 - -RemRem
C
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 111 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20193 -Previous MI (<5 years ago); abnormal stress test; status post (previous) percutaneous coronary 
angioplasty, coronary artery bypass graft surgery or other cardiac surgery (valve 
replacement); moderate CHF (NYHA II-III) or complex medical treatment; bifascicular 
block; PMK placement for cardiogenic syncop e; pericardial effusion or pericarditis
4 -Acute coronary syndrome, unstable angina or acute MI; intractable CHF (NYHA III-IV acute 
or chronic); marked restriction to the normal activity of daily living secondary to cardiac status
HYPERTENSION
Consider only hypertension severity; organ damag e (complications) should be considered into 
the respective categories.
0 -Normotension
1 -Borderline hypertension; hypertension compensated with salt restriction and weight loss, drug 
free (when drug therapy is indicated, but the patient does not take meds, the score is at least 2)
2 -Daily antihypertensive meds: hypertension controlled by 1 pill therapy (even fixed doses 
combinations)
3 -Hypertension requiring two or more pills for control4 -Malignant hypertension, or hypertension non controlled by complex therapeutic regimen
VASCULAR-HEMATOPOIETIC
Artery disease: carotid atherosclerosis, peripheral arteries disease (PAD), aneurysms (every site);
Venous disease: venous insufficiency, varices, deep venous thrombosis (DVT), pulmonary 
embolism, primary pulmonary hypertension;
Hematopoietic disease: anemia, leucopenia, thrombocytopenia, hematological malignancy;
Lymphopoietic disease: chronic lymphatic edema, lymphoma, spleen and thymus disease;Immunologic disease: systemic lupus erythematosus, systemic sclerosis (scleroderma), 
sarcoidosis, hypersensitivity
0 -No problem
1 -Venous insufficiency, varices, lymphedema; carotid stenosis <70%; hemoglobin 10-12 g/dl 
(in females), 12-14 g/dl (in males); anemia of chronic ‚Äúinflammatory‚Äù disease
2 -Previous DVT; one symptom of atherosclerosis disease (claudication, bruit, amaurosis fugax, 
absent pedal pulses) or daily meds (e.g. anti-platelets drugs); PAD IIa-IIb by Fontaine; carotid 
stenosis >70%; aortic aneurysm <4 cm; hemoglobin 8-10 g/dl (in females), 10-12 g/dl (in 
males); anemia secondary to iron, B12 vitamin or folate deficiency, or to chronic renal failure; 
total white blood cell (WBC) 2000-4000 /mmc; mild thrombocytopenia (50000-150000/mmc)
3 -DVT or recent DVT (<6 months ago); two or more symptoms of atherosclerosis (see above); 
PAD Fontaine III or recent/previous angioplasty (with or without stenting); hemoglobin 
<8g/dl (in females), <10 g/dl (in males); dyserythropoietic anemia; WBC <2000/mmc; severe 
thrombocytopenia (<50000/mmc)&(/*(1(35235,(7$5<,1)250$7,21d into into 
d weight loweight l
the score ithe score i
py (even fixpy (even 
comcomplex thplexm
erieries diseaes dis
deep venousdeep venou
nia, thrombnia, thromb
phatphatic edemic ed
upus eryupus ery ththyy
cy, varices,cy, varices
14 g/dl (in14 g/dl (in
VT; one symT; one sym
dal pulses) dal pulses)
s >70%; a>70%; a
es); anemiaes); anemia
otalotal whiwhil te bte bii
3 --DVT or DVT or 
PAD PAD
<8
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 112 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20194 -Pulmonary embolism (acute or recent/previous); atherosclerosis requiring surgical 
intervention (e.g. aortic aneurysm >4 cm, symptomatic carotid stenosis >70%, PAD Fontaine 
IV or amputation for vascular causes, etc.); recent/previous vascular surgery; any 
hematological or vascular malignancy (including multiple myeloma)
In case of immunological disease, score should be assigned by considering blood abnormalities, 
stadium of organ damage and/or functional disability (2: symptoms controlled by daily meds; 3: 
symptoms not well controlled; 4: symptoms impossible to be controlled or short time poor prognosis).
RESPIRATORY
In this category we consider C OPD, asthma, emphysema, restrictive pulmonary interstitial lung 
diseases, malignancies of lung and pleura, pneumonia, and smoking status too.
0 -No problem
1 -Recurrent episodes of acute bronchitis; currently treated asthma with prn inhalers when 
required; cigarette smoker >10 but <20 pack years
2 -Instrumental diagnosis of COPD or pulmonary interstitial disease (x-ray, TC, spirometry); 
daily prn inhalers ( ‚â§2 pharmacological classes); two or more episodes of pneumonia in the 
last 5 years; cigarette smoker <20 but <40 pack years
3 -exertion dyspnea secondary to limited respiratory  capacity, not well controlled by daily meds; 
required oral steroids for lung disease; d aily prn inhalers (3 pharmacological classes); acute 
pneumonia treated as an outpatient
4 -Chronic supplementation of oxygen; respiratory failure requiring assisted vent ilation, or 
previous (at least one episode); any lung or pleural neoplasm; acute pneumonia requiring 
hospitalization
Smoking is an important respiratory and cardiovascular risk, so it is considered as a disease, and 
it is rated according to lifetime pack years : 
Number of cigarette packs smoked per day X Number of years smoked in their lifetime
e.g.    1 pack year = 20 cigarettes/die (1 pack) X 1 year
Ex-smokers should be rated too, but those who have been smoke free for the most recent 20 
years would merit a lower rating than currently smoking
Examples:
A. Patient smoking 20 cig/die (1 pack) for 25 years = 25 pack years - CIRS score: 2B. Patient smoking 40 cig/die (2 packs) for 25 years = 50 pack years ‚Äì CIRS score: 3
C. Ex-smoker of 20 cig/die (1 pack) for 25 years, he stopped 5 years ago ‚Äì CIRS score: 2
D. Ex smoker of 20 cig/die (1 pack) for 25 years, he stopped 20 years ago ‚Äì CIRS score: 1Classification of COPD could be more specific when instrumental data (objective evidence) are 
available: blood gases, forced expiratory volume in 1 second (FEV1), etc.&(/*(1(35235,(7$5<,1)250$7,21titial itial lung lung 
n inhalers wn inhalers w
(xx--rayray, TC, TC
pisodes of isodes of 
tyy, not wel, not we
lers (3 pharlers (3 ph
y failure rey failure r
plpleural neoeural neo
d cardicard ovasova
yearsyears : :23moked per moked per 
igarettes/diigarettes
ated too, buated too, b
ower ratingower ratin
mmoking 20 coking 20 c
t smmoking oking
xx--smsmoker ooker 
D. Ex smokD. Ex smok
llassifassif
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 113 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019EYES, EARS, NOSE & THROAT, and LARYNX
To simplify the potential complexity of this category it was decided to score according to the 
severity of the disability created by se nsory diseases (degree of limited autonomy and 
communication), and avoid rating each type of p athology. Sensory impairments should be rated 
after instrumental correction (corrective lenses, hearing aid, etc.).
Eyes: glaucoma, cataracts, macular degeneration (diabetic/hypertensive retinopathy), any other 
pathology
Ears: otitis, dizziness, any cause of hearing impairment
Nose & Throat: rhinitis, pharyngitis, na sal polyps, sinusitis, malignancies
Larynx: dysphonia, acute and chronic laryngitis, malignancies
0 -No problems
1 -Corrected vision with glasses; mild hearing loss; chronic sinusitis
2 -Difficulty in reading newspaper or drive although glasses; required hearing aid; chronic 
sinonasal complaints requiring medication; vertigo/dizziness requiring daily meds
3 -Severe low vision, partially blind (required an escort to venture out, unable to read 
newspaper); severe ear impairment (conversational heading still impaired with hearing aid); 
laryngeal dysphonia (not neurological dysarthria)
4 -Functional blindness/deafness: unable to read, recognize a familiar face, unable to 
conversational heading, even if ‚Äúorganically‚Äù he is not completely blind or deaf; laryngectomy (every cause, especially malignancies); required surgical intervention for vertigo; aphonia secondary to laryngeal impairment.
UPPER GASTROINTESTINAL SYSTEM
This category is comprehensive of the intestinal tract from esophagus to duodenum, and 
pancreatic trees: dysphagia, GERD, hiatal hernia,  esophageal diverticula, any type of gastritis 
(consider also H. Pylori eradication or not), gast ric/duodenal ulcer, acute or chronic pancreatitis, 
malignancies (comprehensive  of gastric lymphoma).
Pay attention that type 1 diabetes is rated under ‚Äúmetabolic‚Äù.
0 -No problem
1 -Hiatal hernia, GERD or gastritis requiring prn meds; previous ulcer (>5 years ago); previous 
H. Pylori eradication therapy (>5 years ago)
2 -Daily proton pump inhibitor/anti-acid meds; documented gastric or duodenal ulcer or H.P. 
eradication therapy within 5 years
3 -Active gastric or duodenal ulcer; positive fecal occult blood test; any swallowing disorder or 
dysphagia; chronic pancreatitis requiring supplemental pancreatic enzymes for digestion; 
previous episode of acute pancreatitis
4 -Any type of malignancies (see ‚Äú Rating Malignancies ‚Äù); previous gastric surgery because of 
cancer; history of perforated ulcer (gastric surgery not because of cancer, ulcorrhaphy); melena/heavy bleeding from upper GI source; acute pancreatitis&(/*(1(35235,(7$5<,1)250$7,21aring aid; cring ai
ring daily mring daily m
out, unableout, unab
still impairtill im
ze a familize a fam
not complenot compl
cies); requicies); requ
irment.ment
MM
35intestinal trntestinal t
hiatal hernhiatal her
on on or not),or not)
oof f gastrigastri c lc
diabetes is diabetes is 
GERD or gaGERD or ga
adicatadicat ioion thn
oton pump oton pump 
atioon theran ther
ctive gastricctive gastr
dydysphagiasphagia
previoueviou
AnyAny
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 114 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019LOWER GASTROINTESTINAL SYSTEM
Comprehensive of the rest of the G.I. system, from small bowel to anus: Whipple‚Äôs disease, 
diverticulosis, irritable bowel, malignancies. Constipation is rated, too, by type and frequency of 
laxatives required, or by history of impaction.
0 -No problems, previous appendectomy, previous hernia repair (without complications)
1 -Constipation managed with prn meds; active hemorrhoids; intestinal hernia requiring surgery; 
previous hernia repair with co mplications (intestinal adherences, laparocele, etc.); irritable 
bowel syndrome (few symptoms)
2 -Constipation requiring daily bulk laxatives (psyllium, policarbophil, sterculia, guar gum, etc.), 
or stool softeners; diverticulosis (previous diverticulitis); inflammatory bowel disease in 
remission with meds (>5 years ago)
3 -Bowel impaction/diverticulitis within the las t year; daily use of stimulant (irritant) or osmotic 
laxatives (bysacodil, senna, glycerol, sodium docusate; lactulose, polyethylene glycol) or 
enemas; chronic bowel inflammation in remi ssion with meds (<5 years ago)
4 -Diverticulitis flare up; active inflammatory disease; current impaction; hematochezia/active 
bleeding from lower GI source; bowel carcinoma
LIVER AND BILIARY TREES
Comprehensive of liver, gallbladder, biliary trees , portal system: acute and chronic hepatitis 
(viral, alcoholic, toxic, autoimmune, id iopathic), cirrhosis, portal hypertension, 
hemochromatosis, primary biliary cirrhosis, cholelithiasis, cholangitis, primary malignancies. As 
the hepato-biliary system is difficult to assess through the physical examination, therefore, laboratory results must be used.
0 -No problem
1 -History of hepatitis (actually normal values of transaminases); cholecystectomy
2 -Cholelithias is; chronic hepatitis or previous hepatitis (<5 years ago) or any other liver disease 
(hemochromatosis, primary biliary cirrhosis) with  mildly elevated transaminases (within 3-
times normal values); heavy alcohol use within 5 years (to rate in ‚Äúpsychiatric‚Äù, too)
3 -Chronic hepatitis or any other liver disease with marked elevation of transaminases (>3-times 
normal values ); elevated bilirubin
4 -Acute cholecystitis; any biliary obstruction; active hepatitis/liver cirrhosis; any liver or biliary 
tree carcinoma
RENAL
This category is exclusive of kidney: kidney stones, acute/chronic renal failure, 
glomerulonephritis; nephrosic/nephritic syndrome; active/chronic pyelonephritis, diabetic or 
hypertensive nephropathy (albuminuria/proteinuria), renal carcinoma.
Bence-Jones proteinuria in multiple myeloma should not be considered.
0 -No problem
1 -Asymptomatic kidney stone; kidney stone passage within the last ten years; pyelonephritis 
within 5 years; kidney cysts without hematuria&(/*(1(35235,(7$5<,1)250$7,21m, etc.), m, etc.), 
se in se in 
itant) or osmitant) or osm
ylene glycoylene glyco
ago)ago)
n; hematon; hemat
ystemystem : acut: acu
sisis, portal, portal hll
hiasis, choiasis, ch l
ough the phough the p
l values of tvalues of
or previousr previou
iliaryiliary cirrhcirrhy
vy alcohovy alcoho ll
y other liveother live
vated bilirvated bilir uburrr
is; any bili; any bil
aa
ategorytegory iiyys ese
mmerulerulonephoneph
ypertensiveypertensiv
BenceBence --J
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 115 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20192 -Serum creatinine >1.5 but <3 mg/dl without diuretic or antihypertensive medication 
(particularly ACE-inhibitors or SRAA blockers); kidney calculi requiring daily meds
3 -Serum creatinine >3 mg/dl or >1.5 mg/dl in conjunction with diuretics, antihypertensive, or 
bicarbonate therapy; act ive pyelonephritis; nephrosic syndrome; colic symptoms treated as an 
outpatient
4 -Required dialysis; renal carcinoma; colic symptoms requiring hospitalization
GENITOURINARY
Ureters, bladder, urethra.
Genitals, prostate, testicles, penis, seminal vesicles.
Uterus, ovaries. Mammary gland is rated under ‚Äúmetabolic‚Äù .
This category is comprehensive of all GU tract impairments: ureteral or bladder stones, benign 
prostate hypertrophy (BPH), urinary tract infections (UTI‚Äôs), prolapses, etc. Urinary incontinence 
and indwelling catheter should also be considered.
0 -No problem
1 -Stress incontinence; BPH without urinary symptoms; hysterectomy or ovariectomy (uterine 
fibroma, benign neoplasm)
2 -Pathological pap smear (or 2 consecutives abnormal); frequent UTI‚Äôs (3 or more in the past 
year) in female or current UTI‚Äôs; urinary incontinence (not stress) in females; BPH with 
urinary symptoms (frequency, urgency, hesitancy); status post TURP; any urinary diversion 
procedure; indwelling catheter; bladder calculi
3 -Prostatic cancer in situ (e.g. incidentally found during TURP); vaginal bleeding; cervical 
carcinoma in situ; hematuria (any cause); urinary  incontinence (not stress) in males; bladder 
polyps
4 -Acute urinary retention; current urosepsis; any GU malignancies except as above
MUSCULOSKELETAL/INTEGUMENT
This is a very wide category, including: osteo arthritis, osteoporosis, any bone fracture; primary 
neoplasm (bone, muscle, c onnective tissue, skin), distinguishing melanoma from other localized 
skin cancers; rheumatoid arthritis and polymyalgia rheumatica; muscular injuries (rotator cuff, 
long head of the biceps); pressure sores; any dermatological disease.
The scores of this category are strictly correlated to the disability they cause; for the evaluation 
of the level of disability, refer to BADL and IADL.
NOTICE : score the severity of each illness according to the level of disability caused by the 
same illness in this category, without considering the disability caused by other diseases. For example: a patient affected both by osteoarthritis and hemiplegia from a previous stroke has a 
high level of disability, but you have to score 2 for disability by osteoarthritis (in this category) 
and 4 for disability by stroke (in the neurologi cal category); for a patient with both a deforming 
rheumatoid arthritis and a previous stroke without remaining outcomes you have to score 4 for 
disability from arthritis (in this category) and 2 for disability from stroke (in the neurological 
category).&(/*(1(35235,(7$5<,1)250$7,21er stones, ber stones, 
UrinaryUrinary iiyyn
tomy or my or ovov
requent UTquent UT
ce (not stresce (not stre
); status po); status p
und during und during 
; urinary urinary inin
rosepsis; anosepsis;
EGUMENEGUMEN52 y, including, includin
 connectconnect iv
toid arthritioid arthr
ceps); presceps); pres
this categorhis categ
ofof disabilidisabiliff ti
CEE: score thcore th
e illness in e illness in
xample: a pxample: a p
high lhigh l eveeve
nd 4 fn d4f
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 116 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 20190 -No problem
1 -Requires PRN meds for osteoarthritis ( NSAID) or has mild ly limited IADL from joint 
pathology; excised skin cancers (except melanoma); skin infections requiring antibiotics within a year
2 -Daily anti-osteoarthritis meds (NSAID) or use of assisitive devices or little limitation in ADL 
(previous arthroprosthesis or treated fracture with a low level of remaining disability); 
osteoporosis without ve rtebral fractures; d aily meds for chronic skin diseases (even local, as 
psoriasis or pressure sores); non metastatic melanoma; daily meds for rheumatoid arthritis (except steroids) with a low level of disability
3 -Osteoarthritis with a moderate level of di sability in ADL; requires chronic treatment with 
steroids for arthritic conditions or joints‚Äô de formities or severely impaired; osteoporosis with 
vertebral compression fractures
4 -Wheelchair bound for osteomuscular disease; severe joint deformities or severely impaired 
usage; osteomyelitis; any bone or muscle or connective tissue neoplasm (see ‚ÄúRating Malignancies‚Äù); metastatic melanoma.
Fractures and/or arthroprosthesis (both recent and old) have to be scored according to the level of 
disability they cause (considering outcomes too), in order to avoid confusion about possible 
classifications of different fractures or joints. The same for muscular diseases.
CENTRAL AND PERIPHERAL NERVOUS SYSTEM
This category includes the ‚Äúsomatic‚Äù pathologies of the central and peripheral nervous system: 
any kind of stroke, neurodegenerative diseases (Parkinson‚Äôs disease and parkinsonism, multiple 
sclerosis, amyotrophic lateral s clerosis, etc.), myelopathies, traumas with neurological outcomes, 
primary or secondary epilepsy, neuropathies (diab etic, alcoholic, any other etiology), primary 
tumors, chronic headaches (migraine), insomnia, etc.  It must carefully estimate the severity and 
prognosis of the illness but also the functional impairment that the illness causes.
0 -No problem (or fewer convulsions in childhood)
1 -Frequent headaches requiring PRN meds without impairment in Advanced ADL; previous 
TIA (one event); previous epilepsy, actually not treated, without crisis since more than 10 
years ago.
2 -Chronic headache requiring daily meds (even for prophylaxis) or with regularly functional 
impairment in Advanced ADL (bed rest, job withdrawal, etc.); actual TIA or more than one previous TIA; previous stroke without significant residual; mild severity neurodegenerative diseases (see above), treated and well controlled; epilepsy controlled with drugs.
3 -Previous stroke with mild residual dysfunction (hemiparesis, dysarthria); any neurosurgical 
procedure; moderate severity neurodegenerative diseases (see above), not well controlled by 
meds; epilepsy in treatment but with periodic crisis.
4 -Acute stroke or previous stroke with severe residual dysfunction (hemiplegia, aphasia, severe 
vascular dementia) or more than one previous stroke (multi-infarct encephalopathy); severe neurodegenerative diseases (see above) causing disability in ADL; neurological coma.
Alzheimer‚Äôs disease and dementia should not be rated into this category (Psychiatric and 
behavioral diseases): Alzheimer‚Äôs disease should be listed only under psychiatric disorders; if 
dementia stems from vascular and/or mixed dementia and/or other neurological condition (e.g. &(/*(1(35235,(7$5<,1)250$7,21with th 
orosirosis wis withthii
verelyerely impaimpyy
(see ‚ÄúRatsee ‚ÄúRat ingin
ored accordred accord
confusioconfusio nn
cular diseacular 
MM$he centrale central all
rkinson‚Äôs drkinson‚Äôs d
yelopathiesyelopathie
(di(diabetiabeti c, ac, a
oomnia, etc.mnia, etc
nctional imptional im
ns in childh in child
g PRN medg PRN med
s epilepsys epileps
requiring daequiring
Advanced AAdvanced A
A; previous ; previous
see above)see above)
us stroke wstroke w
cedure; mocedure; mo
meds; meds; epilepepile
4 --Acute stAcute st
vascuvasc
ne
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 117 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019Parkinson‚Äôs Disease), both ‚Äúneurologic‚Äù and ‚Äúpsychiatric‚Äù categories should be endorsed at the 
appropriate level for severity, considering in this  category the stroke and the multi-infarct 
encephalopathy responsible for the cognitive impairment (score 3 for stroke with remaining 
outcomes, score 4 for multi-infarct encephalopathy).
ENDOCRINE-METABOLIC SYSTEM AND BREAST (systemic infections and poisonings 
too)
Type 1 and type 2 diabetes (organ damage should be considered into the respective categories, 
like for hypertension), obesity and dyslipidemia (hype rcholesterolemia) represent the core of this 
category; it includes also hypo- and hyper-thyroidism, hypo- and hyper-parat hyroidism, adrenal 
pathologies (Cushing‚Äô or Addison‚Äô disease), hypogonadism, hypopituitaris m, etc. Malignancies 
of these glands, both benignant (like thyroid nodules) and malignant (like thyroid or adrenal 
cancer, vipoma, etc.) are included too.
Even if it is an exocrine gland, breast was included in this category because the authors didn‚Äôt 
find a more appropriate one; so it includes the breast cancer too.
Moreover, it includes: electrolyte disorders, sepsis, systemic infections (like tuberculosis, 
syphilis, AIDS) scored according to their severity and the functional impairment they cause (see 
general indications) and poisonings (chronic by metals or acute by pesticides or carbon 
monoxide).
0 -No problem
1 -Diabetes and/or dyslipidemia compensated  with d iet; mild obesi ty (BMI 30-35 kg/m2); 
hypothyroidism in replacement therapy (L-thyroxin); hyperthyroidism caused by Plummer‚Äô adenoma surgically treated.
2 -Diabetes compensated with oral hypoglycemic drugs or insulin (hemoglobin A1c <7%); 
dyslipidemia well controlled by daily meds (c-LDL lower than the recommended target according to the individual global cardiovascular risk); moderate obesity (BMI 35-45 kg/m
2); 
hyperthyroidism (Basedow, Plummer) in pharmacologic treatment; asymptomatic or 
surgically treated hyperparathyroidism; fibrocystic breast disease.
3 -Diabetes not well compensated by therapy (hemoglobin A1c 7-8.5%, presence of 
complications); dyslipidemia not well controlled (c-LDL higher than the recommended target according to the individual global cardiovascular risk; for instance, c-LDL>100 mg/dl in 
patients with previous myocardial infarc tion or stroke); severe obesity (BMI >45 kg/m
2); 
symptomatic hyperparathyroidism (for instance, hypercalcaemia); replacement therapy for 
adrenal failure; an y electrolytes disorder requiring hospitalization.
4 -Uncontrolled diabetes (hemoglobin A1c >8.5%) or one diabetic ketoacidosis or nonketotic 
hyperosmolar coma during the past year; genetic uncontrolled dyslipidemia; acute adrenal 
failure during hormonal replacement therapy; any neoplasm of thyroid, breast, adrenal gland 
(see ‚ÄúRating Malignancies‚Äù).
NOTICE : when the patient is not treated with drug therapy for diabetes or dyslipidemia but he 
should be for the optimal control of the pathology (for instance, hemoglobin A1c >7%, total 
cholesterol >250 mg/dl), score the pathology acco rding to the laboratory values, which really 
define its severity.&(/*(1(35235,(7$5<,1)250$7,21f this ft h i
drenal drenal 
gnancies gnancies 
r adrenal r adrenal 
he authors he author
ns (like tubes (like tube
al alimpairmmpairm
bybypestpeyy icidd
iet;et;mild obld 
oxin); hypeoxin); hyp
cemic drugcemic drug
meds (cmeds (c -LDL
cardiovascucardiovascu
mmer) in pmer) in p
hyhyroiroiyyydism; dism;
nsated by thnsated by
idemia not idemia n
dividual gloividual glo
vious myous my ococ
hyperparathhyperparath
lure; anyure; any eley
rolled diabeolled diab
erosmorosmo lar clar c
ailure durinailure durin
(see ‚ÄúRat(see ‚ÄúRat
NOTICNOTIC
oul
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 118 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019PSYCHIATRIC AND BEHAVIORAL DISEASES
This category includes both dementia and related behavioral disorders (psychosis, anxiety, 
depression, agitati on) and all the pre-existing and/or not related to dementia psychiatric 
disorders. Since this is the only item analyzing patient‚Äôs mental status (all the others refer to physical status), it is very important to evaluate it considering carefully further information 
derived from the Comprehensive Geriatric Assessment (MMSE; Geriatric Depression Scale, 
Neuro-Psychiatric Inventory if available) (8, 9).
0 -No psychiatric problem or history thereof
1 -Minor psychiatric condition or history ther eof: previous (occasional) psychiatric treatment 
without hospitalization; major depressive event and/or use of antidepressants more than 10 
years ago without hospitalization; occasional use of minor tranquilizers (e.g. BDZ; even if as 
hypnotherapy for insomnia); mild cognitive impairment (MMSE 25-28).
2 -A history of major depression (according to DSM-IV criteria) within the last 10 years (treated 
or untreated); mild dementia (MMSE 20-25); previ ous admission to Psychiatric Department 
for any reason; history of substance abuse (m ore than ten years ago, including alcoholism).
3 -Current major depression (according to DSM-IV criteria) or more than two previous major 
depression episodes in the past 10 years; moderate dementia (MMSE 15-20); current and usual usage of daily anti-anxiety meds (even as hypnotherapy for insomnia); current or within 
the past ten years substance abuse or dependence (according to DSM-IV criteria); requires 
daily antipsychotic medication; previous attempt at suicide.
4 -Current mental illness requiring psychiatric hospitalization, institutionalization, or intensive 
outpatient management (psychiatric emergency, as attempt at suicide or severe depression with suicide purpose, acute psychosis or acute decompensation of chronic psychosis, severe 
substance abuse; severe agitation from dementia); severe dementia (MMSE <15); delirium
(acute confusion or altered mental status for medical (organic) reasons: in this case you have 
to codify also the medical cause in its own cate gory with the appropriate level of severity).
It could be requested psychiatric consult for this category; dementia a nd depression, the most 
frequent diseases in the elderly, can be scored in details using the MMSE and GDS. The severity 
of any mental disorder (dementia, depression, a nxiety, psychosis, substance abuse and all the 
others) has to be scored according to the level of functional impairment or disability they cause.
&(/*(1(35235,(7$5<,1)250$7,21ent en
han 10 han 10 
Z; even if aZ; even if a
st 10 years st 10 years
ychiatrichiatri c DecD e
including acluding
 than two phan two p
MMSE 15MSE 15
pypyffyyor insomor infff
ding to DSMing to DSM
uicide.cide.
alizataliza ioon, inn, in
, as attemp, as attemp
te decompee decomp
mentia); sementia); se
us for medius for med
its own cate own cat
onsult for tonsult for t
can be scocan be sco
entiaentia , depre, depre
ccording toccording to
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 119 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201919.3. Deauville Criteria for PET Scan Interpretation ( Meignan, 2009 )
Interpretation
!A visual analysis using the 5-point scale should be applied
!The preferable reference scale should be the mediastinum and the liver
Scoring per the five point scale 
1. No uptake2. Uptake ‚â§ mediastinum
3. Uptake > mediastinum but ‚â§ liver
4. Uptake moderately increased compared to the liver at any site.5. Uptake markedly increased compared to the liver at any site and/or new sites of disease.
&(/*(1(35235,(7$5<,1)250$7,21w sisites oftes ofii dff
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 120 CC-5013-DLC-002 Amendment #4 Fin al: 12 Jun 201919.4. IWG Response Criteria for NHL ( Cheson, 2014 )
Table 16: IWG Response Criteria for NHL (Cheson, 2014)
&(/*(1(35235,(7$5<,1)250$7,21

Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 121 CC-5013-DLC-002 Amendment #4 Fin al: 12 Jun 2019Table 16: IWG Response Criteria for NHL (Cheson, 2014) (Continued)
&(/*(1(35235,(7$5<,1)250$7,21

Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 122 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201919.5. Cairo-Bishop Definitions of Tumor Lysis Syndrome
Table 17: Cairo-Bishop Definition of Laboratory Tumor Lysis Syndrome (LTLS)
Laboratory Parameter Laboratory Result
Uric Acid ‚â• 476 Œºmol/L(‚â• 8.0 mg/dL) or 25% increase from baseline
Potassium ‚â• 6.0 mmol/L ( ‚â• 6.0 mEq/L) or 25% increase from baseline
Phosphorous ‚â•1.45 mmol/L ( ‚â• 4.5 mg/dL) or 25 % increase from baseline
Calcium ‚â§ 1.75 mmol/L( ‚â§ 7.0 mg/dL) or 25% decrease from baseline
Laboratory tumor lysis syndrome (LTLS) is defined as either a 25% change or level above or below normal, as 
defined above, for any two or more serum values of uric acid, potassium, phosphate, and calcium within 3 days before or 7 days after the initiation of chemotherapy.  This assessment assumes that a patient has or will receive adequate hydration (¬± alkalinization) and a hypouricaemic agent(s) ( Cairo, 2004 ).  
Table 18: Cairo-Bishop Definition of Clinical TLS 
The presence of laboratory TLS and one or more of the following criteria:
1. Creatinine:  ‚â• 1.5 ULN (age > 12 years or age adjusted)
2. Cardiac arrhythmia / sudden death
3. Seizurea
ULN = Upper limit of normal. ( Cairo, 2004 )
aNot directly attributable to a therapeutic agent.
Table 19: Cairo-Bishop Grading System for TLS
Grade LTLS Creatinine Cardiac Arrhythmia Seizure
0- ‚â§ 1.5 x ULN None None
1 + 1.5 x ULN Intervention not 
indicatedNone
2 + > 1.5 ‚Äì 3.0 x ULN Non-urgent medical 
intervention indicatedOne brief generalized seizure; seizure(s) 
well controlled or infrequent; focal motor seizures not interfering with ADL
3 + > 3.0 ‚Äì 6.0 x ULN Symptomatic and 
incompletely controlled 
medically or controlled with deviceSeizure in which consciousness is altered; 
poorly controlled seizure disorder; 
breakthrough generalized seizures despite medical intervention
4 + > 6.0 x ULN Life-Threatening Seizures of any kind that are prolonged, 
repetitive, or difficult to control
5+ DeathaDeathaDeatha
ADL= activities of daily living; LTLS = laboratory tumor lysis syndrome; TLS= tumor lysis sy ndrome; ULN =
upper limit of normal ( Cairo, 2004 )  
aProbably or definitely attributable to clinical TLS.&(/*(1(35235,(7$5<,1)250$7,217,7,7,7,$777
0$50normal, as normal, as 
within 3 daywithin 3 da
has or will recs or will r
criteria:te,1<
$5<7$(7
System forSystem fo
Cardiac ACardiac2352NoneNone52525252In35555
‚Äì‚Äì3.0 x ULN3.0 x (3
> 3.0 > 3.0 ‚Äì‚Äì(1
(*(
4+ +(((/&(55&&&&
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 123 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201919.6. EQ-5D
Health Questionnaire
(English version for the UK)
(validated for use in Eire)
K))
Eire)Eire)
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 124 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019By placing a tick in one box in each group below,  please indicate which statements best describe 
your own health state today.
Mobility
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
Self-Care
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
Usual Activities (eg work, study, housework, family or
leisure activities)
I have no problems with pe rforming my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
Pain/Discomfort
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
Anxiety/Depression
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
&(/*(1(35235,(7$5<,1)250$7,21

ctivitctivit iesies
mfortmfort
comfomfortr
ionion
ous or deprous or dep
deratelyately anxanxy
extremextrem elyelyay
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 125 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019To help people say how good or bad a health state is, we
have drawn a scale (rather like a thermometer) on which the
best state you can imagine is marked 100 and the worststate you can imagine is marked 0.
We would like you to indicate on this scale how good or bad
your own health is today, in your opinion. Please do this by
drawing a line from the box below to whichever point on the
scale indicates how good or bad your health state is today.90
80
70
60
50
40
30
20
10100
Worst  imaginable
health state0Best imaginable
health state
Your own
health state
today
&(/*(1(35235,(7$5<,1)250$7,2100$$0$0$0$5050505808
(3
Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 126 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201919.7. FACT-LYM

Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 127 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019
&(/*(1(35235,(7$5<,1)250$7,21

Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 128 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 2019
&(/*(1(35235,(7$5<,1)250$7,21

Lenalidomide (CC-5013)
Protocol CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 129 CC-5013-DLC-002 Amend ment #4 Final: 12 Jun 201919.8. Pregnancy Prevention Risk Management Plan
The Pregnancy Prevention Risk Management Plan is a standalone document.
&(/*(1(35235,(7$5<,1)250$7,21
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
8VHU1DPH
7LWOH'DWH0RQGD\-XQH$0(DVWHUQ'D\OLJKW7LPH0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
&(/*(1(35235,(7$5<,1)250$7,21
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 3 CC-5013-DLC-002 Amendment #4 Final: 12 Jun 20191. JUSTIFICATION FOR AMENDMENT
The ROBUST clinical database was locked on 12 Apr 2019 for the primary analysis.  All 
patients have been off study treatment for over 1 year.  The study did not meet the primary 
endpoint of demonstrating superiority in progressi on-free survival (PFS) compared to placebo 
plus rituximab, cyclophosphamide, doxorubicin, vincri stine, and prednisone therapy (R-CHOP).  
Protocol Amendment 4 removes the requirement of follow-up assessments for subjects 
continuing in the study except for over all survival (OS) and second primary malignancy ( SPM) 
follow-up. Given the study outcome, observed significant slowing of the event rate, and expected course of the disease, it is reasonable to make this change.  
For many patients, diffuse large B-cell lym phoma (DLBCL) is a curable disease. Most relapses 
occur within the first 12 to 18 months and the event rate slows significantly approximately 12 months after diagnosis, as has been observed in the ROBUST Study. While some patients may 
relapse after 2 years (defined as late relapses), the  rate of late relapse after this time is low and 
patients who are event free at 24 months are considered to have an overall survival equivalent to that of the age- and sex-matched general population ( Maurer, 2014 ; Feldman 2014 ).  Therefore, 
extensive follow-up of the remaining patients in the ROBUST study would place a significant 
burden on patients and clinical professionals without  any reasonable expectation of acquiring 
data which would benefit patients or add to the scientific understanding of the disease. 
 
These changes will also decrease study related radiation exposure and blood draws and allow 
greater flexibility to investigators and patients for overall disease management. The specified assessments (summarized in Table 5) will no longer be required after the 12 Apr 2019 final 
analysis and will not be subject to case report form data collection. Long-term follow-up and 
data collection for OS and SPM remain mandatory. Specific guidance is provided in the amendment.
Changes to the protocol due to the above rationale are summarized below:
!Protocol Summary: Study Design and Length of Study - After the primary analysis, only 
SPM and OS information will be collected.
!Section 4.1.7: Follow-up Period - After the primary analysis, only SPM and OS 
information w ill be collected.
!Section 4.2: Figure 3 Overall Study Design - After the primary analysis, only SPM and 
OS information will be collected.
!Section 4.3: Study Duration - After the primary analysis, only SPM and OS information 
will be collected.
!Table 5: Table of Events - Clarified that the following assessments will no longer be 
required for data collection after the 12 Apr 2019 primary analysis: 
‚àÄPhysical examination, vital signs, complete blood count with differential, lactate 
dehydrogenase, qu ality-of-life assessment, performance s tatus,  
, computed atiation eon exposxpo
or overall dor overall d
longer be rlonger be r
port formport form dad
mandatorymandator
he above rahe above ra
StudyStudy  DesiDey
rmatrmatioion win
FollowFollow --upu
n will be cn will be c
n 4.2: Fi4.2: Fi gugu
informationformatio
SectiSe on 4on 4
will bewill be
!TaTa< ,1)250$7,21ted ed 
relapses apses 
matelmatel y 12 y 12
patipatients ents mm
time is lowime is lo
urvivalurvival equeq
man 2014man 20 )
would placewould plac
le expectatie expecta
tanding otandi ff
5<$5<
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 4 CC-5013-DLC-002 Amendment #4 Final: 12 Jun 2019tomography, response assessment, subsequent antilymphoma therapy, and 
progression 
!Section 6: Procedures - Select follow-up assessments (sp ecified in Table 5), are no longer 
required after the 12 Apr 2019 primary analysis.
Minor grammatical edits were included to ensure consistent word use and clarity in protocol 
changes described above.
The following administrative change was also made:
!Changed the Medical Monitor from due 
to internal Celgene staff changes.
References
Feldman T, Gromko L, Protomastro EA, Starovoitova L, Mato AR, Glisch C, et al. Relapses of 
diffuse large b-cell lymphoma in rituximab era are limited to the first two years after frontline 
therapy. Blood 2014;124:1307.
Maurer MJ, Ghesquieres H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free 
survival at 24 months is a robust endpoint for disease-related outcome in diffuse large b- cell 
lymphoma treated with immunochemotherapy. JCO 2014;32(10):1066-73.due due 
t al. Relapst al. Rela
ars after froars after f
n CA, et al. CA, et al. 
mme in diffuin dif
0):1066):106 -73.30$
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 3 CC-5013-DLC-002 Amend ment #3 FINAL 04 Feb 20191. JUSTIFICATION FOR AMENDMENT
The amendment includes two changes:
!Changed the Medical Monitor from due to 
internal Celgene staff changes (Page 2).
!
 
  
For many patients DLBCL is a curable disease. However, approximately a third of patients will 
either not respond well to initial therapy or respond but relapse early, usually in the first year 
after the first treatment.  Most relapses occur within the first 12 to 18 months and the event rate 
slows significantly approximately 12 months after diagnosis.  While some may relapse after 2 years (defined as late relapses) the rate of late relapse after this t ime is low and p atients who are 
event free at 24 months are considered to have an overall survival equivalent to that of the age-
and sex-matched general population ( Maurer, 2014 ; Feldman 2014 ).  Therefore, incorporation of 
these late events can be complicated by compet ing risks, especially in older patients with 
comorbid health conditions.  
A recent retrospective study demonstrated that relapse rate after 2 years was low (5.9%) in patients 
with DLBCL who achieved complete response (CR) after R-CHOP ( Kang, 2018 ).  Of particular interest, late 
relapse was associated with favorable baseline clinical characteristics such as GCB subtype and lower IPI 
scores (IPI 2 versus IPI2) compared with patients with  early relapse.  Early relapses were associated with 
the ABC subtype and higher IPI scores which have substantially worse outcomes ( Kang, 2018 ).
The ROBUST trial is Phase 3 study of oral lenalidomide plus R-CHOP21 √ó 6 versus placebo-R-
CHOP21 √ó 6 in patients with previously untreated ABC-type DLBCL.  These patients have the highest unmet need with associated worse outco mes and early relapse (within first year) 
following initial therapy.  However, those who respond and achieve 2 years event free could be 
considered to have an overall survival r ate similar to people in the general population. 
A significant slowing of the PFS event rate in the ROBUST study was observed over the past 
year and this may be explained by the information described above.  An early relapse is expected
in the ABC population followed by a falling event rate as subjects have a decreasing probability of progression the longer they remain event fr ee and reach the 18 mont hs to 2-years post 
treatment start time period.  (The median follow-up for the ROBUST  study subjects through the 
end of 2018 was approximately 24.4.months.)  Following this time period, it is anticipated that future events can be characterized as late events that are potentially not lymphoma related, and 
that will potentially complicate analysis.  
 
 
 
Over the course of the past year the Indepe ndent Radiology Adjudication Committee (IRAC) 
assessed PFS event rate has fallen from approximately 8 events per month to the current rate of 2 
to 3 events per month (~6 per quarter)   /*(1(35235,(7$5<,1)250$7,21tiients willents will
first yfirst y ear ear 
d the eventd the event
y relapse ay relapse a
and patienand patien
valent to thavalent to t
ThereforeTherefore
ly in oilder plder 
ter 2 years wr 2 years
HOPOP((Kang, Kang
aracteristicaracteris
early relapsearly rela
substantiallubstantial
lenalidomenalidom
y untreated untreate
worseworse outcoou
er, those wher, those wh
urvivalrvival raterate
e PFS evenPFS eve
plained byplained by
nnfofollollowedwe
llonger theyonger the
time periodtime period
was was approxappro
nts ts can be an be
ill potentialll potential$
(/&(&(&
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 4 CC-5013-DLC-002 Amend ment #3 FINAL 04 Feb 2019&(/*(1(35235,(7$5<,1)250$7,21(/*(1(35235,(7$5<,1)250$7,
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 5 CC-5013-DLC-002 Amend ment #3 FINAL 04 Feb 20192. REFERENCES
Feldman T, Gromko L, Protomastro EA, Starovoitova L, Mato AR, Glisch C, et al. Relapses of 
diffuse large b-cell lymphoma in rituximab era are limited to the first two years after frontline 
therapy. Blood 2014;124:1307.
Kang J, Lee K, Hong JY, Yoon DH, Kim S, Park JS, et al. Low relapse rate after 2 years in patients with 
diffuse large b-cell lymphoma (DLBCL) treated with R- CHOP and achieved complete response [abstract]. 
In: The 60thAnnual Meeting of the American Society of Hematology; 2018 Dec 2; San Diego, CA. Abstract 
nr 2996.
Maurer MJ, Ghesquieres H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free 
survival at 24 months is a robust endpoint for di sease-related outcome in diffuse large b-cell 
lymphoma treated with immunochemotherapy. JCO 2014;32(10):1066-73.
 
 
&(/*(1(35235,(7$5<,1)250$7,21ct ct 
ree e 
e be b--cell cell 
25)21)2,1)<, 1
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 3 CC-5013-DLC-002 Amendment #2 Final: 24 Jan 20171. JUSTIFICATION FOR AMENDMENT
Major changes included in this amendment are summarized below:
!Revised lenalidomide / placebo dose modification rules for neutropenia and 
thrombocytopenia toxicities. Considering the aggressive nature of the disease under study, diffuse large B-cell lymphoma (DLBCL), and the known overlappinghematologic toxicity of R-CHOP and lenalido mide, the dose modification rules were 
re-evaluated based on the investigators‚Äô feedback. This revision has been 
recommended by the Study Steering Co mmittee (SSC) after careful benef it/risk 
evaluation. The purpose of this revision is to maintain the dose and intensity of the 
regimen as much as possible, while managing the hematology toxicity effectively,
thus aiming to provide optimized over all benefit for the patients (Table 8).
The amendment also includes several other minor clarifications and corrections:
!The ‚ÄòAll Cycles Day 1‚Äô column under the  Treatment Period of the Table of Events 
was revised to state ‚ÄòCycles 1-6 Day 1‚Äô (Table 5).
!Changed the 3 months prior to Cycle 1 Day 1 (C1D1) tumor biopsy and bone marrow
biopsy/aspirate collection windows to 8 weeks prior to C1D1.  Upon further 
evaluation with the SSC, it was assessed that subjects enrolling after an 8-week 
interval are likely to have a more indolent course of disease than the expected patient population for this study, which takes into  account the aggressive nature of DLBCL.  
Therefore, patient selection bias may be introduced if a significant number of these 
subjects are enrolled (Table 5, Section 4.1.2, and Section 6).
!Clarified that ‚ÄòPregnancy Testing ‚Äì for FCBP  with Regular or No Menstrual Cycles‚Äô
and ‚ÄòPregnancy Testing ‚Äì for FCBP with Irregular Menstrual Cycles‚Äô is required 24 
hours prior to lenalidomide/placebo dosing (ins tead of 24 hours prior to C1D1), and 
once during day -10 to -14 to highlight that the timing of the pregnancy testing is dependent on lenalidomide/placebo dosing and not on other components of R-CHOP
dosing. The abbreviation ‚ÄòFCBP‚Äô stated above means females of childbearing 
potential (Table 5 and Section 6).
!Typographical error was d eleted for Quality of Life Assessment in the Table of 
Events, as it incorrectly indicated a collection time point at Cycle 6 Day 1. The timing 
of this assessment is the same as for computed tomography (CT) scan collection and 
was correctly stated in Section 6 (Proce dures). Consequently, this table has been 
updated to align with the timing stated in Section 6 (Table 5).
!Clarification that the need to perform a Bone Marrow Biopsy at the End of Treatment 
Visit is dependent on the post Cycle 6 positron emission tomography (PET) scan results, and is required only if the Bone Marrow Biopsy at Screening is positive and 
there is an equivocal post Cycle 6 PET scan finding in the bone marrow. The post 
Cycle 6 PET scan is performed once, 3-4 weeks after completing Cycle 6 (Table 5and Section 6).
&(/*(1(35235,(7$5<,1)250$7,21e e 
sk k 
y of the y of the 
effectivelyffectively
blble 8)e 8)..
ons:ons:
of the Tablthe Taf
) tum) tum or bibioo
or to C1D1or to C1D
ubjects enrojects enr
urse of disrse of di
o account tho accoun
e introducee introdu
on 4.1.2, an 4.1.2, a
ng ng ‚Äì‚Äìfofor FCr FC
r FCBP wiFCBP w i
de/placebo e/placeb
-14 to high14 to hi
doomide/plamide/pla
eviatieviati on ‚ÄòFon 
ble 5leand Seand
hical hical errorerro
, ,as itas it incorincor
hihis assessms assess
was correctwas correct
updated updated 
!!ClClara
VV
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 4 CC-5013-DLC-002 Amendment #2 Final: 24 Jan 2017!Administration of Mandatory Primary Neut ropenia Prophylaxis adde d to the Table of 
Events and Procedures section, to em phasize the protocol requirement of primary 
neutropenia prophylaxis at every cycle dur ing Cycles 1-6 (Table 5 and Section 6).
!Further clarified that the Tumor Lysis Syndrome (TLS) Assessment at Cycles 1-2 
Day 8 has a window of ¬± 1 day (Table 5 and Section 6).
!Clarification added to Adverse Event and Concomitant Medications/Procedures 
collection schedule to emphasize that the pe riod through 28 days after the last dose of 
investigational product, applies to the optional two additional doses of single agent 
rituximab, if administered (Table 5 and Section 6).
!Allowed local laboratory results to confirm eligibility if Screening Central Laboratory 
results are not available and it is necessary to urgently start treatment.  This applies to 
eligibility laboratory requirements for Hepatiti s B Virus (HBV), Hepatitis C Virus 
(HCV), Creatinine Clearance, Complete Blood Count (CBC) with Differential, and Serum Chemistry. In this case, the Celgen e medical monitor must  be consulted, the 
data submitted on the case report form (CRF),  and a central laboratory sample must 
still be collected prior to first dose.  Due to the aggressive nature of DLBCL, there are cases in which treatment must be urgently and immediately started at the 
investigator‚Äôs discretion.  In these cases, it may be possible for eligibility criteria to be 
confirmed against local laboratory result s instead of Central Laboratory results
(Section 6).
!Allowed Lactate Dehydrogenase (LDH) local la boratory results to be used at 
Screening, if Central Laboratory results are not available and it is necessary to urgently start treatment (Section 6).
!Clarified that if RNA viral load for Hepati tis C Virus (HCV) testing is needed, the 
test is done by local laboratory, as it is not automatically performed by the Central 
Laboratory (as opposed to HBV viral DNA load testing, which is automat ically 
performed by the Central Laboratory when  indicated by the protocol) (Section 6).
!Clarified that local pathology CD20+ s tatus may be used to determine eligibility,
instead of the Central Pathology result, if the local and Central Pathology disagree on 
CD20+ status for patients with activated  B-cell (ABC) type c onfirmed by Central 
Pathology. The intent of protocol amendment 1 was for the disagreement on 
diagnosis between local and Central Pathology to also apply to CD20+ status (Section 
7.2).
!Added PET scan finding as another option to determine bone marrow involvement by 
lymphoma, when assessing absolute neutrophil count (ANC) and platelet count for 
eligibility (Section 7.2).
!Corrected typographical error to state that both AST and ALT values must be ‚â§3.0 x 
upper limit of normal (ULN) or ‚â§ 5.0 x ULN in the case of documented liver 
involvement by lymphoma. The intent was to always require both values to determine 
eligibility (Section 7.2).&(/*(1(y.( 35235,(7$5<,1)250$7,21f f 
nt 
LaboratoryLaborator
Thihis appliess applie
atiatitis C Vitis C Viii
DifferentDifferent iai
ust be consst be cons
laboratoryaborator
e nature of nature of
iatelytestartestarte
possibpossib lelfo
d of Centraof Centra
oocalcallllaborabo
s are not avs are not 
for Hepator Hepatfff
oryry, as i, as it tiis i
ooHBV viraHBV v
ralralLabLal oraor
l pathol patholl ogg
Centralntral PathPathll
s s fofor patienr patie
The intenThe inte
osis betweeosis betwee
)..
Added PEAdded PE
lymphoympho
eligielig
!!
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 5 CC-5013-DLC-002 Amendment #2 Final: 24 Jan 2017!Allowed possibility for local radiation to be administered as optional prephase 
treatment to subjects in cases of medical emergencies, in which prephase treatment with corticosteroids is not considered ade quate.  This is not expected to be a common 
occurrence (Section 8.2.1).
!Revised situations in which an investigator may prospectively choose to give local 
radiotherapy after study chemotherapy per  local practice, including subjects at higher 
risk for central nervous system (CNS) l ymphoma, which may be standard pract ice for 
these subjects (Section 8.2.2, Section 10.6.2).
!Added recommended dosing schedules for administration of mandatory primary 
neutropenia prophylaxis, along with clarification that this requirement applies to all 
subjects at every cycle during Cycles 1 ‚Äì 6.  These two schedules of administration 
were recommended by the SSC and was endorsed by the Data Monitoring Committee (DMC) (Section 8.2.3).
!Removed requirement to administer lenalidomide as the first investigational product 
taken on Day 1 of every cycle.  
 
(Section 8.2.5).
!Clarified that dose interruptions (in addition  to reductions) can be  done for reasons in 
addition to what is stated in Table 8, per the investigator‚Äôs discretion.  In previous protocol versions, only reducti ons are mentioned (Section 8.2.5).
!Allowed intravenous dexamethasone as a substitution for prednisone on Day 1 of 
every cycle to accommodate local practice and formulation availabilities (Section 
8.2.10).
!Clarified the intent of the Requalification Criteria for Subsequent Treatment Cycles is 
for non-hematological toxicities to be resolved to ‚â§ Grade 2, instead of all other 
toxicities, as originally stated.  Exceptions  to ANC and platelet count criteria were 
also clarified for cases of spleen involvement secondary to lymphoma, per investigator assessment (Section 8.2.12).
!Clarified exceptions to neutropenia and thrombocytopenia lenalidomide / placebo 
dose modification rules for cases of spleen involvement secondary to lymphoma, per 
investigator assessment (Table 8).
!Clarification added to the titles of Tables  8, 10, 11, and 12 (Table 8, Table 10, Table 
11, and Table 12).
!Corrected typological errors throughout the document (Table 2, Section 7.2, Section 
18, and Table 19).
&(/*(1(35235,(7$5<,1uctionsuctions ))ca
vestvestigator‚Äôsigator‚Äô
oonedned(Sect(Sec
a substa subst itutut
actice and factice and 
qualificatualifica ioi
cititiies to bees to be
tated.ated.   ExcEx
es of spleenes of spleen
smentsment (Sec(Sec
eptepions to nns t
icatcatioion ruln rul
ator assessator assess
rificatificat ioion an
11,1,andandTabTab
CorrectCorrec
18, a18, 1)250$7,21yy
es to all es to all 
nistration nistration 
ring Commng Comm
vestvestigatigatioio
1),1)
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 3 CC-5013-DLC-002 Amendment #1 Final:  25 Aug 20151. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!  
 
!Allowed submission of core needle tu mor biopsy material for eligibility.   
 provided technical validation data in  showing that core 
needle biopsy tissue was acceptable for use in the gene expression profiling (GEP)
assay that is the basis for Activated B-cell (ABC) subtype subject sel ection in this 
protocol.  The validation d ata demonstrates that the GEP assay can be performed with 
core needle tumor biopsy specimens without compromising assay performance.  In 
certain situations a surgical biopsy would pose an unacceptable risk and previously 
such subjects had to be excluded.  With this amendment it will be possible to screen subjects who must use a core needle biopsy. (Sections 6 and 7.2)
!Allowed local pathology diffuse large B-cell lymphoma (DLBCL) diagnosis to 
prevail in the event that Central Pathology confirms ABC subtype but is not able to confirm a DLBCL diagnosis.  In this case, the subject may enroll at investigator discretion.  A retrospective adjudication by a second Central Pathologist will be 
performed for the purposes of defining the mo dified intent to tr eat (mITT) population; 
primary analysis is per the intent to treat (ITT ) population.  A ccording to an 
internationally recognized, expert hematopathologist,  
,t h i s  
should be a rare (< 1%) occurrence, and therefore does not pose a major risk to the existing ITT sample size.  This provision  was added to allow the possibility of 
adjudication by an expert pathologist in difficult cases. (Section 7.2)
!Changed the hemoglobin inclusion criterion 11c from ‚â•10 g/dL (6.2 mmol/L) to ‚â•7.5 
g/dL (4.7 mmol/L) for all subjects, and allow packed red blood cell (PRBC) transfusions as needed during Screening ( PRBC transfusions were already permitted 
during the Treatment Period).  Many DLBCL patients will have depressed 
hemoglobin values regardless of whether they have documented bone marrow involvement by lymphoma.  Additiona lly, lenalidomide impact on hemoglobin value 
is much less common than neutropenia and thrombocytopenia and the protocol does
allow transfusions as need ed. (Sections 7.2 and 9.2.1)
!Included, at investigator discretion, subjects > 80 years if their Eastern Cooperative 
Oncology Group (ECOG) performance status is ‚â§ 1; each of their individual organ 
system scores is ‚â§ 2 using the Modified Cumulative Illness Rating Scale (CIRS); and 
if they would otherwise be eligible for full-dose rituximab, cyclophosphamide, doxorubicin, vincris tine, and prednisone (R-CHOP) per local practice.  (Other entry 
criteria address specific co-morbidities such as cardiac function [left ventricular 
ejection fraction < 45% excluded] and adequate bone marrow, kidney, and liver function [minimum laboratory values]). In the ECOG MC078E study, 9% of the 
subjects were ‚â• 80 years, and the safety profile of the elderly study subjects was 
approximately the same as for the study subjects < 80 years, with no significant safety 
&(/*(1(35235,(e, and theree, and there
provisirovisi ononwnn
thologist inhologist 
n inclusioninclusion
r all r all subjecsubjec
eded duringeded durin
tment Perioment Peri
valvalues regaues regl
ent bynt by  lymplymyy
hleless coss co mm
w transfusiw transfu
Includenclude d,d,
OncoOnco lolo
systesys
ifif(7$5<,1)250$7,21EPP))
n this his 
formform ed wied wi ti
ormance.rmance.  I
andandprevioprev
e possible e possible t
.2)2)
DLBCLDLBCL ))dd
BC subtC subt ypeyp
cttmamay yenro
ond Centraond Centra
difiedified intend inte
TTTT)populapopula
topatholopatho ogiog
,(77
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 4 CC-5013-DLC-002 Amendment #1 Final:  25 Aug 2015signal.  Additionally, this option will more closely align the protocol with standard 
practice in some countries. (Table 5 and Sections 6, 7.2, and 19.2)
!Included hepatitis C virus (HCV) positive subjects who do not have an active 
hepatitis C infection and who are otherwise acceptable candidates for R-CHOP chemotherapy.  All subjects will be teste d for HCV antibodies at Screening by the 
Central Laboratory, and the investigator must further test HCV+  subjects by either 
FibroScan
¬Æ(liver ultrasound for fibrosis), liver biopsy, ribonucleic acid (RNA) viral 
load or other local practice. Within the current Revlimid‚àÄInvestigator‚Äôs Brochure 
(edition 18) Hepatitis C reactivation is not noted as a treatment-emergent adverse 
event.  In addition, there was an eff ective HCV drug (Gilead) approved recently, and 
DLBCL subjects with acceptable liver function and fully controlled infection are routinely tr eated with R-CHOP in areas of high endemic HCV infection.
  (Table 5, 
Sections 6, 7.2, and 7.3)
!Excluded T-cell / histiocyte rich DLBCL cases from the study population.  This 
change was made on the recommendation of the expert hematopathologist,  
 
  The GEP of such subjects would not be typical because of the 
limited number of large B cells that are embedded within a background of abundant T 
cells and histiocytes, resulting in a very lo w tumor cellularity.  Additionally, the high 
inflammatory component of the microenvi ronment could potentially overlap with 
Hodgkin‚Äôs Lymphoma, potentially making it difficult to discriminate from ABC type 
DLBCL. (Sections 7.2 and 7.3)
!Excluded Post-transplant Lymphoproliferative Disorder (PTLPD) cases from the 
study population even if they are a B- cell type and the ABC subtype.  The rationale is 
that PTLPD is considered a separate entity from mature B-C ell neoplasms, which 
include DLBCL, according to the World Heal th Organization 2008 classification.  
(Section 7.3)
!Allowed pre-phase corticosteroid treatment per local practice, with a recommended 
limit of 100 mg/ day prednisone or equivalent for 10 days; rather than mandating a 
limit of 1 mg/kg/day for 7 days.  This would accommodate the variety among local 
practices without unnecessarily excluding an  otherwise eligible subject and without 
impacting the essential intent of no pri or anti-lymphoma treatment.  Additionally, 
pre-phase corticosteroid treatment for elderly subjects in general may be useful 
(Pfreundschuh 2010). (Sections 7.2 and 8.2.1)
!Changed pneumocystis prophylaxis from ‚Äúrequi red‚Äù for all subjects to ‚Äúpermitted‚Äù.  
At most sites pneumocystis prophylaxis is a local standard of care for all patients 
receiving R-CHOP-14, and for the elderly who receive R-CHOP-21; however, the 
practice varies for patients < 65 years who receive R-CHOP-21.  Additionally, there is potential overlap with the myelotoxicity profile of Bactrim¬Æ, a common 
prophylactic drug, and lenalidomide + R-CHOP.  Therefore, the protocol requirement 
was changed to accommodate local practice and to allow the investigator to weigh the risk / benefit on an individual subject basis.  (Section 9.2.2)&(/*(1(35235,(7$5<,1e etypicalpicaly be
ithin a backin a back
r cellularitr cellulari
mentment coulcould d
t difficult tt difficult 
oliferatoliferat ive Dve D
a Ba B--cell tcell t ypyp
parate enarate en titinntyti
to the o the WoWorl
orticosteroiorticostero
day prednisoay prednis
g/day day fofr 77
hhout unnecout unne
g the essentthe essen
hase corticoase cortico
reundschuheundschu
ChangeChange dpdp
AtAtmomo
recerece
pp1)250$7,21e 
ly,y,and nd 
on are n are 
   (Tabl(Tabl e 5,e 5
opulopulatatioion.  n. 
topathologiopatho
,1)
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 5 CC-5013-DLC-002 Amendment #1 Final:  25 Aug 2015!Allowed lenalidomide/placebo - R-CHOP regimen modifications, at investigator 
discretion, in the event of HCV infection or reactivation; or for the following grade 3 toxicities: nausea/vomiting, infection requiring intravenous (IV) antibiotics or 
hospitalization, or other non-hematologic toxicities .  For other toxicities, modification 
should be in accordance with respectiv e product labels . (Section 8.2.11 and Table 12)
!Allowed individual drug dose modifications for cyclophosphamide, doxorubicin and 
vincristine. Certain clinical situations may require the modification of individual 
drugs of the R-CHOP regimen, for example if the toxicity is clearly attributable to just one or two of these drugs, and when it would still be reasonable to continue with 
the chemotherapy regimen. (Sections 8.2.7; 8.2.8; 8.2.9; Table 10 and Table 11)
!Allowed rituximab administration over two days at the beginning of each cycle from 
Day ‚Äì 1 through Day 3 to better manage potential infusion reactions on account of high tumor burden or bulky disease; and to accommodate various standard regional 
practices on this global study.  (Section 8.2.6)
!Allowed IV methylprednisone as a substitu tion for either IV or PO prednisone on 
Day 1 only of every cycle to accommod ate local practice, com pound, and formulation 
availability.  (Section 8.2.10)
!Changed to the most current Internati onal Working Group (IWG) Response Criteria 
for non-Hodgkin‚Äôs lymphoma (NHL) (Cheson 2014 from Cheson 2007).  As a consequence, the End of Treatm ent bone marrow biopsy for sub jects otherwise in CR 
was removed; this is according to the new criteria where a positron emission 
tomography (PET) negative bone marrow will suffice to confirm a complete response 
(CR).  (A subject with lymphomatous involvement of the bone marrow at Screening, who has an equivocal post Cycle 6 PET scan finding in the bone marrow, requires a 
repeat bone marrow biopsy; if the biopsy is negative the subject may then be 
classified as a CR.)  However, the baseline bone marrow biopsy will be retained to document any discordant small cell component; it is also useful to screen out 
myelodysplastic syndrome; and there are other entry criteria related to neutrophil and 
platelet c ounts that require confirmation of bas eline bone marrow involvement.  As a 
second consequence, the B-symptom assessment will also be removed as this is not a 
component of the revised criteria.  (Protocol Summary, Section 4.1.2, Table 5, 
Section 6, Appendix 19.4, and article references throughout the text)
!Allowed for combined PET-computed tomography (CT) without contrast as per local 
standards at Midcycle; End of Treatment; and for PET negative (CR) subjects only , 
also during the Follow-up Period.  There is a key restriction that progression may not be scored on PET positivity alone, but must be confirmed by CT with contrast or a 
biopsy of the PET positive lesion.  This option is consistent with the new IWG 
Response Criteria for NHL (Cheson 2014).  (Sections 4.1.3, 4.1.4, 4.1.5. and 6)
&(/*(1(35235,(7$5<,1)250$7,21witwith h 
1))
h cycle fromcycle from
naccount oaccount o
tandard regandard re
or PO PO prepr
, comcompoundpounmm
g Group (IWg Group (
2014 fro2014 fro mm
rrow birrow bi opsop
w criteria w criteria 
row will surow will s
us invos invo lvemlve
e 6 PET 6 PET scasca
f the biopsyf the biopsy
ver, the basver, the ba
nt small celsmall ce
dromedrome ; and;a n d
at require coat require co
uence, the Bnce, the B
of the revisof the revi
, AppendixAppendi
wwededfofor comrc o
andards at Mdards at 
also durinalso durin
be scorbe scor
biopbiop
R
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 6 CC-5013-DLC-002 Amendment #1 Final:  25 Aug 2015Minor clarifications and corrections include d in this amendment are summarized below: 
!Added the informal study name ‚ÄúROBUST‚Äù to the title page.  The study was named 
to allow easier conversational identification for subjects and health care professionals.
!Explained that the assay used for ABC subtype subject sel ection is technically 
validated, but that it does not have the marketing approval by a health authority beyond Conformit√© Europ√©enne (CE) marking in the European Union. (Section 1.2.1)
!Defined the protocol specific meaning of the term Midcycle (once between Weeks 9 
‚Äì 12 which is after Cycle 3 but before Cycle 4) and thereafter treated it as a proper noun with capitalization. (Protocol Summary; Sections 4.1.3, 6; and throughout the text)
!Clarified that while it is acceptable to perform  a combined PET-CT, or a standalone 
PET in addition to the protocol requi red CT scan at the Midcycle evaluation, 
treatment decisions to switch therapy should not be based so lely on the PET results.  
This position is supported by the Inte rnational Conference on Malignant Lymphoma 
Imaging Working Group recommendations which explain that the positive 
predicative value of interim PET in DBLC is variable.  (Section 4.1.4)
!Corrected the visit window inconsistencies for the Day 1 assessments for Cycles 2-6.  
Dosing and tumor lysis syndrome (TLS) assessment have a ¬± 1 day window and 
should occur on the same day.  All other assessments have a ¬± 3 day window.  (Table 
5, and Sections 6 and 8.2)
!Split and re-ordered the first few inclusion criteria, so that more precise reasons for 
screen failure may be qua ntitatively track ed. (S ection 7.2)
!Clarified that the eligible antibody and anti gen profile described in exclusion criterion 
4c describes a successfully treated hep atitis B-virus (HBV) infection. (Section 7.3)
!Removed the requirement to take prednisone after lenalidomide on Days 2-5.  The 
two drugs are not expected to have any PK interactions.  (Section 8.2.10)
!Confirmed that mandatory neutropenia prophylaxis is ‚Äúprimary‚Äù prophylaxis where 
growth factors are to be administered at the beginning of R-CHOP treatment and prior to a decrease in absolute neutrophil count (ANC) value. (Sections 8.2.3 and 9.2.1)
!Changed the 2 months prior to Cycle 1 D ay 1 (C1D1) tumor biopsy and bone ma rrow 
biopsy/aspirate co llection wi ndows to be 3 months prior to C1D1.  This minor change 
will reduce re-biopsies just for this trial in subjects who have already been diagnosed 
and staged.  (Table 5, and Sections 4.1.2 and 6)
!Changed the 28 days prior to C1D1 PET and CT scan collection wi ndows to be 6 
weeks prior to C1D1.  This change will re quire fewer subjects who have already had 
imaging to repeat their scans just for this trial, and thus reduce radiation exposure.  
(Table 5, and Sections 4.1.2 and 6.)
!Revised pregnancy te sting to occur at a minimum of every 28 days rather than exactly 
at every 28 days.  The option to do more frequent testing was actually more &(/*(1(35235,(7$5<,1)250$7,219 9 
er r 
ut the t the 
r a standaloa standalo
valuatialuati onon, ,
on theon the PETPE
Malignant Malign
that the posthat the po
(Section 4.(Section 4
Day 1 assesDay 1 a
ment have a ent have a
ssments havsments hav
ioion crin criteriaterii
y trackedtracked . . (
odyodyand antand anyy
reated eated hepahep
nt to take t to take p
pected to hapected to h
mamandatoryndatory y
s ars ae to be ae to 
ecrease in ecrease in 
angednged ththe 2e
biopsybiopsy /aspi/aspiyy
will will reduredu
and stnd st
!!CC
Lenalidomide (CC-5013)
Summary of Changes CC-5013-DLC-002 Celgene Corporation
Confidential and Propri etary 7 CC-5013-DLC-002 Amendment #1 Final:  25 Aug 2015convenient for study subjects as the treatment cycles, which are followed by a safety 
and pregnancy assessment, are 21 days in length, not 28 days.  This schedule is 
consistent with the Pregnancy Prevention Plan applicable to all lenalidomide studies 
and with the RevAssist pregnancy preve ntion guidelines app licable to Revlimid 
marketed product. (Table 5, Section 6.0)
!Corrected pregnancy counseling at baseline to require a single counseling session one 
time between signing the informed consent form (ICF) and Day 1 dosing.  This is consistent with the Pregnancy Prevention Plan which requires one counseling session prior to every dispensing of lenalidomide. (Table 5, Section 6.0)
!Deleted the explanation of how to subdi vide tumor biopsy f ormalin-fixed paraffin-
embedded (FFPE) blocks for Central Pathology submission.  Central Pathology will be responsible for sample slide preparation f rom a submitted tumor block; and the 
separate Central Pathology Laboratory Manual will provide necessary sample 
processing details .  (Section 6.0)
!Allowed the lower threshold for ANC and / or platelet c ounts to include lymphoma 
involvement of the spleen, in addition to the previously allowed lymphoma 
involvement of the bone marrow.  Patients wi th spleen involvement by lymphoma (as 
evidenced by splenomegaly) often have depressed ANC and / or platelet values and R-CHOP treatment would st ill be warranted. (Section 7.2)
!  
 
  
 
 
!Changed the 2-sided p-value to a 1-sided p-value in the interim analysis section at the 
recommendation of the data monitoring committee statistician  
since the 1-sided p-value is more appropriate and easier to understand for fut ility 
analysis. (Section 10.8)
!Clarified that in medical emergency cases, investigators are free to un-blind their 
subject‚Äôs treatment assignment via the IVRS.  In such cases it is not required to 
contact the Medical Monitor prior to breaking the blind; Celgene permission is not required.  Additionally, there is no emergency unbinding PIN required. (Section 13.2)
!Added the requirement for investigators to share a summary of study results with 
their subjects at the time results of the study are made available to the public.  Celgene will provide the relevant summary written for a lay person to the investigator. (Section 14.2.)
!Added additional references to Section 18 and cited throughout the document as 
appropriate.
&(/*(1(35235lue tlue to a 1o a 
 data mdata m ono
value is moalue is mo
n 10.8)n 10.8)
t t in inmeddicaic
treatmreatm ent aent
t the Medict the Medic
uiuired.  Addred.  Adiii
AddAddededthth
thheieir sur suiii
CelCel
ini$5<,1)250$7,21on n 
araffinraffin --
olologyogywillwillyy
ock; and theck; and th
aryrysample samplyy
ts to includes to inclu
llowed lymowed lym
n invonlvemevem
ANC and / ANC an
ectioction 7.2)n 7.2)
7$5(7$(7$5,(75,(35